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Abstract 
The obesity epidemic has already reached alarming rates in both developed and developing 
countries. Positive energy balance due to high calorie intake with decreased energy 
expenditure resulted in the current pandemic of obesity. Obesity is associated with other 
metabolic diseases, including type 2 diabetes (T2D). 
Skeletal muscle plays a major role in the control of whole-body glucose and lipid 
metabolism. Obese subjects have an excessive accumulation of lipid species, which interferes 
with the activation of insulin signaling pathways in key metabolic tissues such as the liver 
and skeletal muscle. Therefore, understanding the molecular mechanisms regulating energy 
expenditure in skeletal muscle, in particular, mitochondrial function and mitochondrial 
oxidative capacity has been a major research focus in obesity. 
It has been reported that mice lacking the c-Casitas B-lineage Lymphoma protein (c-Cbl) 
exhibit enhanced energy expenditure and insulin sensitivity, indicating that c-Cbl is a major 
factor contributing to the maintenance of whole-body energy homeostasis. c-Cbl was initially 
identified as an E3 ubiquitin ligase involved in the regulation of tyrosine kinase signaling. 
Previous studies showed that global knockout (KO) of c-Cbl in mice protects against high fat 
(HFat)-induced obesity and insulin resistance by increasing energy expenditure. However, 
this was a whole-body metabolic result and not specific to any tissue. 
Based on the literature review and analysis of the gaps in our current knowledge (Chapter 1), 
the overall aim of this thesis was established to investigate the role of c-Cbl in muscle energy 
metabolism.  
The first aim (Chapter 3) was to characterize the pathologic features and the changes of the 
Cbl family in different metabolic tissues during diet-induced obesity (DIO) in mice by a HFat 
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diet. The working hypothesis was that a HFat diet would induce obesity and glucose 
intolerance in mice and alter Cbl expression in skeletal muscle, which may contribute to body 
weight gain.  
The first aim was addressed in C57BL/6J male mice fed a HFat diet, which induces obesity 
and insulin resistance. The results showed that the HFat diet induced adiposity (as indicated 
by more than 80% of body weight gain and a threefold increase in epididymal fat mass), 
glucose intolerance, lipid accumulation (increased triglycerides deposition in liver and 
muscle), and impaired muscle formation (suppressed myogenin expression levels). 
Associated with the development of metabolic syndrome, c-Cbl content was upregulated in 
skeletal muscle but not in the liver and white adipose tissue, and Casitas B-lineage 
Lymphoma protein-b (Cbl-b) was decreased in skeletal muscle by HFat-fed mice. These 
findings suggest that c-Cbl expression is specifically increased in skeletal muscle during 
HFat-induced obesity. 
Based on these findings the second aim (Chapter 4) was to investigate the mechanism of c-
Cbl regulation in muscle mitochondrial function, mitochondrial oxidative capacity, 
mitochondrial biogenesis, and mitochondrial degradation. The working hypothesis was that c-
Cbl knockdown (KD) may enhance muscle mitochondrial function, mitochondrial oxidative 
capacity and mitochondrial biogenesis and degradation in muscle cells. The second aim was 
addressed in the C2C12 muscle cell line by knocking down c-Cbl. Using a specific short-
hairpin RNA (shRNA), expression of c-Cbl protein was reduced during muscle proliferation 
(myoblasts), and this reduction was maintained until muscle differentiation (myotubes). c-Cbl 
KD resulted in a significant increase in oxygen consumption basally and during maximal 
respiration in myotubes by about 20%. These data suggest that skeletal muscle is likely to be 
a major site of c-Cbl-mediated energy metabolism for the whole-body. We observed a 
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significant increase in the phosphorylation of adenosine monophosphate protein kinase 
(AMPK) and acetyl-CoA carboxylase (ACC) in c-Cbl KD myotubes. The protein levels of 
mitochondrial complexes and the mitochondrial biogenesis in c-Cbl KD myotubes were 
increased compared with control myotubes. These findings suggest that c-Cbl KD increases 
the ability of energy metabolism in muscle cells. 
The third aim (Chapter 5) was to investigate the role of c-Cbl in muscle formation 
/myogenesis. The working hypothesis was that c-Cbl KD may enhance myogenesis and 
reduce lipid accumulation in mature muscle.  
This was addressed in the C2C12 muscle cell line by knocking down the expression of c-Cbl 
to investigate the specific effect of c-Cbl on muscle formation/myogenesis during muscle 
differentiation. The results determined that c-Cbl KD in myotubes enhanced myotube 
formation. While c-Cbl upregulation in skeletal muscle is associated with obesity, 
downregulation of c-Cbl promotes energy expenditure in muscle cells independent of AMPK 
activation. In addition, c-Cbl KD in myogenic differentiation reduced lipid accumulation 
under insulin-resistant conditions. These findings suggest that c-Cbl KD promotes 
myogenesis and may enhance insulin sensitivity. 
Chapter 6 summarizes the major findings and conclusions, and it discusses the limitations of 
studies in this thesis and how future studies could address the remaining issues and potential 
implications for humans. 
Overall, our data demonstrate that obesity affects c-Cbl expression in skeletal muscle. c-Cbl 
KD in mature muscle cells results in enhanced mitochondrial function. These findings 
suggest that c-Cbl in skeletal muscle is an important regulator of energy metabolism, and it 
may be targeted for the treatment of obesity and associated metabolic disorders. 
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Chapter 1: Introduction and Literature Review
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Obesity is a major metabolic disorder worldwide. It is closely related to increased calorie 
intake (e.g. high-fat diet) and decreased energy expenditure. This literature review focuses on 
relevant research to provide: 1) an essential background to obesity and associated metabolic 
disorders; 2) an evaluation of our current knowledge of the impact of muscle energy 
metabolism on obesity; and 3) an analysis of the role of c-Cbl in muscle energy metabolism, 
particularly with regard to the new concepts and hypotheses arising from laboratory-based 
studies. Based on this review of the literature, gaps in our knowledge were identified and 
hypotheses were developed to guide the research presented in this thesis. 
1.1 Obesity 
Obesity is a metabolic disorder that is defined by the World Health Organization (WHO) as 
excessive or abnormal fat accumulation and storage that presents a risk to a person’s health 
(World Health Organization, 2016). A number of national and international organisations, 
including the National Institutes of Health, Centers for Disease Control and Prevention 
(CDC), and WHO, have provided guidelines for classifying body weight status using the 
body mass index (BMI) as “gold standard” to identify people who are at high risk of 
adiposity-associated adverse health outcomes (Centers for Disease Control and Prevention, 
2015; National Institutes of Diabetes and Digestive and Kidney Diseases, 2017; World 
Health Organization, 2016). BMI is calculated by dividing body weight in kilograms by the 
square of the height in metres (Table 1-1). People who have a BMI of 30 kg/m2 or above are 
considered obese and are more susceptible to adverse health effects than those who are 
considered overweight (World Health Organization, 2006). Obesity is characterised by 
increased lipid storage in visceral and subcutaneous adipose and non-adipose tissues 
(Akhmedov & Berdeaux, 2013). 
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According to the CDC, BMI is a screening measurement that cannot be used as a diagnostic 
determinant for body adiposity because BMI does not differentiate between visceral and 
subcutaneous fat (Centers for Disease Control and Prevention, n.d.).  
 
Table 1-1 Classifications of obesity based on BMI. 
BMI (in kg/m2 ) Status 
Below 18.5 Underweight 
18.5-24.9 Normal 
25-29.9 Overweight 
30-34.9 Obese class I 
35-39.9 Obese class II 
40 and above Obese class III 
  (World Health Organization, 2006) 
 
1.1.1 Prevalence and social burden of obesity 
In the past few decades, obesity has dramatically increased throughout the world. The 
prevalence of obesity has almost doubled from 1980 to 2008: 10% of men and 14% of 
women in the world were obese in 2008 compared with 5% and 8% for men and women, 
respectively, in 1980. In 2014, 13% of the adult population were obese and 39% were 
overweight (World Health Organization, 2016). Approximately 2.8 million people die 
annually due to the health problems that derive from being overweight or obese. More than 
42 million children aged 5 or younger were overweight or obese in 2014 (World Health 
Organization, 2016). 
The prevalence of obesity varies among different regions and ethnic backgrounds, while the 
trends are the same across most regions. Figure 1-1 shows the prevalence of obesity in 
 7 
 
different regions of the world. Based on this report, North America, West Europe and Middle 
East regions have the highest prevelance of obesity. In Australia, almost 28% of adults were 
obese in 2014-2015 (Australian Bureau of Statistics, 2015). It is estimated that the prevalence 
of overweight and obesity will rise to 65% in 2025, with almost one-third of Australian adults 
being obese (Walls et al., 2012). A similar trend of increased prevalence has been observed in 
the United States: 23.2% of the adult population were obese in 1991, and this figure increased 
to 70.1% in 2014 (Organization for Economic Co-Operation and Development, 2017). The 
rise of obesity is not only limited to developed countries, but is occurring in developing 
countries as well. In my country the Kingdom of Saudi Arabia, the prevalence of obesity 
from the late 1980s to the mid-1990s was around 20%, ranging from 13.1% among men to 
26.6% among women. By 1995 this figure had already increased to more than 35%. In 2013, 
a total of 36 million Saudis were obese. Within this prevalence, about a quarter of the obese 
population were men 24.1%, while 33.5% were women (Memish et al., 2014). Obesity 
prevalence overall was predicted to increase from almost 12% in 1992 to 41% by 2022 in 
men, and from 21% to 78% in women (Al-Quwaidhi, Pearce, Critchley, Sobngwi, & 
O’Flaherty, 2014). 
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Obesity has caused enormous health, economic, and social burdens. Epidemiological 
evidence shows that obesity is associated with many metabolic diseases that can lead to 
morbidity and/or mortality (Australian Medical Association, 2016; Luo et al., 2007). 
In terms of the economic costs, obesity and its associated diseases have a significant 
economic impact on the health-care system. Medical costs associated with obesity involve 
direct and indirect costs. Direct medical costs may include preventive, diagnostic, and 
treatment services related to obesity. Global spending on obesity and its related complications 
has reached a total of $2 trillion annually and cost 2.8% of global gross domestic product 
(GDP) in 2012 (Dobbs et al., 2014). In Australia, the total direct cost of obesity in 2005 was 
$8.3 billion AUD ($6.6 billion AUD direct health costs and $1.7 billion AUD direct non-
health costs). In addition, the government spent $13.6 billion AUD in subsidies (National 
Health and Medical Research Council, 2014).  
The indirect costs associated with obesity are related to morbidity and mortality costs, 
including the impact of being absent from work (absenteeism), being less productive at work 
than a healthy person (presenteeism), and premature mortality and disability. These costs 
have an economic impact on the nation’s economy through productivity losses resulting in 
lower output (Centers for Disease Control and Prevention, 2017a). 
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1.1.2 Central and peripheral obesity 
Obesity is classified into two types depending on the distribution of body fat, both central 
(android, upper body) and peripheral (gynoid, lower body). In central obesity, fat is 
accumulated in the abdominal region. In peripheral obesity, fat deposits in the hips and thigh 
areas (Aras, Üstünsoy, & Armutçu, 2015). This classification can determine the relationship 
between obesity and associated metabolic diseases. Central obese people are more at risk of 
having obesity-related diseases, including type 2 diabetes (T2D), heart disease, metabolic 
syndrome, and cancer (Booth, Magnuson, & Foster, 2014). Central obesity, also known as 
visceral obesity, can be diagnosed by measuring waist-to-hip ratio or absolute waist 
circumference. In addition to these measurements, computed tomography or dual-energy X-
ray has become a reliable measurement for visceral and subcutaneous fat (Maurovich-Horvat 
et al., 2007). 
Central obesity has become a key component in the definition of the metabolic syndrome. 
Although there is no internationally agreed-upon definition for metabolic syndrome, WHO 
originally defined metabolic syndrome in 1998 as Syndrome X or insulin resistance 
syndrome because insulin resistance is one of the major components in the pathophysiology 
of metabolic syndrome (Kaur, 2014; World Health Organization, 1999). The International 
Diabetes Federation (IDF) updated the definition of metabolic syndrome in 2006 as a cluster 
of clinical symptoms with central obesity, including dyslipidaemia, hypertension, and 
hyperglycaemia (Alberti, Zimmet, & Shaw, 2006; Kaur, 2014). 
The manifestation of insulin resistance includes impaired fasting glucose (IFG, defined as a 
fasting glucose level above 100 mg/dl) or impaired glucose tolerance (IGT, defined as a 
glucose level above 140 mg/dl) or an increase in the homeostatic model of insulin resistance 
(HOMA-IR) values or euglycemic-hyperinsulinaemic clamp with additional factors including 
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central obesity, dyslipidaemia, hypertension, and microalbuminuria (Alberti & Zimmet, 
1998). 
However, peripheral obesity, where fat deposits mainly in the subcutaneous tissue, could be 
protective against metabolic dysfunctions under some circumstances. Peripheral obesity is 
associated with improved insulin sensitivity and reduced risk of developing T2D and 
dyslipidemia compared with central obesity (Konrad, Rudich, & Schoenle, 2007; Ma, Lee, 
Chisholm, & James, 2015; McLaughlin, Lamendola, Liu, & Abbasi, 2011). 
Studies in rodents show that removal of subcutaneous fat does not improve metabolic 
function (Klein et al., 2004). These metabolic improvements have been demonstrated in mice 
using transplantation strategies. In one study, the authors transplanted either visceral or 
subcutaneous fat from donor mice into either visceral or peripheral subcutaneous areas of 
recipient mice. They found that the effects on body weight and metabolism were improved by 
adding subcutaneous fat into visceral areas (Tran, Yamamoto, Gesta, & Kahn, 2008). 
However, in humans, almost 90% of obese people have visceral fat accumulated (Matsuzawa 
et al., 1995). This suggests that obesity is generally detrimental to insulin sensitivity in 
humans. Visceral fat is more easily mobilised to release free fatty acids (FFAs). In addition, 
the functional difference in properties between visceral and peripheral fat may be related to 
their location. The mechanisms for the different roles of visceral and peripheral fat are not 
fully understood. It has been suggested that visceral fat produces more cytokines such as 
tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), and less adiponectin. These 
cytokine changes are related to insulin resistance (Hamdy, Porramatikul, & Al-Ozairi, 2006).  
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1.1.3 Obesity and associated diseases 
Obesity, the excessive accumulation of visceral fat, is a serious health problem that can result 
in metabolic diseases such as T2D, dyslipidaemia, cardiovascular disease (CVD), such as 
heart diseases and stroke, and non-alcohol fatty liver disease (NASH). These metabolic 
diseases appear to be due to excessive lipid accumulation in the relevant organs and cells. As 
reviewed in (Section 1.3.2), many of the lipid metabolites, such as diacylglycerol (DAG), 
ceramides, and phospholipids, are harmful to the cells. Other potential complications include 
respiratory problems, such as sleep apnoea, or musculoskeletal disorders, especially 
osteoarthritis (Webber, 2001). Recent studies indicate that obesity also increases the risk of 
certain types of cancer (American Cancer Society, 2017; Centers for Disease Control and 
Prevention, 2017b), (Section 1.1.3.3). 
1.1.3.1 Diabetes mellitus 
Diabetes mellitus (DM), generally known as diabetes, is a metabolic disease characterised by 
high blood glucose levels (hyperglycaemia). According to the American Diabetes 
Association (ADA) and WHO, the level of fasting plasma glucose 7 mM/L or above (126 
mg/dL) is diagnosed as diabetes (American Diabetes Association, 2017; World Health 
Organization, 2015). Diabetes is a worldwide health problem, and it is increasing at such a 
high rate due to lifestyle factors that are leading to obesity, a main risk factor for diabetes. 
Diabetes was a direct cause of death for 1.5 million patients in 2012, and it affected 9% of 
adults globally in 2014. It is predicted that diabetes will be the seventh leading cause of death 
in 2023 (World Health Organization, 2015). It has been estimated that diabetes will affect 
439 million people by 2030 (Shaw, Sicree, & Zimmet, 2010).  
Every day, 280 Australian adults develop diabetes, with more than 100,000 cases each year. 
It is estimated that 1.7 million Australians have diabetes, and 3 million are pre-diabetic. 
Every year, 20,000 Australian women develop gestational diabetes. The impact of diabetes 
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costs Australia around $14.6 billion each year (Diabetes Australia, 2015). In my country, 
Saudi Arabia faces one of the highest prevalence rates of diabetes in the world, according to 
the International Diabetes Federation (IDF). The prevalence of diabetes was 19.6% in Saudi 
adults in 2011 and 20.52% in 2014. It cost around $1,067.32 USD per person in 2014 
(International Diabetes Federation, 2014). It has been estimated that by 2035, the prevalence 
of diabetes will be 22.3% (Whiting, Guariguata, Weil, & Shaw, 2011).  
Diabetes is classified as two major types depending on the etiology and clinical presentation. 
Type 1 diabetes (T1D), also called juvenile diabetes or insulin-dependent diabetes, is a 
progressive autoimmune disease starting in early life and resulting from a defect in insulin 
production from the β-cell in the pancreas. It is the most common chronic condition of 
childhood caused by genetic predisposition (American Diabetes Association, 2017). Two 
forms of type 1 diabetes exist: Type 1A (autoimmune) diabetes results from a cell-mediated 
autoimmune destruction of the β cells and accounts for 85%-90% of people with T1D. Type 
1B (idiopathic) diabetes, or islet antibody-negative, is a non-autoimmune islet defect in 
autoantibodies of the pancreas that results in ketoacidosis and represents only a minority of 
diabetic patients. T1D accounts for 5%-10% of all types of diabetes and is not associated with 
obesity (American Diabetes Association, 2017). 
Type 2 diabetes (T2D) is another type of DM, which is also known as non-insulin dependent 
or adult-onset diabetes. Unlike T1D, T2D starts as a metabolic disease in which the body 
becomes resistant to the effect of insulin secretion. Approximately 90%-95% of DM is T2D 
(American Diabetes Association, 2017). There are other types of diabetes, such as gestational 
diabetes, which presents during pregnancy (American Diabetes Association, 2017). 
Obesity is the major risk factor for T2D because obesity inflicts lipotoxicity and cytokine 
effects to impair both insulin sensitivity and insulin production. Therefore, the epidemiology 
of T2D is increased as the prevalence of obesity increases. Diabetes can lead to many 
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different diseases, including cardiovascular disease, neuropathy, foot ulcers or amputations, 
or gastrointestinal issues, affecting 30%-50% of diabetic people in their lifetimes (Tesfaye, 
2006). Nephropathy may lead to renal failure, affecting 20%-40% of diabetic people 
(Satirapoj, 2013). Also, 60% of diabetic people develop retinopathy with the possible loss of 
vision (Fong et al., 2004). Diabetic people are as much as five times more likely to have 
coronary heart disease than those who do not have diabetes (National Health Service, 2015). 
Two to three times as many diabetic people than non-diabetic people have cerebrovascular 
disease that leads to stroke (Mankovsky, Metzger, Molitch, & Biller, 1996). Hypertension 
and lipoprotein dysfunction are conditions that are often present in diabetic people (American 
Diabetes Association, 2008).  
In relation to T2D, chronic hyperglycaemia is another major contributor to obesity-associated 
metabolic disease that increases the risk for developing CVD. Hyperglycaemia increases 
mitochondrial superoxide production that may lead to the formation of plaques in 
atherosclerosis (X. Du et al., 2006). Different studies showed that effective glycemic control 
treatments can have beneficial effects on diabetic cardiovascular complications (Ray et al., 
2009; Skyler et al., 2009). 
1.1.3.2 Obesity and cardiovascular disease 
Obesity is a risk factor for CVD, a main cause of death in many countries, including Australia 
(Nichols, Peterson, Alston, & Allender, 2014; World Health Organization, 2017). Obesity-
associated CVD includes coronary heart disease, stroke, cardiomyopathy, peripheral vascular 
disease, hypertensive disease, and heart failure (Australian Institute of Health and Welfare, 
2017; National Heart, Lung and Blood Institute, 2016). For example, a long-term (26-year) 
follow-up, study of 1,558 people (the Framingham heart study) revealed that obesity was an 
independent risk factor for CVD (Hubert, Feinleib, McNamara, & Castelli, 1983). Further, a 
16-year follow-up study showed that obese women are at higher risk for developing CVD 
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than non-obese women (Evans & Frank, 1997). Another long-term follow-up (14-year) study 
in U.S. adults showed a strong association between obesity and the risk of death due to CVD 
(Calle, Thun, Petrelli, Rodriguez, & Heath Jr, 1999).  
There are many different possible mechanisms that link obesity with CVD. White adipose 
tissue releases a number of cytokines and bioactive mediators, including adiponectin, IL-6, 
TNF-α, and leptin, that influence not only body weight homeostasis but also insulin 
resistance, inflammation, and atherosclerosis (Van Gaal, Mertens, & De Block, 2006). 
Obesity is usually associated with chronic inflammation characterised by abnormal cytokine 
production (Wellen & Hotamisligil, 2005). Inflammation increased the risk of the 
development of CVD in obese subjects (Van Gaal et al., 2006). There are two 
proinflammatory cytokines, TNF-α and IL-6, overexpressed in the adipose tissue of obese 
humans (Hotamisligil, Arner, Caro, Atkinson, & Spiegelman, 1995; Tzanavari, Giannogonas, 
& Karalis, 2010) and mice (Hotamisligil, Shargill, & Spiegelman, 1993). A lack of TNF-α 
function improved insulin sensitivity and glucose homeostasis in obese mice (Uysal, 
Wiesbrock, Marino, & Hotamisligil, 1997). These studies provide the link between obesity 
and CVD. It has been shown that systemic inflammation is associated with endothelial 
dysfunction, which may lead to atherosclerotic CVD (Amar et al., 2003). Inflammatory 
cytokines form plaques in atherosclerosis (Ramji & Davies, 2015). Leptin is a bioactive 
mediator that controls food intake and energy expenditure. Obesity is associated with 
elevated leptin levels, which have been proposed to play a role in insulin resistance and 
metabolic syndrome. There may be a direct link between hyperleptinaemia and increased 
cardiovascular disease risk. Leptin-induced thrombogenity in obese subjects enhances the 
calcification of vascular cells, making the arterial wall a target of leptin (Van Gaal et al., 
2006). Adiponectin has a protective effect on endothelial function by suppressing myocardial 
inflammation and apoptosis, and activating adenosine monophosphate protein kinase 
 16 
 
(AMPK)-dependent nitric oxide production (H. Chen, Montagnani, Funahashi, Shimomura, 
& Quon, 2003). However, adiponectin levels are decreased in obesity and CVD (Nakamura, 
Fuster, & Walsh, 2014).  
1.1.3.3 Obesity and cancer 
It has recently been shown that obesity increases the mortality rates of some types of cancer, 
including liver, colon, pancreatic, ovarian, and hematopoietic cancer (Siegel, Miller, & Jemal, 
2016). It has been reported that obese women are at a greater risk than non-obese women to 
have endometrial and breast cancer during menopause due to increased levels of estrogen 
(Munsell, Sprague, Berry, Chisholm, & Trentham-Dietz, 2014; Setiawan et al., 2013). 
Weight loss by bariatric surgery has been reported to reduce the cancer risk in obesity 
(Christou, Lieberman, Sampalis, & Sampalis, 2008; McCawley, Ferriss, Geffel, Northup, & 
Modesitt, 2009).  
The mechanisms underlying the risk of cancer in obesity is not very clear, but many factors 
may contribute to the progression of cancer in obesity, including hyperinsulinemia, 
adipokines and cytokines, and dyslipidaemia. It has been suggested that chronic 
hyperinsulinaemia promotes cancer growth by stimulating the insulin-like growth factor 1 as 
supported by meta-analyses and prospective epidemiological studies (W. Chen et al., 2009; 
Rinaldi et al., 2010). Furthermore, obesity is associated with chronic low-grade inflammation 
that can cause oxidative stress and DNA damage that may lead to cancer (Cerdá et al., 2014). 
1.1.4 Mechanism of the pathogenesis of obesity 
The fundamental cause of the development of obesity is the imbalance of energy intake to 
energy expenditure, namely a state of positive energy balance, as illustrated in Figure 1-2.  
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Figure  1-2 Fundamental cause of obesity. 
Positive energy balance is considered as the essential cause of obesity by increased energy 
intake and/or decreased energy expenditure (World Health Organization, 2016).  
 
However, at the mechanistic level, the development of obesity is highly complex, and it is 
likely to be the consequence of genetic and environmental factors. The significance of genetic 
factors in the development of obesity has been demonstrated in adoption studies (Price, 
Cadoret, Stunkard, & Troughton, 1987; Stunkard, Sørensen, et al., 1986) and twin studies in 
humans (Stunkard, Foch, & Hrubec, 1986). It has been shown that the offspring of mothers 
who had bariatric surgery are at lower risk of developing obesity compared to siblings born 
prior to their mother’s surgery (Smith et al., 2010). Also, studies on non-human animals have 
shown that prenatal high-fat diets increase the risk of offspring obesity (Howie, Sloboda, 
Kamal, & Vickers, 2009). Although the mechanism of this process is not clear, it is proposed 
that an epigenetic mechanism plays a role in the inheritable change in gene expression 
(Herrera, Keildson, & Lindgren, 2011). The epigenetic regulation provides the relationship 
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between gene-environment interactions and long-term consequences of prenatal nutrition in 
the development of obesity (Drummond & Gibney, 2013). 
A range of hormones can influence the balance of energy metabolism to cause obesity 
including an underactive thyroid (hypothyroidism), which slows down one’s energy 
metabolism. Hypothyroidism is associated with decreased metabolic rate and decreased 
thermogenesis, and the cause of thyroid function alteration is not known (Milionis & 
Milionis, 2013). Adipocyte hypertrophy in obesity has been linked to different metabolic 
alteration. These alterations are mediated by infiltration of macrophages that increase 
proinflammatory cytokines (Roerink et al., 2017). Obesity, particularly central obesity, may 
be responsible for insulin resistance and associated hyperinsulinaemia in women with 
polycystic ovarian syndrome (PCOS). Thus, obesity-related hyperinsulinaemia may play a 
role in enhancing hyperandrogenism in these women. Other factors, such as increased 
estrogen production, decreased sex hormone binding globulin synthesis, and high dietary 
lipid intake may be additional mechanisms by which obesity leads to the development of 
hyperandrogenism in PCOS (Gambineri, Pelusi, Vicennati, Pagotto, & Pasquali, 2002). 
 
The hypothalamus is an important organ for energy homeostasis and appetite regulation. 
There are different hypothalamic appetite regulators including ghrelin, neuropeptide Y 
(NPY), agouti-related peptide (AgRP), orexin and cannabinoids (appetite stimulating); and 
amphetamine-regulated transcript (CART), pro-opiomelanocortin (POMC), corticotropin-
releasing hormone (CRH) (Scerif, Goldstone, & Korbonits, 2011), and leptin (appetite 
suppressing) (F. Zhang, Chen, Heiman, & DiMarchi, 2005). Total fat storage is signalled to 
the brain by leptin, which is secreted by adipocytes and insulin, which is secreted from β-
cells in the pancreas (Schwartz, Figlewicz, Baskin, Woods, & Porte Jr, 1992; Trayhurn & 
Bing, 2006). Leptin is a hormone that regulates fat storage and controls signals that trigger 
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energy storage in fat reserves and releases energy from those reserves. Also, leptin adjusts 
hunger sensations; because of this, it is called a satiety hormone. Both leptin and insulin 
hormones are transported from the circulation into the brain; they activate the hypothalamic 
mammalian target of rapamycin (mTOR) and de-activate AMPK, and vice versa, leading to 
decreased food intake and weight loss (Cota et al., 2006). Chronic treatment with leptin 
decreases triacylglycerol levels in rodents’ skeletal muscle on a high-fat diet, and this is 
linked with enhancements of glycogen synthesis and insulin-stimulated glucose uptake 
(Yaspelkis et al., 2004). Ghrelin is the first peripheral hormone to display orexigenic effects 
through its action on the hypothalamic appetite-regulating pathways. Ghrelin hormone levels 
are reduced in obesity. Briggs et al. (2010) indicated that diet-induced obesity (DIO) causes 
ghrelin resistance by reducing NPY/AgRP responsiveness to plasma ghrelin (Williams, Grill, 
Cummings, & Kaplan, 2006). Fibroblast growth factor 21 (FGF21) is a metabolic hormone 
produced by the liver (Woo, Xu, Wang, & Lam, 2013). It has been reported that a systemic 
administration of FGF21 in DIO and ob/ob mice reduced adiposity and increased energy 
expenditure (Coskun et al., 2008). These results highlight the potential role of FGF21 as a 
therapeutic target for obesity. However, higher circulating levels of FGF21 were found in 
obese humans and its associated diseases (Woo et al., 2013). 
 
In addition to genetic and hormonal factors, environmental factors also play an important role 
in the development of obesity. Most cases of obesity are due to a positive energy imbalance 
stemming from the increased consumption of high caloric-content meals and low energy 
expenditure because of a more sedentary lifestyle. Calorie intake is an important cause in the 
development of obesity, and it is controlled by a complex neural network in the central 
nervous system (Morton, Cummings, Baskin, Barsh, & Schwartz, 2006). One common factor 
of increased calorie intake is over-consumption of a high-energy diet or amount of food in 
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humans. This can be mimicked in mice with a high-fat diet, which was used as an animal 
mice model in this thesis. High-fat diet (HFat)-induced obesity and associated insulin 
resistance has been well characterised in different animal models, including rats and mice 
(Darkhal, Gao, Ma, & Liu, 2015; Liu et al., 2015; J. M. Ye et al., 2011). Indeed, the wide 
usage of HFat diet in rodents is well known as a DIO model in laboratory research since the 
1990s. DIO can be used to understand the mechanisms underlying the development of obesity 
and associated insulin resistance to test new treatments for these diseases (Abe et al., 2013; 
Chan et al., 2015; Molero, Waring, et al., 2006; Turner et al., 2008). 
 
Also, as illustrated in Figure 1-2, decreased energy expenditure, such as physical inactivity, 
increases the risk of obesity, and this is becoming a major player in sedentary lifestyles. The 
emergence of the computer/telecommunication age has led to workers being less able to 
utilise energy, and they store the excess calories as fat, leading to an increased prevalence of 
obesity. A sedentary lifestyle decreases the requirement for energy expenditure used for 
muscle contraction and tension. The accumulated energy is converted to fat and stored in the 
liver, skeletal muscle, and adipose tissues, thus contributing to the development of obesity. 
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1.1.5 Contribution of different organs to whole-body energy expenditure 
About 90% of consumed energy is metabolised, with the rest being lost in the urine, faeces, 
or skin in humans (Lam & Ravussin, 2016). Total energy expenditure (TEE) can be divided 
into three categories: energy expenditure from the thermic effect of food (TEF, also known as 
diet-induced thermogenesis), energy expenditure from physical activity, and resting energy 
expenditure (REE, also known as basal metabolic rate, BMR), as illustrated in Figure 1-3 
(Frisard & Ravussin, 2006). 
 
Figure  1-3 Composition of total energy expenditure and resting energy expenditure 
from different organs and tissues. 
TEE consists of REE, energy expenditure for the thermic effect of food (TEF), and activity 
energy expenditure (Activity EE). Skeletal muscle, brain, and liver are the major contributor 
to REE (Frisard & Ravussin, 2006), which largely determines the energy balance in relation 
to obesity in the general population. Among the contributors, skeletal muscle and adipose 
tissue can change their energy expenditure under certain conditions. 
 
TEF is the increased metabolic rate in response to food. TEF is the cumulative increase in 
energy expenditure after the ingestion of food and constitutes around 10% of TEE (Frisard & 
Ravussin, 2006). Measured TEF is 5% to 10% of the caloric content from carbohydrates, 0% 
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to 3% from lipids, and 20% to 30% from proteins (Tappy, 1996). Seguin and Lavoisier were 
the first to observe that oxygen consumption increased after the ingestion of food (Jonee & 
Bray, 1997; Krebs, 1964). It has been observed that the increase in oxygen consumption was 
greater after protein ingestion than the consumption of carbohydrates or fat (Jonee & Bray, 
1997). There are many factors that influence TEF, including energy content and composition 
of the meal, the previous meal, and physical exercise. It has been reported that obese people 
have a smaller reduction in TEF, which may be related to insulin resistance (Jonee & Bray, 
1997). However, TEF is not generally considered to play an important role in the 
development of obesity. 
Physical activity energy expenditure is the most variable component of energy expenditure. 
Physical activity accounts for 20% of TEE in sedentary individuals, and it can increase to 
50% in active individuals (Frisard & Ravussin, 2006). The energy expenditure of physical 
activity is determined by body size and body movement. Thus, assessing physical activity 
against energy expenditure requires adjustment for differences in body size. Physical activity 
requires more energy from muscle to move a larger body than a smaller body, one of the 
reasons why obese people generally move less than lean people (Westerterp, 2013). 
Regular physical activity during moderate-intensity exercise increases the ability of the body 
to use lipids instead of carbohydrates as a source of energy and increase fat oxidation during 
the change to a high-fat diet (Poirier & Després, 2001). Some studies have reported that 
physically active children and adults have less abdominal fat and are leaner than sedentary 
people (Eckardstein, 2006; Vissers et al., 2013). It has been suggested that muscle becomes 
hypoxic during moderate-intensity exercise, a result of improved oxygen consumption 
(Wadley et al., 2006). Further, physical activity is a function of physical capacity, which is 
affected by energy supply and disease (Westerterp, 2013). 
 23 
 
REE is the energy expenditure of an individual at rest in a fasted state. REE is responsible for 
around 50% to 70% of the total energy expenditure in humans. Several factors influence 
REE, such as age, sex, body composition, body size, body temperature, and thermogenic 
hormones (Baker, McCormick, & Robergs, 2010). REE provides the energy used to maintain 
electrolyte gradients in cells and to sustain the cardiovascular and pulmonary system at rest 
(Poehlman & Dvorak, 2000). REE is usually measured by indirect calorimetry with oxygen 
consumption (VO2), carbon dioxide production (VCO2), and respiratory exchange rate 
(Pencharz & Azcue, 1995). The contribution to REE from major tissues and organs is 
estimated to be 19% from the liver, 17% from the brain, 3% from adipose tissue, 7% from the 
kidney, and 8% from the heart, while the combined weight for these organs is less than 6% of 
total body weight (Gallagher et al., 2006). Skeletal muscle contributes to 20% of the total 
REE (Figure 1-3), and accounts for 40% of total body weight in non-obese subjects 
(Gallagher et al., 2006). Thus, larger total tissue mass increases REE and the contribution of 
lean tissue is greater than fat tissue (K. D. Hall et al., 2012). 
Importantly, skeletal muscle is highly regulatable for its energy usage and is proportionally 
reduced in obesity. Skeletal muscle can be built up quickly with a combination of physical 
exercise and a high protein diet (J. Kim, Wang, Heymsfield, Baumgartner, & Gallagher, 
2002). The importance of resting muscle metabolism for whole-body energy expenditure was 
determined by the positive correlation between muscle metabolic rate and basal metabolic 
rate (Zurlo, Larson, Bogardus, & Ravussin, 1990). Thus, individuals with a low resting 
metabolic rate due to decreased muscle energy expenditure are at greater risk of developing 
obesity. However, because skeletal muscle has a great potential to influence REE, it has been 
a major focus of the study of the energy metabolism in relation to obesity. Therefore, this 
thesis chose to investigate the possible role of c-Cbl (reviewed in Section 1.5.3) in regulating 
energy metabolism in muscle cells. 
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Another aspect which has received enormous attention for its potential role in REE is adipose 
tissue. The contribution of adipose tissue to REE is minimal under normal circumstances. 
Many studies suggest that white adipose tissue can be converted to energy-consuming 
“brown-like” adipose tissue, a process called “browning”. Also known as beige fat cells, this 
can significantly increase whole-body energy expenditure (Cypess et al., 2009; Harms & 
Seale, 2013). For example, energy expenditure in rodents increased dramatically in response 
to cold or carbohydrate over-feeding, as these animals oxidise large amounts of glucose and 
fat in brown adipose tissue (Himms-Hagen, 1995).  
1.2 Muscle energy metabolism in obesity 
There are three types of muscle in the body: smooth, skeletal, and cardiac (striated) muscles. 
Cardiac muscle tissue is found only in the heart, while smooth muscle tissue is found in the 
walls of blood vessels and the organs of the gastrointestinal system. All types of muscles 
perform different functions, including strength, endurance, and fatigue, but the major 
function is to generate motion. Also, they share the same properties, including contractility, 
elasticity, excitability, and extensibility (Zimmermann, 2016). Differences that exist between 
smooth and skeletal muscles are that smooth muscle is uni-nucleated and contains 
sarcomeres, which are the functional units of muscle, while skeletal muscle is multi-nucleated 
and contains myofibrils (Wareham, 2011). Cardiac and smooth muscle types will not be 
further described, as they are not relevant to this thesis. 
1.2.1 Types of skeletal muscle energy metabolism 
Total oxygen consumption in skeletal muscle accounts for up to 90% during exercise and 
about 30% at rest (Joyner & Casey, 2015). Oxidative phosphorylation is an aerobic pathway 
that depends on oxygen as the energy substrate (Powers & Howley, 2004). Carbohydrates 
and fats are the primary source for energy expended during exercise and rest (Melzer, 2011). 
Skeletal muscle is one of the largest glycogen storage organs (Berg JM, 2002). Factors 
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regulating fatty acid oxidation and mitochondrial function capacity are likely to affect muscle 
metabolic function (Montgomery & Turner, 2015). Indeed, because of the large contribution 
of skeletal muscle to total body mass, it has a significant impact on whole-body energy 
metabolism. Thus, the critical role that skeletal muscle plays in metabolic homeostasis makes 
this organ of particular interest in obesity. Energy expenditure associated with both exercise 
and non-exercise is an important contributor to body weight maintenance. 
1.2.1.1 Muscle energy metabolism during exercise 
Skeletal muscle contractions during exercise require large amounts of energy by using a 
number of intra- and extramuscular substrates to generate adenosine triphosphate (ATP), 
depending on different factors (West, Burd, Staples, & Phillips, 2010). These factors include 
age, exercise intensity, exercise duration, training, and type of exercise (Röckl et al., 2007). 
The total quantity of ATP stored in the muscle is very small (8 mmol/kg wet weight of 
muscle). Thus, other mechanisms are involved to supply ATP for ongoing muscle 
contractions. There are three major energy systems in muscle responsible for ATP 
resynthesis. These systems are phosphagen system, glycolytic system, and aerobic respiration 
system (Baker et al., 2010).  
The phosphagen system is a creatine phosphate, which is a compound that can store energy in 
its phosphate bond. In resting muscle, excess ATP transfers its energy to creatine, producing 
ADP (adenosine diphosphate) and creatine phosphate. During muscle contraction, creatine 
phosphate and ADP are converted into ATP and creatine by the enzyme creatine kinase. 
Creatine phosphate provides the energy for approximately 15 seconds of muscle contractions, 
after which another energy source has to be available (Hargreaves, 2000). 
After the depletion of ATP from the phosphagen system, muscles generate ATP from 
glycolysis. The glycolysis system is an anaerobic processes that hydrolises glucose to 
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produce lactate. During glycolysis each glucose molecule produces two ATP molecules and 
two pyruvate molecules, which can be used in aerobic respiration when oxygen is available 
or converted to lactic acid if there is no oxygen (Baker et al., 2010; Hargreaves, 2000). Lactic 
acid may contribute to muscle fatigue and pain (Facey, Irving, & Dilworth, 2013). 
The aerobic respiration system is the breakdown of glucose in the presence of oxygen to 
produce ATP, carbon dioxide, and water. Aerobic respiration in the mitochondria of muscles 
uses glycogen from muscle stores, blood-borne glucose, pyruvic acid, FFAs, and some amino 
acids. Most of the ATP required for moderately active muscles is provided by aerobic 
respiration. Aerobic respiration is more effective than anaerobic glycolysis because the 
complete oxidation of each glucose molecule produces 36 ATP (Baker et al., 2010). 
1.2.1.2 Muscle energy metabolism at rest 
Resting metabolic rate is measured in a post-absorptive subject at rest in a supine posture, 
generally using indirect calorimetry to quantify oxygen consumption rates. Under resting 
conditions, glucose and fatty acids are the main energy substrates for skeletal muscle cells. 
Fatty acids are the main fuel while glucose may also be used by the resting muscle. Under 
resting conditions, glucose transport is considered as the rate-limiting factor for glucose 
metabolism (Ziel, Venkatesan, & Davidson, 1988) and is mediated by glucose transporter 
(GLUT) 1 and 4 in skeletal muscle (Richter & Hargreaves, 2013). GLUT1 is involved mainly 
in basal glucose uptake while GLUT4 is involved in insulin-stimulated muscle glucose 
transport (Bryant, Govers, & James, 2002). FFAs are taken from the circulation into muscle 
either by protein-mediated transport or by passive diffusion (Van Hall, 2015). The most 
important proteins regulating fatty acid uptake in muscles are fatty acid translocase 
(FAT/CD36), fatty acid transport proteins (FATP 1-6) and, fatty acid binding proteins 
(FABP) (Van Hall, 2015). 
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1.2.2 Factors influencing muscle energy expenditure in obesity 
Skeletal muscle responses to exercise differ depending on the nature of the adaptive stimulus. 
For example, heavy resistance exercise (strength training) results in muscle hypertrophy with 
an increase in strength, without affecting biochemical adaptations. However, endurance 
exercise results in an increase in the capacity of muscle for aerobic metabolism that is 
mediated by an increase in mitochondria size and number in the skeletal muscle, without 
muscle hypertrophy or an increase in strength (Holloszy, 2008). Loss of muscle mass during 
aging or degenerative myopathy leads to metabolic syndromes (Biolo et al., 2014). Due to the 
large volume of skeletal muscles, their metabolism affects the metabolic condition of the 
whole organism. Skeletal muscle is the primary site of insulin resistance under many 
metabolic disease conditions, including T2D and obesity (DeFronzo and Tripathy, 2009).  
Skeletal muscle represents about 40% of the total body weight, which has a significant 
mitochondrial capacity and accounts for 30% to 50% of all body proteins. The main function 
of skeletal muscle is not only to provide movement, but also to regulate whole-body glucose 
and lipid metabolism as well as to maintain the body’s temperature. Skeletal muscle is one of 
the most significant sites for energy expenditure. It is well known that skeletal muscle 
produces heat after food intake, and different molecular studies have shown that the 
production of heat is caused by enhanced adaptive thermogenesis by changing cellular 
metabolism or function (Lowell & Spiegelman, 2000). It is also responsible for around 80% 
of whole-body glucose uptake in insulin-stimulated conditions (DeFronzo & Tripathy, 2009; 
O'Neill, 2013). Skeletal muscle is the main site for glucose clearance in the body, which 
occurs in response to insulin via the transduction of GLUT4 from the intracellular membrane 
to the cell surface. Then, glucose is either broken down and used for the production of ATP 
or stored as glycogen. Glucose uptake is important during exercise to provide the energy for 
working muscles and replenish the muscle glycogen store after exercise. 
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Triglyceride is stored as the major energy reserve in the body. Fatty acids come from the 
stored triglyceride through lipolysis (hydrolysis) and discharge into the blood as FFAs. FFAs 
are then transported to the muscle to be used as energy. During the post-absorptive state, 
FFAs oxidation provides energy for resting muscle (Richter, Kiens, Galbo, & Saltin, 2013). 
Excessive FFA released for oxidation in skeletal muscle inhibited insulin-stimulated glucose 
uptake and enhanced glucose production. Obese people are hyperinsulinaemic, and insulin is 
an inhibitor of lipolysis. Thus, the hyperinsulinaemia suppresses FFA turnover (Campbell, 
Carlson, & Nurjhan, 1994). Reduced fatty acid oxidation in skeletal muscle is associated with 
obesity, lipid accumulation, and insulin resistance (Oakes, Kjellstedt, Thalén, Ljung, & 
Turner, 2013). Muscle mass relies on the balance between protein synthesis and the 
degradation of nutritional status, physical activity, hormonal balance, and disease (Frontera & 
Ochala, 2014). Many factors trigger skeletal muscle metabolism, including chronic diseases, 
degenerative disorders, starving, overload, and strength training (Flück, 2006; Gosker et al., 
2002).  
The size of skeletal muscle is determined by the number and sizes of single muscle fibres, 
also known as myofibres or muscle cells. Muscle fibres (myofibres) are multinucleated, and 
post-division (mitotic), each nucleus within a muscle fiber regulates the type of protein 
synthesised in a specific area in the cell known as the nuclear domain. A muscle fiber is a 
striated cell and is surrounded by sarcolemma (cell membrane) and sarcoplasm (cytoplasm) 
(Frontera & Ochala, 2015). Muscle fibres are classified into type 1 and type 2. Type 1, also 
known as slow twitch (contraction), and oxidative fibres have many mitochondria, are insulin 
sensitive and generate ATP from oxidative metabolism. However, types 2, or fast contraction 
time fibres, are sub-classified into two sub-groups: type 2a, or fast twitch, and oxidative 
fibres, which have a metabolic nature similar to those of type 1 fibres. Type 2b, or fast twitch, 
and glycolytic fibres have low mitochondrial density and generate ATP from glycolytic 
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metabolism (Maltin, 2008). Some studies have shown that a relationship exists between 
muscle fiber type and obesity. One study observed that obese people have more type 2b 
muscle fibres and fewer type 1 muscle fibres (Hickey et al., 1995). Type 2 muscle fibres have 
more myoblasts per myofibres (Akhmedov & Berdeaux, 2013). Myotubes with low nutrient 
conditions are associated with increased NAD+ levels, which stimulate deacetylase sirtuin 1 
(SIRT1) activity. SIRT1 promotes myoblasts proliferation and prevents myogenic 
differentiation via myoblasts determination protein (MyoD) deacetylation. However, obesity 
and high nutrients would not maintain quiescent satellite cells for proliferation after injury. 
Obesity dys-regulates the balance between muscle growth and muscle atrophy (Akhmedov & 
Berdeaux, 2013). 
1.2.3 Cellular mechanism of muscle energy metabolism in relation to obesity 
1.2.3.1 Mitochondria oxidative phosphorylation in muscle 
Mitochondria are organelles that oxidise the substrates from the Krebs cycle to generate 
energy; this process is called oxidative phosphorylation (OXPHOS). OXPHOS is one of the 
key functional units in energy metabolism, combining electron transport chain (ETC) with 
ATP synthase and cell respiration. ETC located within the mitochondria inner membrane. 
ETC is composed with four different complexes, including complex I (CI, NADH ubiquinone 
oxidoreductase), complex II (CII, succinate ubiquinone oxidoreductase), complex III (CIII, 
ubiquinol cytochrome c oxidoreductase) and complex IV (CIV, cytochrome c oxidase). ATP 
synthase (complex V, CV) synthesized ATP from ADP in the mitochondrial matrix from the 
energy provided by the proton electrochemical gradient from ETC (Hüttemann, Lee, 
Samavati, Yu, & Doan, 2007). Mitochondria biogenesis, degradation, and different shapes, 
including fission and fusion, are integrated with one another to maintain proper OXPHOS. 
Metabolic change from glycolysis to OXPHOS is a major source of energy during muscle 
differentiation. ATP production from the mitochondria depends on the ETC, and 
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mitochondria protein production inhibition is correlated with impairment in cell 
differentiation. Thus, mitochondrial enzyme activity is linked to muscle differentiation. It is 
known that skeletal muscle from diabetic people with obesity or severely obese mice have an 
impairment of mitochondrial function, which is due to low mitochondrial content (Bollinger, 
Powell, Houmard, Witczak, & Brault, 2015). Several lines of evidence have associated 
mitochondrial defects with obesity and insulin resistance suggesting that mitochondria are 
key players in maintaining energy homeostasis (Gonzalez-Franquesa, De Nigris, Lerin, 
Garcia-Roves, & Cseri, 2012). There are many factors that can regulate energy metabolism in 
skeletal muscle, including those that will be discussed below. 
1.2.3.2 Role of fatty acid β-oxidation in muscle 
The relationship of lipid metabolism in skeletal muscle with obesity rests largely on fatty acid 
oxidation (FAO). This is because skeletal muscle is a major site in the body for FAO but does 
not contribute to fatty acid synthesis. A reduction in FAO is linked with lipid accumulation 
and insulin resistance in skeletal muscle of obese people (Kelley, Goodpaster, Wing, & 
Simoneau, 1999). FAO can occur in different forms: α, β, and γ. FAO is the main pathway 
for oxidising fatty acids for energy metabolism, and this occurs in mitochondria.  
FAO represents 80% of energy from the liver and heart. The oxidation of fatty acids in the 
liver provides the synthesis of ketone bodies, acetoacetate, and 3-hydroxy butyrate, which are 
other energy sources for the brain. Long-chain fatty acid oxidation is important in cellular 
homeostasis, which is involved in different physiological processes, such as cell signalling 
and phospholipid synthesis. It provides energy for thermogenesis in brown adipose tissue 
(Rinaldo, Matern, & Bennett, 2002).  
1.2.3.3 Post-translational regulation: AMPK 
AMPK is 5-adenosine monophosphate-activated protein kinase enzyme that acts as a cellular 
energy sensor to regulate energy expenditure (Stapleton et al., 1996). AMPK is expressed in 
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many tissues, such as brain, liver, adipose tissue, and skeletal muscle. There are various 
hormones, such as adiponectin, and leptin, in skeletal muscle and adipose tissue that can 
activate AMPK. AMPK can also be activated to regulate energy metabolism through changes 
in the AMP/ATP ratio and the cellular Ca2+ concentration (B. B. Zhang, Zhou, & Li, 2009). 
AMPK is activated in skeletal muscle during muscle contraction or increased energy demand 
(Steinberg et al., 2006). AMPK in skeletal muscle can regulate different metabolic processes, 
such as mitochondria biogenesis, glucose transport, glycogen synthesis, and FAO (O'Neill, 
2013). It regulates FAO via malonyl-CoA signaling. Malonyl-CoA is an inhibitor of the 
mitochondria enzyme carnitine palmitoyltransferase1 (CPT-1), which controls the transfer of 
long-chain fatty acids into the mitochondria (Lage, Diéguez, Vidal-Puig, & López, 2008). 
AMPK activates malonyl-CoA decarboxylase to stimulate FAO (Saha et al., 2000). AMPK 
mediates glycogen synthase enzyme, which represents the last step of glycogen synthesis. It 
has also been found that AMPK regulates the transcriptional co-activator PPARᵧ co-activator-
1α, which promotes mitochondria biogenesis (D. Grahame Hardie, 2011). Glucose transport 
can be promoted through AMPK by increasing the translocation of the GLUT4 to the plasma 
membrane of cells (Fryer et al., 2002).  
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Figure  1-4 Regulation of fuel metabolism by AMPK in skeletal muscle (Long & Zierath, 
2006). 
During exercise and glucose deprivation, AMPK translocates glucose uptake through GLUT4 
(glucose transporter). AMPK stimulates mitochondrial biogenesis through peroxisome 
proliferator-activated receptor-gamma coactivator (PGC)-1α and fatty acid oxidation by 
phosphorlyating and inhibiting acetyl-CoA carboxylase (ACC2). P; phosphorlyation. 
 
1.2.3.4 Role of mitochondria biogenesis in muscle 
Mitochondria biogenesis is the result of interactions between the mitochondrial nuclear and 
genomes to form new mitochondria in the cell. It is well known that physical exercise and 
different types of environmental stress, such as oxidative stress, low temperature, caloric 
restriction, cell division, and differentiation increase mitochondrial content in muscle 
(Jornayvaz & Shulman, 2010; Lanza & Nair, 2009). Mitochondrial biogenesis is 
accompanied not only by number but also by size and mass (Jornayvaz & Shulman, 2010). 
Many studies have shown that mitochondrial biogenesis is an important process for muscle 
development (Remels et al., 2010; Romanello & Sandri, 2015). Thus, enhancing or 
suppressing mitochondrial biogenesis alters myogenic differentiation in cells and animal 
models (Jornayvaz & Shulman, 2010; Kraft et al., 2006). Lower levels of mitochondrial 
biogenesis markers, such as peroxisome proliferator-activated receptor-gamma coactivator 
(PGC)-1α and nuclear respiratory factor 1 (NRF-1), exist in the skeletal muscle of obese 
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people with T2D (Russell, Foletta, Snow, & Wadley, 2014). As reviewed below, a number of 
factors play important roles in the regulation of mitochondrial biogenesis. 
1.2.3.4.1 PGC1α 
Peroxisome proliferator-activated receptor-gamma (PPAR-γ) coactivator-1 alpha (PGC1α) is 
a family member of transcription co-activators that play a role in the regulation of cellular 
energy metabolism. PGC1α mediates mitochondrial biogenesis by activating nuclear 
respiratory factors (NRFs) -1 and 2 as well as fibre-type switching, which is more oxidative 
and less glycolytic. NRFs-1 and 2 regulate the expression of mitochondrial transcription 
factor A (TFAM), also known as mtTFA (Jornayvaz & Shulman, 2010). PGC1α participates 
in the regulation of mitochondrial biogenesis through these transcription factors. PGC1α is 
under the regulation of AMPK. It has been suggested that activation of AMPK such as by 
exercise increases mitochondrial biogenesis via an upregulation of PGC1α (Jäger, Handschin, 
Pierre, & Spiegelman, 2007). It has been shown that there was no change in the level of the 
PGC1α protein expression in muscle from c-Cbl KO mice (Molero et al., 2004), reviewed in 
(Section 1.5.3). 
1.2.3.4.2 TOM20 
Up to 150 proteins are present in the mitochondria, of which most are encoded by 
mitochondria deoxyribonucleic acid (DNA), synthesised as preproteins on the ribosomes in 
the cytosol targeting the mitochondria, and imported into the organelle. These proteins are 
recognised by receptors on the mitochondria surface that translocate in the outer (TOM20) 
and inner mitochondria membranes, which mediate the import and intra-mitochondrial 
proteins’ organisation. ATP and the membrane are likely used as energy sources. TOM20 
was used in different biological experiments to check mitochondrial fraction purity (Yano et 
al., 1998). It has been shown that there is an increase in TOM20 expression when skeletal 
muscle undergoes mitochondrial biogenesis (Takahashi, Chesley, Freyssenet, & Hood, 1998). 
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Lack of TOM20 causes a reduction in mitochondrial oxidative phosphorylation, protein 
synthesis, and cell growth (Grey et al., 2000). These reports indicate TOM20 is essential for 
mitochondrial biogenesis and metabolic function. However, there is no study showed the 
effect of c-Cbl (reviewed in Section 1.5.3) on TOM20. 
1.2.3.5 Role of mitochondria dynamic in OXPHOS 
Mitochondrial dynamics (fusion and fission) play an essential role not only in the regulation 
of mitochondrial morphology but also in different bioenergetics and mitochondrial 
maintenance (Otera, Ishihara, & Mihara, 2013). The frequencies of fission and fusion are a 
balance to maintain mitochondrial morphology (Jheng et al., 2012). Also, they contribute to 
mitochondrial responses to stress and quality control to maintain mitochondrial homeostasis. 
Mitochondrial dynamics are associated with the regulation of reactive oxygen species (ROS) 
(B. Kim et al., 2013). A defect in mitochondrial morphology regulation is linked to many 
metabolic diseases, such as obesity, diabetes and myopathies (Wallace, 2005). 
1.2.3.5.1 Mitochondrial fission 
Mitochondrial fission, also known as mitofission, is important for sustaining mitochondrial 
metabolic functions. Mitochondrial fission is mediated by dynamic-like protein (Drp1) in 
mammals and fission protein 1 (Fis 1). Drp1 is a cytosolic protein that is recruited to 
mitochondria during fission. DRP1 is a member of the GTPase family, which has different 
membrane fission proteins. Mitochondrial fission separates depolarised mitochondrial 
sections; the dysfunctional mitochondria are isolated from respiration active mitochondria 
within the cells and are then eliminated by mitophagy (Otera et al., 2013). Knocking down 
DRP1 in H2c9 and HL-1 (cardiac cells) reduces hyperglycaemia-induced apoptosis and even, 
prevents formation of reactive oxygen species (ROS) during increased glucose levels (Twig 
& Shirihai, 2011). Kim et al. (2013) found that during the differentiation of C2C12 
myoblasts, total DRP1 expression increased gradually and phosphorylation (activation) of 
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DRP1 at Ser-637 decreased. Also, inhibition of DRP1 leads to impaired myotube formation, 
which is associated with apoptosis and impaired mitochondrial biogenesis (B. Kim et al., 
2013). These findings suggested that mitochondrial fission is essential for myogenic 
differentiation. 
1.2.3.5.2 Mitochondrial fusion 
Mitochondria change their shapes depending on cell physiology, environment, pathologic 
condition, and developmental stage. Mitochondria are dynamic and fuse to allow efficient 
mixing of mitochondria contents, leading to protein complementation, equal distribution of 
metabolites, and mtDNA repair. Mitofusion proteins are regulated by two outer 
mitochondrial membranes (OMM), mitofusin 1 (MFN1) and mitofusin 2 (MFN2) proteins, 
and one inner mitochondrial membrane (IMM), optic atrophy 1 (Opa1) (A. Hall, Burke, 
Dongworth, & Hausenloy, 2014). Lack of MFN1 or MFN2 in mice resulted in severly 
fragmented mitochondria (Hsiuchen Chen et al., 2003). A defect in mitochondrial fusion 
results in mitochondria dysfunction and the loss of respiratory capacity (Seo et al., 2010). 
MFN2 expression is an important factor in mitochondrial metabolism. MFN2 is induced 
during myogenesis, and contributes to the operation and maintenance of the mitochondrial 
network. Skeletal muscle of obese subjects and T2D subjects showed low expression levels 
of MFN1 and MFN2 compared to lean subjects (Bach et al., 2005; Bach et al., 2003). 
1.2.3.6 Role of mitophagy in mitochondrial function 
Protein degradation is also an important regulator for skeletal mass and function. The protein 
mostly degraded by the ubiquitin-protease system (UPS) or the autophagic/lysosomal system. 
Mitophagy is the elimination of dysfunctional, depolarised mitochondria by autophagic 
machinery through fission and fusion processes. Sometimes mitophagy removes functional 
mitochondria under some physiological settings. There are two forms of autophagy: selective 
autophagy, which removes misfolded proteins and damaged mitochondria, and nonselective 
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autophagy, which is stimulated by starvation. Mitophagy in mammalian cells is regulated 
mainly by the cytosolic E3 ubiquitin ligase Parkin (VásquezǦTrincado et al., 2016). Inhibition 
of Atg7, which is one of theautophagy-related genes (Atgs), leads to increased oxidative 
stress in mice embryonic fibroblast cells (MEFs), reduced mitochondrial respiration in mice 
skeletal muscle, and induced insulin resistance (Twig & Shirihai, 2011). Reduction of 
autophagic activity is found in the liver of obese mice (Ding & Yin, 2012). Bollinger et al. 
(2015), reported that the flux through major protein degradation pathways is decreased in 
obese human skeletal muscle (Bollinger et al., 2015).  
1.2.4 Muscle formation/regeneration and obesity 
Several recent studies suggest a link between abnormal muscle formation and obesity 
(Akhmedov & Berdeaux, 2013; M. Du, Yan, Tong, Zhao, & Zhu, 2010; Nguyen, Cheng, & 
Koh, 2011). The complexity of the muscle regeneration process in repairing damaged muscle 
tissue and subsequent formation of new muscle fibres has been known for many years 
(Charge & Rudnicki, 2004). Damage is known to be induced by excessive exercise, trauma, 
diseases and myotoxic agents (Z. Hu et al., 2010; Tedesco, Dellavalle, Diaz-Manera, 
Messina, & Cossu, 2010). In obesity and diabetes models, skeletal muscle regeneration is 
significantly impaired due to impaired muscle progenitor cell function (Akhmedov & 
Berdeaux, 2013). Also, impairment in muscle growth after injury is found in obese ob/ob and 
db/db mice but not in mice fed a high-fat diet. This is due to leptin signaling as ob/ob and 
db/db mice are deficient in leptin signaling (Nguyen et al., 2011). Thus, leptin signaling is 
important for muscle regeneration. Repair and growth (regeneration) of skeletal muscle is 
linked to the action of myogenic satellite cells (myoblasts). During the activation of these 
cells, they will proliferate, differentiate, and fuse with myotubes/myofibers (Remels et al., 
2010). Skeletal muscle maintenance depends on continuing muscle regeneration, repair, and 
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growth, which decline with aging. Muscle regeneration is linked with an increase in 
mitochondria enzyme activity (Wagatsuma & Sakuma, 2013).  
Myoblasts proliferate to increase the number of another type of cells, myotubes through 
differentiation. Deregulation of this process may lead to cancer (Agathocleous & Harris, 
2013). Myoblasts have low energy demands, low ATP production, and low oxygen 
consumption (Akhmedov & Berdeaux, 2013). Obesity increases aging and lipid overload that 
impairs muscle cell regeneration and maintenance through different factors. Factors that 
impair muscle regeneration under the condition of obesity are the accumulation of toxic lipid 
metabolites and low-grade inflammation (Akhmedov & Berdeaux, 2013). Many studies 
showed that load-induced hypertrophy in humans and rodents requires myoblast activation, 
proliferation, and fusion with exciting myotubes (Hindi, Tajrishi, & Kumar, 2013), while 
recently they found that hypertrophy does not require myoblasts to fuse to myotubes 
(McCarthy et al., 2011). Therefore, skeletal muscle regeneration in obese animals after injury 
reduced recovery of muscle mass and function in response to mechanical overload (Jackson 
et al., 2012; McCarthy et al., 2011). Cbl-b (reviewed in Section 1.5.1) has been shown to play 
a role in muscle wasting in response to mechanical overload (Nakao et al., 2009). 
Muscle differentiation/ myogenesis is where clusters of myoblasts (satellite cells) fuse to 
form small multi-nucleated cells called myotubes, which are 0.1-0.3mm in length (Lieber, 
2002). Myogenic differentiation begins during embryonic development and in the 
regeneration of muscle after injury/stress. Myoblasts often proliferate and sometimes migrate 
to express muscle regulatory factors (MRFs), and then they enter the cell cycle to 
differentiate and produce myotubes. Differentiation starts by targeting the main regulators of 
myogenic differentiation as myogenin, which is an MRF required for differentiation, and 
myocyte enhancer factor 2 (MEF2) (Yun & Wold, 1996). This process is regulated by growth 
factors and hormones, platelet-derived growth factor and fibroblast growth factors. 
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Mitochondria activity and function increase during muscle differentiation (Wagatsuma & 
Sakuma, 2013). Differentiation was measured by numbers of myofibres, expression of 
myogenin, myoD, and myosin heavy chain (MHC) (Tamilarasan et al., 2012). Fatty acids or 
lipid metabolites reduce expression of myogenic transcription factors during myoblasts 
differentiation. Thus obesity can affect myoblasts and myofibres directly. Blocking 
mitochondrial biogenesis reduces myogenic differentiation (Remels et al., 2010). There is no 
study showed the effect of c-Cbl in myogenesis. 
1.3 Insulin resistance in muscle 
In addition to the contribution to whole-body energy metabolism, skeletal muscle is a major 
organ for insulin action to control glucose homeostasis. Insulin resistance in skeletal muscle 
is a fundamental metabolism disorder in obesity and T2D (DeFronzo & Tripathy, 2009; 
Eckardt, Taube, & Eckel, 2011; J. Yang). 
Insulin is an anabolic hormone that is secreted from the β cells in the pancreas’ in response to 
high blood glucose after food intake, and it affects many biological processes. Insulin plays 
the most important role in blood glucose and lipid homeostasis. Different tissues are 
responsible for insulin action in terms of blood glucose regulation, including the stimulation 
of glucose uptake in skeletal muscle and adipose tissue and the inhibition of glucose 
production in the liver to lower the glucose level in the bloodstream (Figure 1-5). 
Insulin regulates glucose uptake into the cells by translocating GLUT4 from the cytosol to the 
cell surface through the IRS-PI3K-AKT pathway in skeletal muscle (Rowland, Fazakerley, & 
James, 2011). Insulin does not merely promote glucose transport but also regulates protein, 
triglycerides, and glycogen metabolism in adipose and skeletal muscle tissues. It also 
regulates the uptake of fatty acids and amino acids from the blood-stream to synthesise lipids 
and proteins (Dimitriadis, Mitrou, Lambadiari, Maratou, & Raptis, 2011). 
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In the liver, insulin stimulates the storage of glucose in the form of glycogen and suppresses 
glucose production. Insulin also promotes fatty acid synthesis and inhibits intracellular lipase 
that catalyses triglyceride to produce fatty acids and glycerol. Glycerol from the adipose 
tissue and FFAs from the liver are used to produce triglyceride in the adipocytes.  
Insulin enhances glucose uptake and storage in skeletal muscle. It plays a role in cellular 
growth, survival, and differentiation (Scavo, Karas, Murray, & Leroith, 2004). Thus, insulin 
resistance can lead to different metabolic actions; Figure 1-5 demonstrates this. 
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Figure  1-5 Insulin resistance in the whole-body. 
Insulin resistance inhibits glucose uptake in skeletal muscle, increases gluconeogenesis and 
glycogenolysis in the liver, which leads to hyperglycaemia. Insulin resistance also promotes 
lipolysis in adipose tissue, which increases the production of FFA and glycerol. 
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1.3.1 Insulin signaling pathways 
Circulating insulin provides a combined set of signals that allows for available nutrient 
balance and caloric demand. Insulin with the opposing hormone glucagon maintains glucose 
homeostasis to ensure proper function.  
1.3.1.1 The IRS/PI3K/AKT pathway 
Insulin signaling begins by binding insulin to an insulin receptor (IR) with the sub-family of 
the receptor tyrosine kinase, which includes insulin receptor-related receptor (IRR) and 
insulin-like growth factor (IGF)-1 receptor. The binding of the insulin results in an auto-
phosphorylation of insulin receptor substrates (IRS) (Saltiel & Kahn, 2001). There are two 
subunits: IRS1 and IRS2 (White & Kahn, 1994). IRS1 and IRS2 are the most important 
substrates involved in the regulation of lipid and glucose homeostasis. Deficient IRS1 protein 
mice are insulin resistant (Araki et al., 1994; Saltiel & Pessin, 2002; Tamemoto et al., 1994), 
while animals with deficient IRS2 have both diabetes and impaired glucose tolerance 
(Kadowaki, 2000; Withers et al., 1998). Excessive accumulation of fat, particularly ceramides 
and DAG, can interfere with the activation of this insulin signaling pathway in metabolic 
tissues, including skeletal muscle and liver (Delarue & Magnan, 2007). 
The phosphatidylinositol 3-kinases (PI3Ks) are involved in different physiological processes, 
such as insulin-mediated glucose transport in the skeletal muscle (Shepherd et al., 1997) as 
well as adipocytes (Lund, Holman, Schmitz, & Pedersen, 1995). Further, they also control 
cell death and survival, protein synthesis, metabolism, proliferation, and migration 
(McNamara & Degterev, 2011). There are three classes of PI3Ks. The class 1 PI3Ks is a 
heterodimeric protein which comprises a p110 catalytic subunit and a p85 regulatory or 
adapter subunit (Cantrell, 2001; McNamara & Degterev, 2011; Saltiel & Kahn, 2001). The 
class 1 PI3Ks plays an essential role in glucose homeostasis and insulin signaling (Rameh & 
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Cantley, 1999). The class II PI3Ks is a catalytic domain that mediates calcium/lipid binding. 
Class III PI3Ks are typified by the yeast protein to regulate vesicle transport.  
1.3.1.2 The CAP/Cbl/TC10 pathway 
It has been proposed that the CAP/Cbl/TC10 pathway mediates insulin signaling along with 
the intracellular phosphatidylinositide 3-kinases (P13K-AKT) signaling pathway. Insulin 
stimulates insulin receptors that recruit and phosphorylate Cbl protein by an adaptor with 
pleckstrin homology and Src homology-2 domains (APS). The phosphorylation of Cbl leads 
to elimination of the CAP/Cbl complex from the insulin receptor, which then activates TC10. 
TC10 is a small signaling binding protein which is around 21kD and belongs to the Rho 
family. TC10 controls the translocation of GLUT4 with PI3K. This activation leads to the 
translocation of c-Cbl to lipid rafts. It is dependent on binding c-Cbl to CAP. CAP functions 
as an adaptor protein for Cbl, which is expressed in insulin-sensitive tissues. CAP binds c-Cbl 
via flotillin, a lipid raft protein, and SH3 domains. CAP interacts with the proline-rich 
domain through the carboxylterminal Src-3 homology domain (Saltiel & Kahn, 2001). It has 
been shown that the CAP/Cbl/TC10 pathway is activated in adipocytes (Baumann et al., 
2000) and cardiac muscle and functions to regulate glucose transport, a process that is 
impaired in obesity and diabetes (Gupte & Mora, 2006). However, Molero et al. (2004) 
showed that c-Cbl does not have an effect on insulin signaling. c-Cbl knockout (KO) mice 
exhibit an increase in whole-body energy expenditure, an improvement in the insulin action 
as the phosphorylation of AMPK and acetyl-CoA (ACC) were high, and a lower adiposity. 
1.3.2 Lipid-induced insulin resistance 
Obese people are generally insulin resistant, which includes the impairment of glucose output 
by the liver and the promotion of glucose uptake in adipose tissue and muscle. Insulin 
resistance is the hallmark of metabolic diseases such as T2D (Bonora et al., 2002). Different 
mechanisms contribute to insulin resistance in skeletal muscle, including intracellular lipid 
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derivatives accumulation, impaired gene transcription, endoplasmic reticulum stress, and 
proinflammatory signals (Gonzalez-Franquesa et al., 2012).  
It has been suggested that fatty acids, which are markedly increased in obesity and associated 
diseases, play an important role in the development of insulin resistance in skeletal muscle 
(Shulman, 2000). Prolonged exposure to high levels of fatty acids in skeletal muscle caused 
severe insulin resistance (Griffin et al., 1999). Among the different types of fatty acids, 
saturated long-chain fatty acids such as palmitic acids have been demonstrated as potent 
inducers of insulin resistance (Hirabara, Curi, & Maechler, 2010).  
The inverse relationship between fatty acid availability and glucose utilisation was the first 
mechanistic explanation proposed by Randle et al. also known as the glucose-fatty acid cycle 
or Randle’s cycle (Randle, Garland, Hales, & Newsholme, 1963). They found that an 
elevation in the supply of fatty acids to the isolated heart is associated with an elevation in 
FAO and impairment in glucose utilisation and glycolytic flux. An elevation of FAO raises 
the production of acetyl-CoA, which leads to a reduction in pyruvate dehydrogenase activity 
and an elevation of citrate levels in the tricarboxylic acid cycle. Citrate with an elevation ratio 
of ATP/ADP reduces the activity of phosphofructokinase and glucose flux through the 
glycolytic pathway. Thus glucose 6-phosphate and cellular glucose content are accumulated 
and hexokinase II is reduced, leading to a reduction in glucose uptake (Dresner et al., 1999). 
In contrast to Randle’s cycle, in which intracellular glucose accumulation leads to glucose 
uptake inhibition, further studies demonstrated that insulin resistance induced by fatty acids is 
the primary cause of impaired glucose uptake rather than changes in hexose metabolism 
(Dresner et al., 1999; Griffin et al., 1999). 
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1.3.3 Lipid accumulation in skeletal muscle 
Lipids in skeletal muscle have been extensively studied in relation to insulin sensitivity. 
Moreover, lipid accumulation in skeletal muscle also affects muscle maintenance and 
regeneration. Lipids in skeletal muscle include two different types; extramyocellular lipid 
(EMCL), located in adipocyte between myofibres, and intramyocellular lipids (IMCL), 
located within myocytes (Sinha et al., 2002). While several mechanisms are responsible for 
lipid accumulation within skeletal muscle, the major mechanisms are reduced FAO by 
muscle mitochondria and increased fatty acid uptake from circulation into muscle (Turner et 
al., 2007). Many forms of lipids accumulate in skeletal muscle, which may cause the 
development of insulin resistance, including FFAs, DAGs, triglycerides, long-chain fatty 
acyl-CoA, and ceramides. 
Elevated levels of plasma FFAs are linked to several physiological conditions, including 
obesity, insulin resistance, and T2D. It has been reported that elevated plasma FFA levels 
affect about 50% of obese people with T2D (Boden, 2008). Elevations of plasma FFA inhibit 
insulin stimulated-glucose uptake, glycogen synthesis and insulin signaling in skeletal 
muscle. 
Intracellular fatty acid accumulation impairs muscle cells differentiation. Increased fatty acid 
uptake leads to increased ectopic lipid accumulation in skeletal muscle, which leads to 
lipotoxicity, known to impair muscle insulin sensitivity (Jheng et al., 2012). Fatty acyl-CoA 
and DAG levels, which activates protein kinase C (PKC-θ) leads to decreased IRS-1 tyrosine 
phosphorylation, which results in decreased insulin-stimulated glucose transport activity 
(Samuel & Shulman, 2012). 
Diacylglycerol (DAG) is a simple hydrophobic lipid that is composed of glycerol and two 
fatty acyl groups, and it can be stored in a lipid droplet. DAG oil can be synthesised by 1, 3 
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specific lipase. This enzyme has the ability to improve β-oxidation and weight loss, as well as 
suppress fat accumulation and decrease triacylglycerol levels (Rudkowska et al., 2005). The 
accumulation of DAG can impair the insulin signalling pathway by activating PKC family, 
which physically work together with membrane-embedded DAG. DAG kinase δ (DAGKδ) 
activity is associated with obesity-related insulin resistance in skeletal muscle (Finck & Hall, 
2015). 
Obesity leads to elevated levels of TG, which cause fat accumulation (ectopic fat deposition) 
or steatosis (Van Herpen & Schrauwen-Hinderling, 2008). TG is hydrolysed to FFAs and 2-
monoacylglycerol (MAG) by lipase in intestine lumen. It has been shown that the 
accumulation of intramuscular TG is associated with insulin resistance, and it can also 
interfere with the insulin signaling pathway by supplying DAG and LCACoAs (Holloway, 
Han, Jain, Bonen, & Chabowski, 2014). The elevated TGs content and lipid droplets within 
muscle fibres has been detected in muscle biopsies obtained from obese people (Malenfant et 
al., 2001). 
Long-chain acyl-CoAs (LCACoAs) play a role in lipid metabolism and in the regulation of 
different cellular functions. They are the activated forms of FFAs and are produced by acyl-
CoA synthase. LCACoAs inhibit muscle glucose utilisation through the activation of PKC 
directly or via the generation of DAG, which interferes with the insulin signaling pathway 
(Hegarty, Furler, Ye, Cooney, & Kraegen, 2003; Houmard et al., 2002).  
Ceramides are composed of sphongnosine and fatty acids. Sphongnosine is the essential 
molecule of the sphingolipid pathway that serves as a messenger for proliferation, 
differentiation, and apoptosis (Mebarek et al., 2007). Ceramide synthesis results from the 
hydrolysis of sphingomyelin through sphingomyelinases or ceramide synthases. They can be 
found in cell membranes and are involved in many biological processes, such as cell growth, 
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adhesion, migration, differentiation, and apoptosis. Ceramide accumulation has been found in 
insulin-resistant tissues, which inhibits insulin action through the inactivation of protein 
kinase B (PKB), also known as AKT. Elevated levels of plasma ceramide concentration are 
an indicator of T2D, which can lead to insulin resistance and inflammation (Haus et al., 
2009). Mice fed a high-fat diet for 12 weeks showed an elevated level of plasma FFAs, 
DAGs, and ceramides in muscle, while they did not show an increase in proteolysis, 
apoptosis, and autophagy in muscle (Turpin et al., 2009). Ceramide involved in muscle 
wasting, which is associated with elevated levels of proinflammatory cytokines, such as 
TNFα and interleukin-1β (IL-1β). 
 
Figure  1-6 Lipid-induced insulin resistance in skeletal muscle. 
Insulin activates the insulin receptor tyrosine kinase, which subsequently tyrosine 
phosphorylates IRS1. Through many steps, this leads to activation of AKT2. AKT2 
activation promotes the translocation of GLUT4 to the plasma membrane permitting the entry 
of glucose into the cell and promoting glycogen synthesis. Diacylglycerol (DAG) mediated 
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activation of PKCθ and subsequent impairment of insulin signaling, as well as ceramide 
impair AKT2 (Samuel & Shulman, 2012).  
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1.4 Prevention and treatment of obesity 
Obesity prevention and/or treatment can be classified into three categories. The first one is 
lifestyle interventions, including increased physical activity and reduced food intake. A large 
body of clinical evidence suggests that calorie restriction alone, or combined with physical 
exercise, is an effective method for weight loss (Sweeney, Hill, Heller, Baney, & 
DiGirolamo, 1993; Wadden, 1993). However, calorie restriction can be difficult to adhere to, 
because of the lack of satiety suppression and loss of ghrelin (Williams et al., 2006). Diet 
modification could improve the adherence to calorie restriction. It has been reported that 
Mediterranean diets are inversely associated with obesity and related metabolic diseases (Da 
Silva et al., 2009). However, the ketogenic diet, which contains low levels of carbohydrates, 
high levels of fat, and moderate levels of protein, is an effective nutritional method for 
reducing obesity by suppressing appetite (Yancy, Olsen, Guyton, Bakst, & Westman, 2004). 
In terms of energy expenditure, physical activity is the main lifestyle intervention in which 
the increased energy expenditure largely comes from skeletal muscle. The guideline of 
physical activity for adults is 30 minutes of moderate activity daily. However, this guideline 
is not sufficient for obese people, who require 45 to 60 minutes of moderate activity daily 
(National Institute for Health and Care Excellence, 2014). 
The second category of obesity treatment is surgical methods, including bariatric surgery or 
weight loss surgery. The most commonly used techniques are gastric bypass, sleeve 
gastrectomy, and gastric banding. The surgical method has the greatest long-term effect, but 
is suitable only for very obese individuals with a BMI greater than 40 kg/m2 or with a BMI of 
35 kg/m2 with obesity-related disorders (Padwal, Rucker, Li, Curioni, & Lau, 2010). It has 
been reported that 50% of T2D patients can maintain normal glycaemia for five years follow-
up after gastric bypass surgery (Mingrone et al., 2015). However, these surgeries require 
adherence to dietary recommendations and supplementations with vitamins and minerals. It 
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has been reported that bariatric surgery increases morbidity rate (Healy, Clarke, Reynolds, 
Arumugasamy, & McNamara, 2016). Thus bariatric surgeries are not used as the first option 
for the treatment of obesity.  
The third category is pharmacological methods, or drug therapy. This therapy is suitable for 
people with BMI ≥ 30 kg/m2 with one or more obesity-related disease (Hainer, Toplak, & 
Mitrakou, 2008). Anti-obesity drugs, which reduce energy intake, can be divided into three 
classes based on Food and Drug administration (FDA) approval for long-term therapy: drugs 
that suppress appetite, increase satiety, and increase thermogenesis. These drugs act by 
modifying norepinephrine, dopamine, and serotonin in the central nervous system 
(Mohamed, Ibrahim, Elkhayat, & El Dine, 2014). Sibutramine is a widely used drug 
approved for a long-term use which inhibits re-uptake of serotonin and norepinephrine to 
suppress appetite. The most common side effects of this drug are increases in blood pressure 
and heart rate (Bray, 2000). Also, it can increase renergic activity, which leads to dry mouth, 
headache, insomnia, and constipation (Padwal et al., 2010). Drugs that inhibit fat absorption, 
such as Orlistat, can be used, but they have many side effects such as fat malabsorption, 
which leads to steatorrhea, bloating, oily discharge, and fecal incontinence (Padwal et al., 
2010). These drugs are specifically for decreased energy intake. However, because of the 
unacceptable side effects and inadequate long-term effects, these drugs have thus far met with 
limited success. 
Anti-obesity targeting energy expenditure is an alternative strategy that could be used. 
Dinitrophenol, a non-selective uncoupler of mitochondrial oxidation, increased energy 
expenditure that could be sustained without tolerance. While it provides the proof-of-
principle for the treatment of obesity by stimulating energy expenditure in various tissues 
including skeletal muscle, dinitrophenol has many side effects that preclude its use as therapy 
(Goldgof et al., 2014). It has been suggested that browning of white adipose tissue can 
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increase the energy expenditure and ameliorate obesity and associated metabolic diseases 
(Kusminski, Bickel, & Scherer, 2016). It has been shown in many rodent models that 
increased browning of the white adipose tissue was able to protect against diet-induced 
obesity and insulin resistance, and the metabolism was improved (Vegiopoulos et al., 2010; 
L. Ye et al., 2012). Therefore, brown fat and the induction of brown fat like properties in 
white fat, have been considered as a target for preventing obesity (S. H. Kim & Plutzky, 
2016).  
Thus, most of the targets have been focused on the processes that are involved in adaptive 
thermogenesis for targeting energy expenditure. So, there is a need to find the right cellular 
target for skeletal muscle to develop novel anti-obesity drugs in humans. 
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1.5 Cbl in obesity and associated diseases 
1.5.1 The Cbl family and functions 
Casitas b-lineage lymphoma (Cbl) is an ubiquitin ligase and multi-functional adaptor protein 
that is implicated in the regulation of signal transduction in different cell types and in 
response to different stimuli. It is a negative regulator for receptor tyrosine kinase (RTKs) 
protein. c-Cbl was originally recognised as a cellular homologue of v-Cbl, which is the 
transforming gene of the Cas NS-1 murine retrovirus that leads to different diseases, such as 
pro-B-cell lymphoma and myeloid leukaemia in mice, and converts different fibroblast cell 
lines (Langdon, Hartley, Klinken, Ruscetti, & Morse, 1989). Two other mammalian family 
members, Cbl-b and Cbl-3/Cbl-c have been identified (Rao, Dodge, & Band, 2002; Smit & 
Borst, 1997). Three proteins are encoded by different genes: c-Cbl (a.k.a CBL2, RNF55), 
Cbl-b (a.k.a RNF56) and Cbl-c (a.k.a. Cbl-SL, RNF57) (Kales, Ryan, Nau, & Lipkowitz, 
2010). 
c-Cbl is a 120 kD protein with 355 N-terminal amino acids that comprises different molecular 
domains. The cellular form of c-Cbl matches 906 proteins in humans and 913 in mice. The 
Cbl protein is localised in the cell membrane, cytoskeleton (Swaminathan & Tsygankov, 
2006), and cytoplasm. c-Cbl mRNA has been shown in different tissues, including the brain, 
lung, heart, and spleen, and most abundantly in the testes and thymus as well as the 
hematopoietic cell lines. The c-Cbl protein has been found in mast cells, primary 
macrophages, osteoclasts, osteoblasts, platelets, epithelial cells, fibroblasts, adipocytes, and 
smooth muscle cells (Tsygankov, Teckchandani, Feshchenko, & Swaminathan, 2001). All 
Cbl proteins contain an N-terminal transforming region (Cbl-N), which comprises a tyrosine 
binding domain (TKB) and a C-terminal region (Cbl-C) (Figure 1-6). The Cbl-C region 
contains a Really Interesting New Gene (RING) finger E3 ubiquitin ligase activity that 
promotes ubiquitylation by adding a single ubiquitin (monoubiquitination) to the substrate or 
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on different sites on the substrates (multi- monoubiquitination) or on one or more lysines on 
the substrate (polyubiquitination) (Mohapatra et al., 2013). This leads to subsequent 
degradation, relocation, or change in the activity of other proteins that regulate signal 
transduction in different pathways (Nau & Lipkowitz, 2008). Ubiquitin or ubiquitin-like 
proteins are attached to their targets through activation and conjugation by the ubiquitin-
activating enzyme (E1), a ubiquitin- carrier enzyme (E2), and a ubiquitin protein ligase (E3) 
(Schulman & Harper, 2009). 
 
 
 
 
 
 
 
 
 
 
Figure  1-7 The Cbl family proteins. 
All Cbl proteins share a high level of sequence conservation between their tyrosine kinase 
binding (TKB), linker (L), and RING finger (RF) domains. c-Cbl and Cbl-b have extensive 
proline-rich (P) regions in their C-terminal halves that mediate interactions with SH3-
domain-containing proteins. The TKB domain is composed of three interacting regions 
comprising a four-helix bundle (4H), a calcium-binding (EF) hand, and a variant (SH2) 
domain that is connected to the RF by a short linker domain. The C-termini of the Cbl 
proteins contain tyrosines (Y) that can become phosphorylated and mediate interactions with 
SH2-containing proteins. The C-termini also contain proline-rich regions (P) that mediate 
interactions with SH3-containing proteins. The UBA domain at the C-terminus of c-Cbl and 
Cbl-b refers to a region with homology to UBA domains (C. B. F. Thien & Langdon, 2001). 
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The TKB region mediates binding with tyrosine phosphorylated protein; the proline-rich 
region that provides a binding site for SH3 domains; a leucine zipper that allows for a 
dimerization domain of c-Cbl; the ubiquitin-associated domain (UBA); and tyrosine, serine, 
and threonine phosphorylation sites (Joazeiro et al., 1999). The TKB domain is at the N 
terminus of the protein and contains different sub-domains: the four-helix (4H) bundle 
domain, the calcium-binding EF hand domain, and a variety of Src homology 2 (SH2) 
domains as seen in Figure 1-7 (C. B. F. Thien & Langdon, 2001). c-Cbl and Cbl-b have UBA 
domains at the C-terminal ends that can interact with ubiquitin and ubiquitin-like domains of 
proteins to allow c-Cbl and Cbl-b to form homo-dimers and hetero-dimers. However, a study 
in 2004 showed that Cbl-b but not c-Cbl UBA domains can interact with ubiquitin (Davies et 
al., 2004). Cbl-c is different from other family members, c-Cbl and Cbl-b. The physiological 
roles of Cbl-c are currently unclear. Despite the different structure of Cbl-c , Cbl-c KO mice 
exhibited normal physiological functions (Griffiths et al., 2003). Suggesting that lack of Cbl-
c is complemented by c-Cbl and/or Cbl-b. 
Due to these structural complexities, many different proteins interact with c-Cbl. 
Approximately 150 proteins are associated with or regulated by c-Cbl (Schmidt & Dikic, 
2005), including adaptors, cytoskeletal proteins, ubiquitin, and many receptors such as 
receptor protein tyrosine kinases (PTKs) and non-receptor PTKs (Figure 1-8) (Swaminathan 
& Tsygankov, 2006). Therefore, it is not surprising that c-Cbl may be involved in many 
biological processes. For example, c-Cbl has been reported to play a role in haematopoiesis, 
the immune system, bone formation, and tumorigenesis (C. B. F. Thien & Langdon, 2001).  
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Figure  1-8 The Cbl interactome. 
The diagram shows many different proteins that are known to interact with Cbl. Proteins are 
grouped according to Cbl binding sites (A). Methods that were used for the detection of the 
protein–protein interactions are represented by different colours (B). TKB: Tyrosine kinase-
binding domain, RING: Ring finger domain, PXXP and PXXXPR: Proline-rich domains, 
UBA: Ubiquitin-associated, LZ: Leucine zipper, pSer: Phosphorylated serine, pTyr: 
Phosphorylated tyrosine, GST: Glutathione-S-transferase. Note immunoblotting method does 
not determine the exact binding side on Cbl (Schmidt & Dikic, 2005). 
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1.5.2 Altered c-Cbl and diseases 
c-Cbl mutation, which affects either the tyrosine kinase binding domain, linker region 
domain, or ring finger domain, can lead to the development of myeloid leukaemia and 
splenomegaly (Rathinam, Thien, Flavell, & Langdon, 2010). It can also lead to a Noonan 
syndrome-like disorder (Martinelli et al., 2010) and tissue hyperplasia in mice, while bone 
development and remodelling were normal (Murphy et al., 1998). c-Cbl is over-expressed in 
several colorectal cancer cell lines (Cristóbal et al., 2014). Overexpression of c-Cbl may 
cause gastric carcinoma (Dong, Liu, Qu, Hou, & Li, 2010). Mutant Cbl led to generalised 
mastocytosis and myeloproliferative disease (Bandi et al., 2009). The inhibition of c-Cbl 
improved cardiac function after chronic myocardial ischemia and reduced the risk of death 
through enhancing angiogenesis and increasing the expression of the vascular endothelial 
growth factor type 2 and receptor-a (Rafiq et al., 2014; J. Wang, Li, & Jiang, 2015). c-Cbl is 
highly expressed in breast cancer, and knocking down Cbl resulted in the high expression of 
tumor suppresser activity (TGF-β) (J. M. Kang et al., 2012). c-Cbl is a negative regulator of 
angiogenesis in endothelial cells (Singh et al., 2007). 
1.5.3 Role of c-Cbl in energy metabolism in relation to obesity and insulin resistance 
Previous studies by Baumann et al. (2000) and Chiang et al. (2001) showed that upon insulin 
stimulation, c-Cbl phosphorylation recruited signaling molecules to the cell surface, thus 
promoting the translocation of glucose transporter to the plasma membrane and increasing 
glucose uptake in fat cells. According to these studies, the lack of c-Cbl would be expected to 
impair glucose uptake and lead to insulin resistance. However, this issue remains 
controversial because other studies showed that 3T3-L1 adipocytes depleted of c-Cbl 
exhibited normal glucose uptake (Mitra, Zheng, & Czech, 2004). In addition, fat cells from c-
Cbl KO mice showed no effect on glucose uptake in skeletal muscle (Molero et al., 2004). 
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Interestingly, the study by Molero et al. (2004) exhibited that mice with the global KO of c-
Cbl have improved insulin action and less adiposity despite increased food intake due to 
enhanced energy expenditure (so called ‘hot mice’). Follow-up studies showed that c-Cbl KO 
mice fed a high-fat diet exhibited lower adiposity due to increased FAO and greater insulin 
sensitivity due to increased oxygen consumption (Molero, Waring, et al., 2006). A third study 
by the same group examined mice expressing normal levels of a mutant c-Cbl protein with 
the ubiquitin ligase activity ablated (c-CblA/-). Similar to c-Cbl KO mice, c-CblA/- mice were 
leaner and exhibited greater energy expenditure and insulin sensitivity (Molero, Waring, et 
al., 2006). Depletion of the ubiquitin ligase activity of c-Cbl is associated with elevated 
phosphorylation of AMPK and energy expenditure in the soleus muscle (Molero, Waring, et 
al., 2006). These results suggest that c-Cbl plays a key role in the control of whole-body 
energy expenditure. However, the target tissue responsible for the reported increase in energy 
metabolism has not yet been identified. 
Although Cbl-b has a structure similar to that of c-Cbl (Figure 1-7), some targets of c-Cbl and 
Cbl-b are different. There are many differences in the metabolic phenotypes between c-Cbl 
and Cbl-b KO mice. It has been reported that Cbl-b KO mice displayed more severe adiposity 
and hyperlipidaemia on a high fat diet (Abe et al., 2013). These findings suggest that Cbl-b 
may be also involved in the regulation of energy expenditure and lipid metabolism.  
c-CblA/- mice significantly increase the mitochondrial size (Molero, Waring, et al., 2006). 
Furthermore, Cbl-b but not c-Cbl is highly expressed in atrophied skeletal muscle from rats 
that have been in a gravity-free environment (Nakao et al., 2009) or from people who have 
been resting in bed for 20 days (Ogawa et al., 2006). Cbl-b-deficient mice were resistant to 
muscle wasting (Nakao et al., 2009). However, further study is essential to elucidate the role 
of Cbl-b in muscle energy homeostasis. 
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1.6 Summary, aims and hypothesis 
Obesity is a state of metabolic disorder characterised by excessive fat accumulation. It is a 
major risk factor for the development of insulin resistance (Section 1.3.3). It is increasingly 
evident that obesity has become a pandemic (Section 1.1.1), placing a significant social 
burden on both individuals and countries. Central obesity is the most common type which 
accounts for approximately 90% of people with obesity (Section 1.1.2). The fundamental 
cause of obesity is an energy imbalance between increased energy intake and decreased 
energy expenditure (Section 1.1.4).  
Skeletal muscle constitutes around 40% of body weight in humans and accounts for about 
20% of metabolic rate at rest (Section 1.1.5). Because of its large contribution to total body 
mass, mitochondrial function has a significant impact on whole-body energy metabolism. 
Thus, the critical role that skeletal muscle plays in metabolic homeostasis makes this organ of 
particular interest in obesity. 
Although c-Cbl plays an important role in the reduction of adiposity, it is not clear whether c-
Cbl is modulated in insulin-resistant tissues during obesity. In addition, c-Cbl plays a role in 
regulating whole-body energy expenditure, but it is not known if skeletal muscle is a major 
site responsible for this metabolic effect. 
Based on the literature, the following thesis aims were set to address these gaps in our 
knowledge.  
Overall Aim 
To investigate the role of c-Cbl in muscle energy metabolism in relation to obesity and 
associated metabolic disorders. 
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Specific Aims 
1. To characterise the changes in Cbl proteins in key peripheral organs during high fat diet-
induced obesity and glucose intolerance in mice (Chapter 3). 
2. To investigate the role of c-Cbl in energy metabolism of muscle cells through examining 
mitochondrial function, mitochondrial capacity and mitochondrial biogenesis (Chapter 4). 
3. To investigate the role of c-Cbl in myogenesis/muscle differentiation and lipid 
accumulation (Chapter 5). 
Working hypothesis (illustrated in Figure 1-9) 
High fat diet would induce obesity and glucose intolerance and may up-regulate c-Cbl 
expression in insulin-resistant skeletal muscle; c-Cbl may have a direct effect on the 
regulation of muscle mitochondrial function and mitochondrial capacity that leads to 
enhanced energy expenditure; and c-Cbl may have a direct effect on the regulation of muscle 
cell differentiation that leads to enhanced energy expenditure. 
The results from these studies are likely to determine whether c-Cbl is a possible key 
regulator of energy metabolism in skeletal muscle and identify its possible role in obesity.  
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Figure  1-9 Study hypothesis of the research aims in muscle. 
Illustration of the study hypothesis for the investigation of the role of c-Cbl in skeletal muscle 
energy metabolism in relation to obesity. 
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Chapter 2: Materials and Methods
 
 
60 
 
2.1 Introduction 
This chapter presents in detail all the common materials and methods that have been used in 
this thesis. All of the materials (reagents and solutions) were purchased from commercial 
suppliers, such as Invitrogen, Sigma-Aldrich, Cell Signaling, Abcam, and In Vitro. Special 
methods and techniques for a particular study are described separately in the corresponding 
chapters. 
2.2 Studies in animal model (In Vivo) 
To characterise the changes in Cbl expression with diet-induced obesity and insulin resistance 
for aim one, male C57BL/6J mice were obtained from Lipid Biology and Metabolic Disease 
group, which was approved by the Animal Ethics Committees of the RMIT University 
(#1414) in accordance with the guidelines of the National Health and Medical Research 
Council of Australia on animal experimentation. 
Mice aged 10–12 weeks were purchased from the Animal Resources Centre (Perth, 
Australia). For 1–2 weeks from arrival, mice were kept in a temperature-controlled room at 
22±1°C on a 12-hour light/dark cycle to acclimatise in the animal facility at RMIT 
University. Mice were first fed ad libitum with a standard chow diet and given free access to 
water during this period. 
2.2.1 Diet preparation 
The standard chow diet (CH) was purchased from Specialty Feeds, Western Australia.  It was 
ground into powder, which contains 65% calories from carbohydrate, 23% calories from 
protein, and 12% calories from fat. 
A high fat diet (HFat) was prepared based on the ingredients presented in (Table 2-1)–35% 
carbohydrate, 20% protein, and 45% fat and this diet has been used in our lab(J. Ye et al., 
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2003) to induce obesity and insulin resistance (Storlien, James, Burleigh, Chisholm, & 
Kraegen, 1986). All of the diets were stored at -20°C for less than 1 month, and were 
changed daily during the experiments. 
 
Table  2-1 Composition of high fat diet 
Ingredients Manufacturer Catalogue No. 
Amount 
(g) 
% in 
weight  
Casein MPD Dairy Products ACIDCASEIN 261.0 2.61 
Sucrose Hudson Pacific Corp. - 230.0 2.30 
Starch (cornflour) Hudson Pacific Corp. FLCO1 193.0 1.93 
AIN-76Mineral MP Biomedicals 0290545502 51.0 0.51 
Trace Minerals MP Biomedicals 0296026401 14.8 0.148 
Bran Hudson Pacific Corp. BC20KGA 57.0 0.57 
Methionine Sigma-Aldrich M9500 3.4 0.034 
Gelatine Hudson Pacific Corp. GEPO1 23.0 0.23 
Choline bitartrate Sigma-Aldrich C1629 4.6 0.046 
Safflower oil Stoney Creek Oil Products SAFFLOWER 34.0 0.34 
Lard Allowrie Prime Lard 250.0 2.50 
AIN Vitamin Mix 76 MP Biomedicals 0296009801 14.8 0.148 
  Total 1136.6 11.36 
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2.2.2 Blood and plasma parameters 
Blood glucose levels were measured using a glucometer (Accu-Chek Performa Nano; Roche, 
Australia). Blood samples were collected using heparin capillary tubes (SteriHealth 
Laboratory Products, Australia) from the tail tip and immediately diluted with sterile saline to 
prevent clotting for the plasma measurement. Plasma was segregated by centrifugation at 
13,000 rpm for 1 minute. The centrifuged samples were transferred to a new Eppendorf tube 
and stored at -80°C for the following measurements. 
Plasma insulin levels were determined by radioimmunoassay (Catalogue No. SRI-13K, 
Merck Millipore, Australia). Fasting blood glucose levels were measured in mice 5-7 hours 
after food removal. Blood samples were also collected for the measurement of plasma insulin 
levels. 
2.2.3 Glucose and insulin tolerance test 
Body weight (BW) was measured before administering glucose tolerance test (GTT) for the 
calculation of glucose load. On the day of testing, mice were fasted for 5–7 hours before the 
test. Mice were injected intraperitoneally (ip) with glucose (1.5 or 2.0 g/kg BW). Blood 
glucose levels were measured before the injection and at 10 minutes, 15 minutes, 30 minutes, 
60 minutes, and 120 minutes after injection. 
Blood samples were collected for the measurement of insulin at the same time points using 
heparin capillary tubes. Values of blood glucose from GTT and ITT were plotted against 
time, and the incremental area under the curve (iAUC) was calculated to assess glucose 
tolerance and insulin tolerance. 
2.2.4 Triglyceride extraction and determination 
After mice were killed by cervical dislocation, liver and muscle samples were freeze-clamped 
and stored at -80ºC. To extract triglyceride, the samples were chipped to 20–30 mg and 
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homogenised with 4 ml of extraction solution (chloroform/methanol, 2:1) using a glass pestle 
tissue grinder. After transferring the sample homogenate to a new 15 ml falcon tube, the 
homogenate was rinsed with another 2 ml of extraction solution. The tubes were tightly 
capped and rotated on a vertical rotator at room temperature overnight to certify complete 
solubilisation of the triglyceride. On the following day, 2 ml of 0.6% NaCl was added to the 
tubes followed by vortex mixing. The samples were then centrifuged at 2,000 rpm for 10 
minutes to separate the aqueous phase from the organic phase. The organic phase containing 
triglyceride was transferred into glass tubes and dried under nitrogen or air at 45ºC. The 
extracts were reconstituted in 500 μl absolute ethanol.  
Triglyceride levels were measured using a commercial enzymatic method called a 
Peridochrom triglyceride GPO-PAP reagent, where glycerol was used as a reference 
according to the manufacturer’s protocol (Roche Diagnostic, Australia). Briefly, 5 μl of liver 
or muscle triglyceride samples and standard glycerol solutions (Catalogue No.G5516, Sigma-
Aldrich, Australia) were mixed with 300 μl of triglyceride reagent in 96-well plate and 
incubated at 37°C for 10 minutes. Internal standards with different glycerol standard dilution 
were measured to create a standard curve between the ranges of 0 μg/well to 1.050 μg/well. 
The absorbance was measured at 485 nm using a Clariostar Microplate Reader (BMG 
Labtech, Germany).  
2.3 Studies in cell model (In Vitro) 
All cell culture experiments were achieved according to the standard operating procedures of 
physical containment (PC1 and PC2) in the Laboratoriesat RMIT University, Melbourne, 
Australia. 
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2.3.1 Cell culture 
Cell culture is the growth of cells obtained from multicellular eukaryotes including humans 
or animals, outside of their bodies in a design place under special conditions involving 
nutrition, temperature, humidity and freedom from contaminations. 
2.3.1.1 Cell culture components 
1. C2C12 cell line is an immortal line of the skeletal myoblasts of a mouse derived 
originally from satellite cells from a 2 month-old female C3H mouse donor after 70 hours 
of a crush injury. As a model of skeletal muscle we used murine C2C12 myoblasts. 
Cells were obtained from the American Type Culture Collection (ATCC) and were 
used as satellite cells, which served as a model of myoblasts and myotubes, an in 
vitro model of muscle fibres (Yaffe & Saxel, 1977). 
2. Minimum essential medium (MEM)–alpha is a medium that contains L-glutamine, rib-
nucleosides, and deoxy-ribonucleosides. Featuring sodium pyruvate, non-essential amino 
acids, lipoic acid, vitamin B12, biotin, and ascorbic acids. It can be used in different cell 
lines or tissues, such as a fibroblast, human tumour, embryfibroblast, etc. (adopted from 
Thermo Fisher scientific website). It was stored at 4°C (Invitrogen, #12571063). 
3. Fetal bovine serum (FBS) is the most common supplement with a low cost in cell 
culture media. It is a supplement that provides optimal culture growth media. The serum 
provides transporters for hormones, water-insoluble nutrients, growth factors, and 
protease inhibitors, and it binds and neutralises toxic elements to the cells. The serum was 
heat-inactivated for 30 minutes at 56°C before use to inactivate complement. For short-
term use, the serum was stored at 4°C, and for long-term use, it was stored at -80°C 
(Invitrogen, #10099-141). 
4. Penicillin streptomycin glutamine (PSG) (10,000 units/ml penicillin; 10,000 μg/ml 
streptomycin and 29.2 mg/ml L-glutamine). The antibiotics of penicillin and streptomycin 
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were used to prevent bacterial contamination in cell cultures. PSG combined their action 
against gram-positive and gram-negative bacteria. For short-term use, the serum was 
stored at 4°C, and for long-term use, it was stored at -20°C (Invitrogen, #10378-016). 
5. Trypsin, 0.25% (1x) - EDTA was used in cell culture because of its function of 
dissociating cell monolayers from plates or flasks. For short-term use, it was stored at 
4°C, and for long-term use, it was stored at -20°C (Invitrogen, #25200056). 
6. Phosphate buffered saline (PBS) is a buffer that has been used in cell cultures to 
maintain a constant pH and osmolarity of the cells. 10x PBS was prepared as follows 
(Table 2-2), and all the chemicals used were from Sigma-Aldrich. 
7. Lipofectamine 2000 reagent is the most common transfection reagent that contains a 
lipid subunit to form liposomes. Lipofectamine has been used in cellular biology to 
increase the transfection efficiency of ribonucleic acid (RNA), including siRNA or 
mRNA, or DNA plasmid in a cell culture. The reagent was stored at 4°C (Invitrogen, 
#11668019). 
8. Opti-MEM reduced serum medium is a medium that contains different compounds, 
including HEPES, 2.4g/L sodium bicarbonate, L-glutamine, transferrin, insulin, 
hypoxanthine, and thymidine. These components allow for a reduction in serum 
supplementation by at least 50%. It contains a sodium bicarbonate buffer (2.4 g/L) that 
requires a 5% CO2 environment in order to maintain a pH balance (Invitrogen, 
#31985070).  
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2.3.1.2 Cell culture procedures 
1. Cell culture 
C2C12 cells were cultured in a minimum essential medium (α MEM) supplemented with 
heat-inactivated 10% fetal bovine serum (FBS) and 1% penicillin streptomycin glutamine 
(PSG) in a 75cm2 flask (Coring, Australia). Cells were incubated at 37°C in an atmosphere 
of 95% humidity and 5% CO2. The growth medium, PBS (pH 7.4) and trypsin 0.25% were 
incubated in a water bath at 37°C before the cell culture started. The cells were sub-cultured 
when cells reached 70% to 80% of confluence, and the cell passage numbers from 3 to 23 
were used for all of the experiments. The passage number should be documented in order to 
keep the cells at a low density to stimulate further growth. The cell growth medium was 
changed every 2 to 3 days. Brief sub-culturing of the cells was performed in the fume hood 
by rinsing the cells in a 75cm2 flask with 10 ml PBS to maintain constant pH and osmolarity. 
PBS was aspirated and 1 ml trypsin 0.25% (1x)–EDTA was added into the flask for 2 to 3 
minutes to detach the cells from the flask by tapping with an effort. The required dilution 
from the fresh growth medium was added into the cells, and they were re-suspended by 
pipetting up and down a few times to break down the clusters. The day before the experiment, 
cells were seeded with the desired cell number using the cell counting method (see below). 
The transfection method was used after cell confluence. This technique was used to observe 
the effect of changing c-Cbl activity, excluding the effect of external factors.  
2. Counting cell numbers 
Cell counting required the use of a device called haemocytometer (Grace Davison Discovery 
Sciences, Australia), which consists of a thick microscope slide with two chambers, each 
containing 0.1 cubic mm of the sample. The coverslip should mount on the top of the 
chambers after they have been rinsed with alcohol. The cell number was estimated by adding 
15 μl to 20 μl of the suspended cells per side. The haemocytometer should place under the 
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microscope using 20x magnifications. Each side of the haemocytometer has nine squares; the 
cell numbers in each of the 4 outer squares that have 16 small squares were counted (Figure 
2-1). The mean was calculated by dividing the number of cells by the number of areas, and 
then multiplying this by 104 to calculate the number of cells per ml. This technique was used 
to observe the number of cells. 
 
 
Figure  2-1 Haemocytometer. 
Counted cell number = cell number of sum (Area A + Area B + Area C + Area D). Cell 
number/ml = counted cell number/4 x 104. 
 
3. Cell freezing 
Using the same method as cell culture, cell freezing was performed by seeding 10 flasks of 
C2C12 in αMEM growth medium with a dilution of 1:10. The cells were rinsed with sterile 
PBS in each flask. 2 ml 0.25% (1x)–EDTA trypsin was added into one flask. The trypsin was 
passed to other flasks, and 8 ml of a fresh growth medium was added. The cells were placed 
in a 15ml falcon tube; the cells were centrifuged for 3 minutes at 700rpm (Allerga X-22R 
Centrifuge). After aspirating the supernatant, two falcon tubes were prepared, one with 4 ml 
growth medium and 1 ml 20% FBS and; the other with 3 ml growth medium, 1 ml 20% FBS, 
and 1 ml 20% dimethyl sulfoxide (DMSO, Sigma-Aldrich, #D4540). The 5 ml medium with 
FBS was mixed with the cell pellets and re-suspended. The other 5 ml with FBS and DMSO 
was added drop by drop, as DMSO is toxic to cells and should not be exposed to the cells at 
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room temperature for longer than 30 minutes (Katayama et al., 1997). The cells were aliquot 
in a 2 ml freezing tube and placed at -80°C for 1 day, then placed in the liquid nitrogen. This 
technique was used to store the cells for further experiment. 
4. Cell thawing 
After the freezing method, cells were diluted with α MEM medium immediately and placed 
in a centrifuging tube. The cells were centrifuged at 1200 rpm for 5–10 minutes. After the 
centrifugation, the clarity of supernatant and the visibility of a complete pellet were checked. 
Cells were gently re-suspended in α MEM growth medium and transferred into a 75 cm2 flask 
and allowed to grow after thawing for several days. 
2.3.2 Plasmid amplification 
Luria Broth (LB) from Luria Broth Base (Miller’s LB Broth Base) was prepared and 100 
μg/ml ampicillin (Invitrogen, Australia) was added. LB agar was prepared by adding 1.5% 
agar to LB. Preheated LB agar (20–25 ml) was poured into petri dishes to have LB agar 
plates. DH5α™ competent cells (Invitrogen, Australia, #18258-012) were used to amplificate 
the protein and transformed following manufacturer protocol. Briefly, DH5α™ competent 
cells were thawed and 15 ml falcon tubes were pre-cooled on wet ice. For each reaction, 15 
μl of DH5α™ competent cells was taken from the vial and placed into the ice-cooled falcon 
tube and 1 μl of the DNA solution was added. The tube was tapped gently to the mix and 
incubated on ice for 30 minutes. The DH5α™ competent cells were heat-shocked in a 42 ºC 
water bath for 45 seconds. The cells were placed on ice for 2 minutes. Super optimal broth 
(0.9 ml) with catabolite repression medium (S.O.C., Invitrogen, #15544-034) was added to 
the cells and the culture dish was placed on a shaker for 1 hour at 37ºC. The reaction was 
diluted with S.O.C. medium (1:100) and 100 μl of the reaction was spread on LB agar plates. 
The remaining cells were diluted with glycerol 1:1 and frozen at -80ºC. Plates were incubated 
at 37ºC overnight. Formed white colonies on the plate were picked using a sterile yellow tip. 
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The tip with cells was placed in a falcon tube containing 5 ml LB broth and the culture plate 
was incubated overnight on the shaker. The next day, 100 μl of the culture was transferred 
into a 250 ml conical bottle containing 100 ml LB broth (1:1000), and the culture was grown 
for another day.  
2.3.3 Plasmid purification 
Bacterial cells and plasmids were extracted and purified using Qiagen Plasmid Midi Kit 
(Qiagen, #12123) following manufacturer protocol. Briefly, bacterial cells were pelleted from 
the culture by centrifuging the cells at 6000 rpm for 15 minutes at 4ºC. The bacteria pellet 
was resuspended in 4 ml of P1 buffer (LyseBlue and RNase A added) and 4 ml of P2 buffer. 
Another 4 ml of ice-cooled P3 buffer was added and vortexed again. The cells were incubated 
on ice for 15 minutes following 12,000 rpm centrifuge for 30 minutes at 4ºC. After 
calibrating Qiagen tip with 4 ml QBT buffer, the plasmid supernatant was loaded onto 100 
columns for DNA binding. Columns were washed with 10 ml QC buffer two times and DNA 
was eluted by 5 ml QF buffer. DNA in the eluent was precipitated by loading 3.5 ml 
isopropanol and centrifuged at 9500 rpm for 30 minutes at 4ºC. DNA pellets were washed 
with 2 ml 70% ethanol and centrifuged again for 20 minutes at 4ºC. After removing the 
solvent through air-drying, the DNA pellet was re-suspended with Tris-EDTA buffer (pH 
8.8). 
2.3.4 Cell transfection 
Transfection is a process of introducing nucleic acids, such as a DNA or RNA vector, to the 
cells. To deplete c-Cbl from cells, short hairpin RNA inference technology was used. The 
DNA sequences encoded the short hairpin RNA for c-Cbl is 5’-
GACACTTTCCGGATTACTA-3’, and the DNA sequences encoded for the non-relevant 
GFP the short hairpin RNA for green fluorescent protein (GFP) is 5’ 
CAGTCGCGTTTGCGACTGG-3’. Sh GFP was used as a control because it signals for GFP 
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degradation and was not found in mammalian cells (Dantuma, Lindsten, Glas, Jellne, 
&Masucci, 2000). These constructs were cloned in a pBluescript vector. To overexpress c-
Cbl in cells, Hemagglutinin tagged human c-Cbl cDNA was cloned in psRαNeo vector (Hu-
HA c-Cbl psRαNeo), and plasmid without c-Cbl DNA vector was used as a control vector. 
ShRNA plasmids were transfected with Lipofectamine 2000 following manufacturer 
protocol. Briefly, the day before transfection, 75 x104 C2C12 cells in 1 ml growth medium (α 
MEM supplemented with 10% heat-inactivated FBS and 1% PSG) were seeded into each 
75cm2 flask to attain 60% to 70% confluence. On the day of transfection, 10 μg plasmid was 
diluted with 1.5 ml Opti-MEM (serum free medium), and 3 μl Lipofectamin 2000 Reagent 
was diluted with 1.5 ml Opti-MEM. After 5 minutes of incubation at room temperature, the 
plasmid and Lipofectamine dilutions were mixed and further incubated for 20 minutes. The 3 
ml complexes were added to a 75cm2 flask and mixed by moving the flask back and forth. 
The flask was kept in the incubator for 4 to 5 hours with the mixture. Transfected cells were 
incubated with growth medium for 48 hours and either lysed for myoblasts or promoted to 
differentiate for myotubes. This technique was used in this thesis to deplete or over-express 
c-Cbl levels in the C2C12. 
2.3.5 Myoblast differentiation 
Following cell transfection, C2C12 myoblasts under appropriate conditions can be 
differentiated into myotubes. To induce differentiation, 2 days post-transfection C2C12 were 
incubated in a differentiation medium which contained α MEM supplemented with 2% heat-
inactivated FBS and 1% PSG for 3 days or more. 
2.4 Western blotting 
All chemicals and reagents were purchased from Sigma-Aldrich, Australia, unless other 
companies are indicated. All western blot buffers and reagents were prepared as follows 
(Table 2-2). 
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Table  2-2 Preparation of buffers and reagents for immunoblotting 
Name Preparation Concentration 
Catalogue 
number 
RIPA buffer 
Trizma® base (Tris) 
Sodium Chloride (NaCl)  
Ethylenediaminetetraacetic Acid (EDTA) 
Nonide-P 40 substitute (NP-40) 
Sodium Dodecyl Sulphate (SDS) 
Sodium-deoxycholate 
Glycerol 
pH 7.5 
Stored at 4°C 
65mM 
150mM 
5.0mM 
1.0 % 
0.1% 
0.05% 
10.0 % 
 
#T1503 
#S3014 
#E6758 
#74385 
#L4390 
#D6750 
#49770 
HES buffer 
Sucrose 
HEPES 
EDTA 
pH7.4 
Stored at 4°C 
250mM 
20mM 
1mM 
#S9378 
#H3784 
#E6758 
 
Lysis buffer 
Sodium Fluoride (NaF) 
Sodium Orthovanadate (Na3VO4) 
Phenylmethanesulfonyl Fluoride (PMSF) 
Sodium Dodecyl Sulphate (SDS) 
Protease inhibitor 
Phosphatase inhibitor 
Added to HES or RIPA buffer 
Stored at 4°C 
10 mM 
1 mM 
1 mM 
0.1% 
10 μl/ml 
10 μl/ml 
#S7920 
#S6508 
#78830 
#L4390 
#P8340 
#P5726 
4x Laemmli’s 
buffer 
(100ml) 
 
SDS 
Glycerol 
0.5M Tris-buffer 
1% Bromo-phenol blue 
Added to DL-Dithiothreitol (DDT) 
Stored at -20°C 
8.2g 
40ml 
50ml 
500μl 
6.2mg 
#L4390 
#49770 
#9BP1525 
#114391 
#D9779 
10x Running 
buffer (1L) 
 
Tris base 
Glycine  
SDS  
Dissolved in dH2O 
30g 
144g 
10g 
#BP152-5 
#G8898 
#L4390 
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pH 8.8 
Stored at room temperature 
10x Transfer 
buffer (1L) 
Tris base 
Glycine  
Dissolved in dH2O 
Stored at room temperature 
30g 
144g 
#BP152-5 
#G8898 
10x TBS (1L) 
Tris base 
NaCl 
Dissolved in dH2O 
pH 7.6  
Stored at room temperature 
2g 
80g 
#BP152-5 
#S3014 
 
1xTBS-Tween 
(TBST, 1L) 
 
10x TBS buffer 
Tween® 20  
Dissolved in dH2O 
Stored at room temperature 
200 ml 
1 ml 
 
#P9416 
Stripping 
buffer (1L) 
 
1M Tris-HCl  
SDS  
Dissolved in dH2O 
pH 6.7 
Stored at room temperature 
Add to 2-Mercaptoethanol before use 
6.25% 
20% 
 
 
 
100 mM 
 
#L4390 
 
 
 
#M7154 
Primary 
antibody 
dilution 
Bovine Serum Albumin(BSA), (Bovogen) 
Soduim azide 
Phenol red  
Dissolved in 1X TBST buffer 
Stored at -4°C 
1% 
0.02% 
0.0025% 
#BSAM1 
#S8032 
#114529 
Tris-HCL 1M 
buffer (1L) 
Trizma® base (Tris) 
Hydrochloric (HCl) pH7.5 
1.5M Tris-HCl buffer pH 8.8 
0.5M Tris-HCl buffer pH 8.8 
121.14g 
80ml 
 
#T1503 
#258148-2 
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2.4.1 Tissue homogenisation 
Tissue samples, 20–30mg, were homogenizsed in 200–300 μl ice-cold RIPA lysis buffer. The 
stock of RIPA buffer was mixed with lysis buffer before homogenising. Tissue lysate was 
centrifuged at 15,000 rpm for 20 minutes at 4°C. Supernatant containing protein extraction 
was collected and stored at -80°C. 
2.4.2 Cell homogenisation 
To obtain the cell lysates, cells were washed with ice-cold PBS and the appropriate volume of 
lysis buffer was added approximately 1 ml for 100mm tissue culture dish or 150 μl per 6 
wells-plates (Costar, #3516). In the lysis buffer, NaF was added to inactivate endogenous 
phosphatases and protect protein phosphorylations, detergent SDS to dissolve cell membrane, 
Orthovanadate to help preserve the phosphorylation state of proteins, and PMSF to prevent 
protease degradation. Cells were then scraped with a cell scraper and transferred to labelled 
Eppendorf tubes. The cell lysates were then homogenised by passing the lysate through a 
25G needle (Terumo,#NN2519RA) and 3cc/ml syringe (Terumo,#SS03S) 10 times or 
sonicate for 1 minute. The lysate was centrifuged at 15,000 rpm for 10 minutes at 4°C. 
Supernatant containing protein extraction was collected and stored at -80°C. 
2.4.3 Protein quantification 
Protein concentrations from tissues and cells were measured using commercially available 
colorimetric Pierce™ Bicinchoninic Acid (BCA) protein assay kit (Thermo Scientific, 
10xPBS 
 
Sodium Phosphate Dibasic Dihydrate 
(Na2HPO4) 
Sodium Chloride (NaCl) 
Potassium Phosphate Monobasic (KH2PO4) 
Potassium Chloride (KCl) 
pH 7.4 
Autoclaved and stored at room temperature 
10.0 mM 
 
0.2 M 
2.0 mM 
3.0 mM 
#71633 
 
#S3014 
#P5655 
#P3911 
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#B9643). The protein concentration is shown by the transformation of the test solution from 
green to purple according to the concentration of protein. This change in colour was 
measured by a micro-plate reader. Briefly, 20 μl of the protein standard (BSA dissolved in 
distilled H2O) and samples (1:20 dilution for tissue and 1:10 for cell lysate) were added in the 
microplate in a combination with 200 μl BCA reagent mix (50 parts reagent A to 1 part 
reagent B) to detect the concentration of protein in each sample. The reaction was mixed and 
incubated at 37°C for 30 minutes prior to the determination of absorbance by 
spectrophotometry at 562 nm using a POLARstar Optima microplate reader (BMG Lab 
Technologies, Germany). In every BCA assay, varying dilutions of BSA protein were 
included to create a standard curve in the range of 0 μg/ml to 2 μg/ml. 
Protein samples were diluted with dH2O for tissues or lysis buffer for cells and mixed with 
4X Laemmli buffer with dithiothreitol (DDT). Samples were then boiled at 95°C for 10 
minutes and subsequently stored at -80°C. 
2.4.4 SDS-PAGE 
SDS-PAGE (Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis) technique was 
used for running small molecules like proteins to separate proteins of interest. 
Polyacrylamide glycine gels with different percentages were prepared to separate the protein 
of interest depend on their molecular weight (Table 2-3). 
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Table  2-3 Recommended polyacrylamide % gel for separation molecular weight 
Polyacrylamide gel percentage (%) Separation molecular weight (KDa) 
8 25-200 
10 15-100 
12 10-70 
14 12-45 
 
Running gel was prepared as follows (Table 2-4) by mixing all the buffers gently and poured 
into the two glass plates, with the short plate facing inward to form the inner buffer chamber, 
to the first green line of the casting frame. Ethanol was added gently on top for 45 minutes to 
remove the bubbles and washed. The stacking gel (Table 2-5) was poured on top of running 
gel with the plastic combs for 30 minutes, and the combs were removed. Gels 
polymerisations were catalysed by the addition of both Ammonium Persulfate 
(APS,#A3678) and N,N,N’,N’-Tetramethylethylenediamine (TEMED,#T9281). Equal 
amounts of protein were subjected to SDS-PAGE alongside protein ladders (Bio-Rad 
Laboratories Inc., Australia) of known molecular weight markers and were separated at 120 
voltages until the markers were well separated in the running buffer. 
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Table  2-4 Compositions of the running gel (for 2 gels) 
Ingredients 8% 10% 12% 14% 
1.5M Tris buffer, pH 8.8 5.0 ml 5.0 ml 5.0 ml 5.0 ml 
30% Acrylamide/Bis-acrylamide 5.3 ml 6.7 ml 8.0 ml 9.3 ml 
10% SDS 0.2 ml 0.2 ml 0.2 ml 0.2 ml 
dH2O 9.5 ml 8.1 ml 6.8 ml 5.5 ml 
10% APS 0.2 ml 0.2 ml 0.2 ml 0.2 ml 
TEMED 0.02 ml 0.02 ml 0.02 ml 0.02 ml 
 
Table  2-5 Compositions of the stacking gel (for 2 gels) 
Ingredients Volume (ml) 
0.5M Tris buffer, pH 6.8 1.25 
30% Acrylamide/Bis-acrylamide 1.7 
10% SDS 0.1 
dH2O 7.0 
10% APS 0.1 
TEMED 0.02 
 
2.4.5 Immunoblotting 
After the separation of proteins by SDS-PAGE, the polyvinylidene fluoride (PVDF, Bio-Rad 
Laboratories Inc., USA) was soaked with methanol for 5 minutes and washed with distal 
water for activation. The transfer castle was prepared by adding the soaked sponge, then 2 to 
3 filter papers, PVDF, gel, another 2 to 3 filter papers, and finally the sponge on the 
transparent side. Proteins were then transferred from the gels to PVDF transfer membranes by 
electrophoretic process. The transfer castle was closed and placed in the transfer tank at 90 V 
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for 90 minutes. Non-specific binding proteins in the membrane were blocked with 3% BSA 
in TBST for 1 hour at room temperature. The membranes were then incubated in the 
appropriate primary antibody concentrations for antigen detection (Table 2-6). Antibodies 
from Cell Signaling and Abcam were diluted to 1:1000, and those from Santa Cruz were 
diluted 1:500, with primary antibody dilution for 2 hours at room temperature or overnight at 
4°C.  
After primary antibody incubation, membranes were washed with 1xTBST for 10 minutes 6 
times to remove any unbound antibody. The membranes were subsequently incubated with 
appropriate horseradish peroxidase-conjugated secondary antibody (1:3000 dilutions in 1x 
TBST) (Table 2-6) containing 1% BSA for 2 hours at room temperature. The membranes 
were washed again with TBST for 10 minutes 6 times to remove excess unbounded 
secondary antibody. The bound antibody was detected using a Chemiluminescence system 
with Western Lighting Ultra Solution (Perkin Elmer, #NEL113001EA) by applying it onto 
the membrane. The membrane was exposed in a ChemiDoc (Bio-Rad Laboratories Inc., 
USA) for image capturing. Quantitative densitometry analysis of bands of interest was 
performed using ImageLab software. Relative protein expression was normalised by the band 
intensity of Tubulin as loading control. Briefly, the density of a protein of interest and their 
background were measured to calculate the mean density of the background and subtracted 
from the mean density of their band.  
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Table  2-6 Antibody list 
 Name Supplier Cat. No 
Cbl family 
c-Cbl 
Cbl-b 
Phospho-c-Cbl (Tyr731) 
BD Transduction Laboratories 
Cell Signaling 
Cell Signaling 
#610442 
#9498 
#3554 
Mitochondrial 
metabolism 
MitoMix 
SIRT1 (D1D7) 
Abcam 
Cell Signaling 
#MS604 
#9475 
AMPK 
pathway 
ACC2 
AMPKα 
Phospho-ACC (S79) 
Phospho-AMPKα (Thr172) 
Cell Signaling 
Cell Signaling 
Cell Signaling 
Cell Signaling 
#3662 
#2532 
#3661 
#2531 
Mitochondrial 
markers 
TOM20  
HSP70 
Santa Cruz  
Enzo  
#11415 
#C92F3
A-5 
Mitochondrial 
Dynamic 
DRP1 
Fis1 
MFN1 
MFN2 
Phospho-DRP1 (S637) 
Phospho-DRP1 (S616) 
Cell Signaling 
BioVision 
Abcam 
Cell Signaling 
Cell Signaling 
Cell Signaling 
#D6C7 
#3497 
#126575 
#9482 
#5558 
#4867 
Myogenesis 
 
HDAC2 
MEF2D 
MyoD (C-20) 
Myogenin 
MHC 
Cell Signaling 
BD Transduction Laboratories 
Santa Cruz  
Santa Cruz 
Developmental Studies 
Hybridoma 
#2540 
#610775 
#304 
#12732 
#MF20 
Mitophagy 
LC3 A/B 
Parkin 
Cell Signaling 
Cell Signaling 
#4108 
#4211 
Loading 
control 
α-Tubulin 
β-Actin 
Cell Signaling 
Santa Cruz  
#3873 
#47778 
Secondary 
antibodies 
Goat Anti Mouse 
Goat Anti Rabbit 
Donkey Anti Goat 
Santa Cruz  
Santa Cruz  
Santa Cruz  
#2005 
#2004 
#2020 
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2.5 Immunofluorescence 
Glass coverslips were placed on 6 well-plates and C2C12 cells were grown on coated 
coverslips with 0.01% Poly-L-LYSINE (Sigma-Aldrich, #P4707, Australia) at a density of 
250,000 cells/ml. Following transfections, cells were fixed with 10% neutral buffered 
formalin (Sigma-Aldrich, #HT501128) for 30 minutes after medium removal. Coverslips 
were then washed with PBS 3 times for 5 minutes and blocked with 5% goat serum (Sigma-
Aldrich, #G9023) and 0.2% Triton™ X-100 (Sigma-Aldrich, #T8787) in PBS for 15 minutes. 
Cells were incubated with rabbit anti-desmin (Abcam, #15200) for 1 hour at a 1:200 dilution 
in 1% BSA followed by 3 times washing with PBS. Then coverslips were incubated for 1 
hour with anti-rabbit Alexa Fluor®488 (Cell Signaling, #4412S) at a 1:200 dilution in 1% 
BSA. After washing the coverslips 3 times, the coverslips with 200 μl 4', 6-diamidino-2-
phenylindole (DAPI, 1:1000) (Life Technologies, #D3571) were incubated for 10 minutes at 
room temperature in the dark. Coverslips attached to cells were mounted with a fluorescence 
mounting medium (Dako, #S3023) onto a SuperFrost® WHITE (Lomb, #3204480) slide. 
Three different images were taken for each plasmid using a fluorescence microscope.  
2.6 ImageXpress 
The Image-Xpress Micro XLS High Content Analysis System consists of a Widefield 
automated microscope that is capable of transmitted light, fluorescent and phase contrast 
fixed end point imaging, and time-lapse live cell assays. In this device, the transmitted light 
option was used to perform live cell images. With the help of this device, stained cell with 
DAPI images were taken. Cell nuclei were measured for proliferation, differentiation, and 
migration cells studies.  
2.7 XFe24 extracellular flux analyser 
The XFe24 extracellular flux is a cellular bioenergetics analyser that measures the change 
rate of pH and oxygen in a culture medium. Thus, this instrument was used to measure 
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cellular oxidative metabolic rate in mitochondria and glycolytic metabolism. Oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) were measured in 
confluent myoblasts and myotubes in order to assess cellular functions. To measure OCR and 
ECAR, after confluency the C2C12 cells were transfected in a flask to certify an equal 
transfection and were seeded in 100 μl per well in a XFe24 seahorse plate (Seahorse 
bioscience, #SEA102340100) for 24 hours with 150 μl growth medium. For calibrations, the 
cartridge sensor was hydrated with 1 ml/well calibrate solution (Seahorse bioscience, 
#100840-000), and the cartridge was incubated overnight in a non-CO2 incubator at 37οC. On 
the day of the experiment, cells were washed with PBS and XFe medium. The XFe medium 
was prepared with 5.5 mM glucose (Sigma-Aldrich, #G5767), 1 mM sodium pyruvate 
(Sigma-Aldrich, #P8574), and 4 mM L-glutamine (Sigma-Aldrich, #G8540), and the pH was 
adjusted to 7.3 at 37ºC. The growth medium was changed with the 600 μl XFe medium in 
each well and incubated in a non-CO2 incubator at 37ºC for 1 hour prior to the measurement. 
The mitochondrial stress test was performed to measure bioenergetics status. The 
measurements of OCR were gained before and after the additions of ATP inhibitors 
Oligomycin (1μM), inner membrane uncoupler carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone (FCCP, 1μM), and Antimycin A (1μM) and Rotenone (1μM). These 
inhibitors of complex III and I are important parameters of mitochondrial function to 
measure basal respiration (baseline respiration before compounds addition), ATP production 
(oligomycin sensitive respiration), proton leak (oligomycin-insensitive respiration), maximal 
respiration (maximal uncoupled respiration), and spare respiratory capacity (maximal 
uncoupled respiration minus basal respiration), respectively (Figure 2-3). For normalization, 
after the measurement cells were washed with PBS and fixed with methanol. For cell 
detection, DAPI was added to count the number of cells. 
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Figure  2-2 Measurement of mitochondrial oxygen consumption rate 
The measurements of OCR were gained before and after the additions of Oligomycin, FCCP, 
and Antimycin A and Rotenone. Data were expressed as pmol/ min. (B) Effects of each 
reagent on various phases of mitochondrial oxygen consumption. Oligomycin blocks H+ 
flow through CV and therefore stops ATP production. This causes lack of H+ inside cells and 
therefore a decrease in the conversion of O2 to H2O by CIV. FCCP uncouples the flow of H+ 
across the membrane by CV and therefore allows the intracellular concentration of H+ to 
increase. This causes a large increase of H+ inside cells and therefore drives the ETC to 
maximum capacity. The increased electron flow and H+ available causes an increase in the 
conversion of O2 to H2O by CIV, therefore increasing OCR to the maximum. Rotenone and 
Antimycin A are inhibitors of ETC. Rotenone blocks CI, and Antimycin A blocks CIII. This 
prevents the electron chain from starting and therefore stops conversion of O2 to H2O. OCR 
decreases to its minimum point. 
 
B 
A 
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Glycolytic activity (ECAR) was determined with mitochondrial respiration, and the same 
parameters were calculated including basal ECAR (before the addition of compounds), 
Oligomycin-stimulated ECAR, and glycolytic reserve capacity (Oligomycin-stimulated 
minus basal ECAR). Data were expressed as mpH/ min. 
2.8 Quantitative real-time PCR 
Isolation of RNA, cells and tissues were homogenised with 1 ml TRIZOL® reagent 
(Invitrogen, #15596026) for 40 mg tissue or 10cm2per 6-well plate (Costar, #3516). 
Chloroform (VWR, #22711324) was added to each homogenised sample and mixed by 
inverting many times. The samples were incubated for 5 minutes at room temperature. The 
homogenate samples were centrifuged at 1300 rpm for 15 minutes at 4°C. The upper phase 
containing RNA was collected and mixed with isopropanol (Sigma-Aldrich, #I9516). RNA 
was centrifuged again at 1300 rpm for 20 minutes at 4°C. The supernatant was removed, and 
the remaining RNA was washed with 75% ethanol. After that, the ethanol was removed by 
centrifuging at 1300 rpm for 5 minutes at 4°C. The RNA pellet was air-dried and dissolved in 
DEPC water (Invitrogen, #AM9916) to measure RNA concentration. 
2.8.1 Measurement of RNA concentration 
Quantification of nucleic acids is an essential tool in molecular biology that requires 
reliability, accuracy, and the use of increasingly smaller sample volumes. RNA 
concentrations were measured using a NanoDrop Spectrophotometer (Eppendorf Thermo 
Scientific, Australia) at the absorbance of 260/280 nm. The NanoDrop Spectrophotometer 
was calibrated using 1 μl of DEPC water. RNA samples were used to measure nucleic acid 
purity and concentration. Purified RNA was used to measure complementary DNA (cDNA) 
with random primers according to the manufacturer’s instruction using the reverse 
transcription system. The RNA concentration of each sample was normalised to 1 μg/8 μl 
with DEPC water in an Eppendorf tube. DNase I reaction buffer and DNase I amplification 
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grade (master mix, Invitrogen, #11904-018) were added to the RNA sample and incubated at 
room temperature for 15 minutes, to remove the original DNA in mRNA. EDTA 25mM was 
added to the RNA sample and incubated at 65°C for 10 minutes to inactivate DNase I 
enzyme. The purified RNA sample was reverse transcribed using a high-capacity cDNA 
reverse transcription kit, containing reverse transcription buffer, dNTP mix, random primers, 
reverse transcriptase, and DEPC water. The samples were placed in controlled-temperature 
heat block and equilibrated at 25°C for 10 minutes, 37°C for 2 hours, 85°C for 5 seconds, and 
finally maintained at 4°C. The cDNA products from reverse transcription reactions were 
stored at 4°C to be used for real-time PCR. 
2.8.2 Real-time PCR 
The cDNA samples were analysed by real-time polymerase chain reaction (rt-PCR) for genes 
of interest using the SYBR Green real-time PCR system (Bio-Rad Laboratories Inc., USA). A 
reaction of master mixture including 1x IQ SYBR Green Supermix (Bio-Rad Laboratories 
Inc., USA; #170-8882), forward primers, and reverse primers, DEPC water for each gene of 
interest was prepared and added to each cDNA sample in a sterile plate. The plate was placed 
in a controlled-temperature heat block equilibrated at 50°C for 2 minutes, 95°C for 3 minutes 
and 40–50 cycles of 95°C for 15 seconds and 72°C for 30 seconds. The gene expression was 
analysed in duplicates from each sample and normalised against the ribosomal housekeeper 
gene 18S (GeneWorks, Australia). All reactions were performed on the iQTM 5 Real-time 
PCR Detection System (Bio-Rad Laboratories Inc., USA). Primers used for specific genes are 
in (Table 2-7).  
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Table  2-7 Primers sequences for measurements of gene expressions 
 Gene Primer sequences 
Loading 
Control 
18 S 
Forward      5’-CGCCGCTAGAGGTGAAATTCT-3’ 
Reverse       5’-CGAACCTCCGACTTTCGTTCT-3’ 
Myogenesis Myogenin 
Forward      5’-TCT ACC GGA GCC CCA CTTC-3’ 
Reverse       5’-CAT CAG GAC AGC CCC ACT TA-3’ 
 PGC1α 
Forward       5’-AAA CTT GCT AGC GGT CCT CA-3’ 
Reverse       5’-TGG CTG GTG CCA GTA AGAG-3’ 
Mitochondrial 
Biogenesis 
FOXO1 
Forward      5’-TTCAATTCGCCACAATCTGTCC-3’ 
Reverse5’-GGGTGATTTTCCGCTCTTGC-3’ 
 
TFAM 
Forward      5’-GAAGGGAATGGGAAAGGTAGA -3’ 
Reverse5’-AACAGGACATGGAAAGCAGAT-3’ 
 
NRF1 
Forward      5’-ATCCGAAAGAGACAGCAGACA -3’ 
Reverse5’-TGGAGGGTGAGATGCAGAGTA-3’ 
Mitochondrial 
Energy 
metabolism 
UCP3 
Forward     5’-AGAAGTTGCTGGAGTCTCACCTGT-3’ 
Reverse      5’-GGAGCGTTCATGTATCGGGTCTTT-3’ 
 
2.9 Statistical analyses 
Data were presented as means ± SE in this thesis. A two-tailed Student’s t-test was used for 
the comparison of relevant groups. The analysis was performed using GraphPad Prism 
software (5.0, GraphPad Software Inc, CA, USA). Differences at p<0.05 were considered to 
be statistically significant. 
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Chapter 3: Changes in the Cbl Family in Peripheral Tissues 
during Diet-induced Obesity 
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3.1 Introduction 
The overall aim of this chapter was to characterise the changes in the Cbl family in peripheral 
tissues and muscle formation in relation to the pathologic features of obesity and glucose 
intolerance induced by a high-fat diet (HFat) in mice. The HFat mouse is one of the most 
commonly used rodent models in laboratories for studying the underlying mechanisms in the 
development of obesity and associated diseases, which mimics the changes in humans (Hariri 
& Thibault, 2010; Y. S. Lee et al., 2011; Surwit, Kuhn, Cochrane, McCubbin, & Feinglos, 
1988). This nutritional rodent model of obesity and insulin resistance is well established in 
our laboratory (Iglesias et al., 2002; Li et al., 2016; Tan et al., 2008; J. Ye et al., 2003; J. M. 
Ye et al., 2011; Zeng et al., 2012). 
As reviewed in Section (1.1.5), obese subjects usually have greater adipose tissue cell mass 
than lean subjects (Ravussin, Burnand, Schutz, & Jequier, 1982). Obesity is associated with 
increased lipid storage in the liver and skeletal muscle, which causes insulin resistance 
(Hegarty et al., 2003; Shulman, 2014). The contribution of different tissues to the overall 
energy production in the whole-body is different. Insulin resistance is associated with obesity 
often because of impaired insulin-mediated suppression of glucose production in the liver, 
impaired insulin-mediated suppression of lipolysis in adipose tissue, and impaired insulin-
mediated glucose uptake in skeletal muscle (Hardy, Czech, & Corvera, 2012). Skeletal 
muscle tissue is the principle site of insulin stimulated glucose disposal. In healthy people, 
around 80% of the glucose is taken up by skeletal muscle following glucose ingestion 
(DeFronzo & Tripathy, 2009). Thus, liver, adipose tissue, and skeletal muscle were chosen to 
characterise the changes in the Cbl family in HFat-fed mice. 
c-Casitas B-lingase lymphoma (c-Cbl) is an E3 ubiquitin ligase that plays a role in regulating 
the process of energy metabolism at the whole-body level (Molero, Turner, et al., 2006; 
Molero, Waring, et al., 2006). It has been reported that mice with global c-Cbl KO are 
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protected against HFat diet-induced obesity, lipid accumulation in muscle and liver, and 
insulin resistance by increased energy expenditure (Molero, Waring, et al., 2006). Although 
the investigators attributed these protective effects to skeletal muscle, this study did not 
examine whether Cbl-b, another Cbl family member, may also be altered in response to c-Cbl 
KO. On the other hand, it has been reported that Cbl-b KO mice fed an HFat diet showed 
adiposity, lipid accumulation and insulin resistance (Abe et al., 2013). Furthermore, it is not 
known whether and how these Cbl isoforms may be altered in the liver, skeletal muscle and 
adipose tissues during the development of obesity and insulin resistance in HFat feeding. 
To investigate whether or not the Cbl expression in insulin-resistant tissues is altered during 
obesity, we used an HFat feeding-induced obesity model to measure the protein levels of c-
Cbl and Cbl-b and their tyrosine phosphorylation in insulin-resistant liver, white adipose 
tissue and skeletal muscle. 
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3.2 Materials and methods 
3.2.1 Animal model 
Male C57BL/6J mice of 10-12 weeks old were purchased and housed as described in Section 
2.2. After acclimatisation, 6 mice were fed either ad libitum a standard chow diet (CH) or a 
high-fat diet (HFat, 45% of calories derived from fats) with free access to water (Turner et 
al., 2009; Zeng et al., 2012). CH and HFat diets were prepared as previously described 
(Section 2.2.1). Although studies from our laboratory and others demonstrate that HFat 
feeding for more than 2 weeks induced obesity and insulin resistance (Buettner, Schölmerich, 
& Bollheimer, 2007; Chan et al., 2015; D. Zhang et al., 2010), for the study of this thesis, 
mice were fed CH and HFat diets for 6 weeks based on the previous work from our lab (J. M. 
Ye et al., 2011). This was done in order to characterise the possible changes in Cbls in the 
liver, skeletal muscle, and adipose tissue, as these regulatory proteins would be expected to 
respond to HFat-induced obesity and insulin resistance. 
 
 
 
 
 
Figure  3-1 Experimental design for diet-induced obesity and characterization of Cbl 
proteins. 
C57BL/6J male mice (10 to 12-week-old) were acclimatised for 1 to 2 weeks before 
receiving a chow (CH) or a high fat (HFat) diet for 6 weeks. After 2 weeks of CH and HFat 
feeding, CLAMS were performed on mice. An ipGTT was performed at week 4 of feeding. 
After 5 weeks of feeding, mice were fasted for 6 hours prior to an ipITT. At the end of the 
Week 0 2 3 51  6 
CLAMS ipGTT ipITT 
CH   or   HFat 
Fat weight 
 
Tissue lipid content 
 
Tissue Cbl changes 
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study, mice were culled by cervical dislocation, and tissues were weighted and freeze-
clamped immediately. Changes in Cbl protein levels were quantified by immunoblotting with 
specific antibodies in collected tissues. 
 
3.2.2 Assessment of obesity and whole-body energy expenditure 
The effect of dietary fat on obesity was assessed by measuring body weight of mice twice a 
week and measuring the weight of epididymal fat depots using a standard analytical balance. 
The food intake of the mice was measured twice a week by the weight difference of the diet 
divided by the number of days. 
As reviewed in Chapter 1 (Section 1.1.4), obesity can be caused by increased energy intake 
and/or reduced energy expenditure. After 2 weeks of feeding, the whole-body energy 
metabolism of mice was measured using an indirect calorimeter (Comprehensive Laboratory 
Animal Monitoring System or CLAMS, Columbus Instruments). Mice were weighed and 
placed in the metabolic chamber (20 cm × 10 cm × 12.5 cm) at 6p.m. After overnight 
acclimatisation, oxygen consumption (VO2) and respiratory exchange ratio (RER) were 
monitored continuously for 24 hours according to the manufacturer’s instructions. During the 
experiment, mice had ad libitum access to food and water. 
3.2.3 Assessment of glucose tolerance and insulin tolerance 
During the intraperitoneal glucose tolerance test (ipGTT), blood glucose levels were 
measured before and at 15, 30, 60, and 120 minutes after the injection of glucose at 2.0 g/kg 
BW as described in (Section 2.2.3).  
The whole-body insulin sensitivity of mice was measured at week 5 by an intraperitoneal 
insulin tolerance test (ipITT). Mice were fasted for 5 hours before the measurement of blood 
glucose levels. Insulin (Novo Nordisk Novorapid Penfill) was injected intraperitoneally to 
mice at a dosage of 0.75 IU/kg as described in (Section 2.2.3). 
 90 
 
Mice were killed at the end of week 6 by cervical dislocation, and liver, white adipose tissue 
and skeletal muscle were immediately freeze-clamped and stored at -80ºC for further 
experiments.   
3.2.4 Assessment of lipid accumulation 
Triglyceride concentrations in liver and muscle tissues were extracted and measured as 
described in (Section 2.2.4). Briefly, liver and muscle samples were homogenised with 
extraction solution (chloroform/methanol, 2:1) using a glass pestle tissue grinder. On the 
following day, 0.6% NaCl was added and followed by vortex mixing. The samples were then 
centrifuged to separate the aqueous phase from the organic phase. The organic phase 
containing triglyceride was dried. The extracts were reconstituted in ethanol. Triglyceride 
levels were measured using a Peridochrom triglyceride GPO-PAP reagent (Roche Diagnostic, 
Australia).  
3.2.5 Assessment of mitochondrial fatty acid metabolism markers in skeletal muscle 
Skeletal muscle samples were homogenised in 175 mM KCl and 1.98 mM EDTA buffer (pH 
7.4) with a glass homogeniser and were subjected to 3 freeze-thaw cycles. The activities of 
mitochondrial FAO enzymes, citrate synthase (CS), and β-hydroxyacyl-CoA dehydrogenase 
(β-HAD) were determined at 30ºC using a Flexstation 3 plate reader (Molecular Devices, 
USA). For CS activity measurement, the samples were mixed with 100 mmol/l Tris-HCl, 1 
mmol/l EDTA, 1 mmol/l MgCl2, 0.3 mmol/l acetyl CoA, 0.5 mmol/l oxaloacetate, and 0.2 
mmol/l dithio-bis (2-nitrobenzoic acid) (pH 8.2). The rate of absorbance change was 
monitored at 412 nm. For β-HAD activity measurement, the samples were mixed with 0.15 
mmol/l NADH, 50 mmol/l imidazole, and 0.1 mmol/l acetoacetyl CoA (pH 7.4). The activity 
of β-HAD was measured at 340 nm by monitoring the disappearance of NADH. Oxidative 
phosphorylation in mitochondria plays an important role in energy metabolism. The protein 
content of mitochondrial respiratory complexes and uncoupling protein-3 (UCP3) in muscle 
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were measured as an indication of the mitochondrial oxidation capacity. The expression of 
transcription factors involved in mitochondrial biogenesis, including PGC1α, mitochondrial 
transcription factor 1 (TFAM) and nuclear respiratory factor 1 (NRF1), were also measured 
by qRT-PCR (Section 2.9). 
3.2.6 Western blotting 
Freeze-clamped liver, skeletal muscle and white adipose tissue were homogenized in ice-cold 
RIPA lysis buffer at pH 7.4 supplemented with protease and phosphatase inhibitors. Tissue 
homogenates were centrifuged at 15,000 rpm for 20 minutes at 4°C. Protein levels in 
homogenised tissues were measured using BCA method. Protein samples were separated by 
SDS-PAGE and transferred to PVDF membranes. After blocking, the membrane was 
incubated with specific antibodies (Table 2-6); c-Cbl (1:1000) mouse monoclonal; phosphor-
c-Cbl at Tyr73, 1:1000), Cbl-b (1:1000), or α-Tubulin (1:1000), Mitomix (1:1000). Protein 
bindings were exposed to HRP-secondary antibody (Table 2-6) and detected using 
Chemiluminescence substrate. Blots were quantified using ImageLab software. 
3.2.7 Real-time polymerase chain reaction (rt-PCR) 
Total RNA was extracted from the cells using Trizol® reagent as described in (Section 2.9) 
according to manufacturing methods. Real-time PCR was carried out using the SYBR green 
PCR master mix method for mitochondrial markers, including UCP3, PGC1α, TFAM, NRF1, 
and Myogenin (Genework, Australia). The expression of each gene was analysed in triplicate 
and normalised against the expression of housekeeping gene 18S. The primer sequences were 
previously mentioned in Section 2.9, Table2-7.  
3.3 Statistical analyses 
Statistical analyses were performed as described in Section 2.9. 
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3.4 Results 
3.4.1 Effects of high fat diet on body weight and adiposity 
The body weight was similar between the groups at the beginning of the study (23-25g). As 
expected from the previous work of our laboratory (Li et al., 2016; Turner et al., 2008), the 
HFat diet-induced greater body weight gain compared to the CH diet throughout the time 
period of the experiment (Figure 3.2, A), and adiposity as indicated by measuring epididymal 
fat mass was significantly increased in mice fed a HFat diet (3 fold, ~69%,p<0.01) compared 
to CH-fed mice (Figure 3.2, B). This difference between HFat-fed mice and CH-fed mice was 
not due to an increase in food intake as both groups consumed comparable amounts of food 
during the study period (Figure3.2, C). The cumulative calorie intake was higher in HFat-fed 
group (Figure 3.2, D). 
  
 93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3-2 Metabolic characteristics of HFat diet-induced obesity in mice. 
Male C57BL/6 mice (10-12 weeks old) were fed a high-fat (HFat) diet ad libitum or a 
standard laboratory chow (CH) diet for 6 weeks. (A) Body weight gain over time. (B) The 
weight of epididymal fat depots was measured at the end of the study. (C) Food intake and 
(D) Calorie intake were measured twice a week. Data are expressed as mean ±SE from 6 
mice per group (*p<0.05,**p<0.01). 
 
 
 
 
A 
C 
B 
D 
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3.4.2 Effects of high fat diet on energy expenditure, fat oxidation and physical activity 
The measurements of VO2, RER, and physical activity were conducted. VO2 was used as an 
indication of whole-body energy expenditure. VO2 of CH and HFat-fed mice during baseline, 
daytime, night-time and over a 24hour period did not change (Figure 3.3, A). However, RER 
values (VCO2/VO2) of HFat-fed mice were significantly lower than CH-fed mice, regardless 
of the time of day (all p<0.01, Figure 3.3, B). This indicates that mice fed a HFat diet relied 
on fat as a main energy source. The HFat diet did not significantly change the physical 
activity in mice during daytime and night-time, except over a 24hour period HFat-fed mice 
were significantly less active compared to CH-fed mice (p<0.01, Figure 3.3, C). 
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Figure  3-3 Effects of HFat diet on whole-body energy expenditure, fat oxidation and 
physical activity. 
(A) Oxygen consumption (VO2 in ml/kg/hr), (B) The respiratory exchange ratio (RER) of the 
mice was calculated using the ratio of VO2 to carbon dioxide elimination (VCO2). (C) The 
physical activity of mice was monitored using infrared photo cell technology. Data are 
expressed as mean ± SE from 6 mice per group (**p<0.01).  
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3.4.3 Effects of high fat diet on glucose metabolism 
HFat-fed mice had impaired glucose tolerance, and this was indicated by higher levels of 
blood glucose after the glucose challenge compared to CH-fed mice. This was also 
determined by their glucose incremental area under the curve (iAUC) values, and it was 
significantly higher (iAUC 1450 vs. iAUC 710, p<0.01) than CH-fed mice (Figure 3.4, A). 
This indicates that a HFat diet induced glucose intolerance. 
To determine the response of blood glucose levels to insulin stimulation, an ipITT was 
performed. HFat-fed mice showed impairment in insulin tolerance 20, 40, 60, and 80 minutes 
after insulin injection. These were determined by iAUC values, which were significantly 
higher (iAUC 515 vs. iAUC 633, p<0.01) than in CH-fed mice (Figure 3.4, B).  
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Figure  3-4 HFat diet-induced glucose intolerance and insulin resistance. 
Male C57BL/6 mice at 10-12 weeks of age were fed a CH or HFat diet for 6 weeks. (A) The 
blood glucose curve during ipGTT was performed with an injection of glucose (2.0 g/kg) 
after 5-7 hours of fasting and iAUC. (B) The blood glucose curve during ipITT was 
performed with an injection of insulin (0.75IU/kg) and iAUC. Data are expressed as mean ± 
SE from 6 mice per group (**p<0.01). 
  
A 
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3.4.4 Effects of high fat diet on liver and muscle triglyceride levels 
It is well known that obesity is associated with lipid accumulation in liver and skeletal muscle 
(Hegarty et al., 2003; Shulman, 2014). It shows that intracellular lipid accumulation in these 
tissues leads to an impairment in the insulin signaling pathway (insulin resistance). Liver 
triglyceride levels were increased by more than 60% in HFat-fed mice compared to CH-fed 
mice (Figure 3.5, A). Additionally, the levels of muscle triglyceride in HFat-fed mice were 
elevated by threefold compared to CH-fed mice (Figure 3.5, B). 
 
 
 
Figure  3-5 Changes in TG levels in liver and muscle tissues. 
C57BL/6J mice were fed a CH or HFat diet for 6 weeks. TG levels in liver (A) and in skeletal 
muscle tissues (B) were measured. Data are expressed as mean ± SE from 6 mice per group 
(**p<0.01). 
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3.4.5 Effects of high fat diet on Cbl in liver, adipose tissue, and skeletal muscle 
c-Cbl and the related Cbl-b, another member of the Cbl family, were expressed in white 
adipose tissue and skeletal muscle (Hirasaka et al., 2007), but their levels in obese mice were 
not well defined. Since the liver is the main source for endogenous glucose production, 
accounts for 2.6% of body weight, and is responsible for around 21% of basal metabolic rate 
(Elia, 1991), we first assessed c-Cbl protein expression in the liver. c-Cbl expression in HFat-
fed mice was not changed compared to CH-fed mice (Figure 3.6, A). Additionally, tyrosine 
phosphorylated c-Cbl, which is phosphorylated in response to a variety of external stimuli 
(Tanaka, Neff, Baron, & Levy, 1995), was not changed in HFat-fed mice (Figure 3.6, B), 
while the overall function of c-Cbl was decreased in HFat-fed mice (Figure 3.6, C). However, 
Cbl-b, another Cbl family member that may lead to insulin resistance (Abe et al., 2013; 
Hirasaka et al., 2007) was significantly elevated (Figure 3.6, D, p<0.01) in the liver of HFat-
fed mice (Figure 3.6, B). 
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Figure  3-6 Changes in Cbl protein expression in liver. 
Male C57BL/6J mice were fed a CH or HFat diet for 6 weeks. The total capacity levels of c-
Cbl (A), c-Cbl tyrosine phosphorylation function (p-c-Cbl, B), the overall function of c-Cbl 
(C), and the total levels of Cbl-b (D) were quantified. Liver tissues were obtained from 6 
mice per group. Data are expressed as mean ± SE (**p<0.01).  
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White adipose tissue is the main site for fat storage. In the white adipose tissue of HFat-fed 
mice, c-Cbl protein expression was increased significantly (2.3 fold, p<0.01, Figure 3.7, A) 
compared with the CH group, and the phosphorylation levels of c-Cbl was decreased in HFat-
fed mice (Figure 3.7, B). However, the overall function of c-Cbl in the HFat group was not 
significant (Figure 3.7, C), and there was no change in the expression of Cbl-b (Figure 3.7, 
D). 
 
 
 
 
      
 
 
 
Figure  3-7 Changes in Cbl protein expression in white adipose tissue. 
Male C57BL/6J mice were fed CH or HFat diet for 6 weeks. The total capacity levels of c-
Cbl (A), c-Cbl tyrosine phosphorylation function (p-c-Cbl, B), the overall function of c-Cbl 
(C), and the total levels of Cbl-b (D) were measured. White adipose tissues were obtained 
from 6 mice per group. Data are expressed as mean ± SE (**p<0.01). 
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Further, we determined the level of Cbls family in skeletal muscle. The level of c-Cbl in 
HFat-fed mice showed that c-Cbl content was significantly increased in skeletal muscle (by ~ 
35%, p<0.01) in HFat-fed mice (Figure 3.8, A). Additionally, c-Cbl phosphorylation was 
increased (2.34 fold, p<0.01) in HFat-fed mice (Figure 3.8, B), and the overall function of c-
Cbl was even higher in HFat-fed mice (Figure 3.8, A). However, Cbl-b shows a different 
pattern compared to c-Cbl. The level of Cbl-b was reduced in HFat-fed mice. This means that 
Cbl-b has different functions in skeletal muscle compared to c-Cbl. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3-8 Changes in Cbl protein expression in skeletal muscle. 
C57BL/6J mice were fed a CH or HFat diet for 6 weeks. The total levels of c-Cbl (A), c-Cbl 
tyrosine phosphorylation (p-c-Cbl, B), the overall function of c-Cbl (C), and the total Cbl-b 
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levels (D) were quantified. Skeletal muscle tissues were obtained from 6 mice per group. 
Data are expressed as mean ± SE (**p<0.01). 
 
3.4.6 Markers for mitochondrial metabolism in skeletal muscle 
We examined the levels of several subunits of the oxidative phosphorylation complexes 
which play an important role in energy metabolism. The protein content of mitochondrial 
respiratory complexes was measured as an indication of the mitochondrial oxidation capacity. 
Complex I-IV contributes to the ETC, while complex V synthesises ATP from ADP within 
the mitochondria. All oxidative phosphorylation complexes were not changed in HFat-fed 
mice (Figure 3-9, A). Additionally, the mRNA levels of UCP3 were determined because it 
has been suggested that UCP3 is an important protein for the regulation of energy 
expenditure (Schrauwen, 2002). The mRNA expression of UCP3 was not changed in HFat-
fed mice. Moreover, the activities of two key regulatory enzymes involved in muscle 
mitochondrial energy homeostasis, CS and β-HAD, did not change with the HFat diet (Figure 
3-9, B).  
Further analyses were conducted with muscle samples by measuring relevant transcription 
factors involved in the regulation of mitochondrial biogenesis, including PGC1α, TFAM, and 
NRF1. No significant change was observed in PGC1α mRNA expression between CH-and 
HFat-fed mice. HFat-fed mice had a higher mRNA expression level of TFAM andNRF1 than 
CH-fed mice (Figure 3-9, C). 
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Figure  3-9 Changes in mitochondrial markers in skeletal muscle. 
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Mice were fed CH or HFat diet for 6 weeks. (A) The protein levels of mitochondrial complex 
were measured by Western blotting and normalised against α Tubulin. (B) UCP3 mRNA 
expression was quantified by qRT-PCR. (C) β-Hydroxyacyl-CoA dehydrogenase (β-HAD) 
activity was measured by the disappearance rate of NADH. (D) Citrate synthase (CS) activity 
was measured by detecting the rate of CoA-SH production using DTNB. (E) PGC1α, (F) 
NRF1, and (G) TFAM mRNA expressions were quantified by qRT-PCR, from the skeletal 
muscle of 6 mice per group. Data are expressed as mean ± SE (*p<0.05, **p<0.01). 
 
3.4.7 Effects of high fat diet on myogenesis 
To determine the relationship between muscle formation and the risk of obesity, the 
expression of the myogenesis marker myogenin was examined in skeletal muscle. Around 
60% reduction of myogenin was found with HFat-fed mice compared to CH-fed mice (Figure 
3-10), suggesting that there was a defect in the development of skeletal muscle formation in 
HFat-fed mice. 
 
 
Figure  3-10 Myogenin expressions in skeletal muscle. 
C57BL/6J mice were fed a CH or HFat diet for 6 weeks. Myogenin mRNA expression was 
quantified by qRT-PCR. Skeletal muscle tissues were obtained from 6 mice per group. Data 
are expressed as mean ± SE (*p<0.05). 
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3.5 Discussion 
The purpose of this chapter was to study the relationship between obesity-associated 
metabolic diseases and the expression of Cbl proteins in liver, adipose tissue, and skeletal 
muscle. The first aim was to establish the model of HFat diet-induced obesity, glucose 
intolerance, and lipid accumulation. As expected, 6 weeks of HFat feeding induced obesity, 
glucose intolerance, and deposition of TG in liver and skeletal muscle. This is consistent with 
the previous studies showing that dietary fat is the major factor leading to the development of 
obesity and insulin resistance in humans (Erion & Shulman, 2010) and rodents (Kraegen et 
al., 1991).  
The data on energy expenditure were expressed by oxygen consumption per mouse. Although 
it should be adjusted by the lean mass of mouse, because fat mass contributes more to energy 
expenditure (Butler & Kozak, 2010), lean mass could not be obtained at the time due to lack 
of a measuring instrument. A previous study showed that 4 to 8 weeks of HFat feeding does 
not significantly change the lean mass of C57BL/6 mice (Friedline et al., 2016; C. C. Hu, 
Qing, & Chen, 2004). Based on these reports, further analysis was performed using the unit 
of ml/mouse for VO2. The results confirm that there was no significant difference in VO2 
(ml/mouse) between HFat-and CH-fed mice. In comparison, HFat feeding clearly reduced 
RER, indicating an increased utilisation of fat. These phenotypes are also consistent with 
previous reports (Turner et al., 2007). 
Next, we examined the effects of HFat on muscle mitochondrial capacity and function. 
Previous studies in obese humans show that mitochondrial respiratory chain complex 
activities were reduced in skeletal muscle (Kelley, He, Menshikova, & Ritov, 2002; Ritov et 
al., 2010). Interestingly, in mice, it has been shown that a HFat diet increases mitochondrial 
capacity in skeletal muscle (Hancock et al., 2008; Li et al., 2016; Turner et al., 2007). 
Consistent with the previous studies in HFat-fed mice, we found significant increases in the 
 107 
 
expression of the transcription factors for the mitochondrial biogenesis NRF1 and TFAM. 
One of the upstream regulators for the expression of NRF1 and TFAM is PGC1α, a co-
transcriptional regulation factor (Jornayvaz & Shulman, 2010). However, HFat-fed mice did 
not have significant effects on PGC1α mRNA levels. The reason is not clear, but it has been 
reported that the activity of PGC1α is regulated by posttranslational modifications such as 
phosphorylation and acetylation (Fernandez-Marcos & Auwerx, 2011). Further studies are 
needed to examine the role of PGC1α protein in obesity related insulin resistance in muscle. 
We further examined the activity of muscle mitochondrial enzymes associated with oxidative 
capacity, including CS and β-HAD. Consistent with earlier studies (Hoeks et al., 2011; 
Lionetti et al., 2007), mitochondrial enzymes activity were not significantly different between 
HFat-and CH-fed mice. HFat-fed mice had no effect on UCP3 mRNA level in the present 
study. This suggests that the compensatory increase in muscle energy metabolism may be 
more related to the upregulation of mitochondrial capacity than mitochondrial enzyme 
activity. 
The second and major aim was to determine the effects of a HFat diet on the expression of 
Cbl proteins in insulin target tissues. Until recently, only a few researchers studied the 
relationship between HFat diet and the expression of Cbl proteins in different metabolic 
tissues (Abe et al., 2013; Wadley et al., 2004). Previous studies from our group found that c-
Cbl plays an important role in the regulation of energy metabolism (Molero et al., 2004). 
However, the identity of the molecular players is still unknown, as there are more than 150 
proteins that interact or are targets of the ubiquitin activity of c-Cbl (Schmidt & Dikic, 2005). 
Many of these proteins interact with Cbl-b. Although c-Cbl is a Cbl protein that has a similar 
structure to Cbl-b, some of the functions of c-Cbl and Cbl-b are different (Abe et al., 2014). It 
has been shown that global c-Cbl KO mice fed a HFat diet showed less adiposity and higher 
insulin sensitivity (Molero, Waring, et al., 2006). However, a HFat diet causes adiposity, 
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glucose intolerance, and insulin resistance in Cbl-b KO mice due to macrophage activation 
and pro-inflammatory pathways that interfere with insulin action (Abe et al., 2013). 
Therefore, it is important to determine the protein expression of c-Cbl and Cbl-b in liver, 
muscle, and adipose tissue in HFat-induced obesity and associated metabolic diseases. In the 
liver, the protein level of Cbl-b was significantly increased in HFat-fed mice while c-Cbl 
(both total and phosphorylation) did not show significant changes. Although the intrinsic 
function (indicated by p-c-Cbl/t-c-Cbl) was increased in white adipose tissue, the overall 
function (p-c-Cbl/α Tubulin) remained unchanged due to a decrease in the total content of c-
Cbl in HFat-fed mice compared to CH-fed mice. 
Skeletal muscle of HFat-fed mice showed significant increases in both c-Cbl protein level as 
well as their phosphor tyrosine level. As p-c-Cbl and c-Cbl content were both increased in 
HFat-fed mice, this suggests that the overall activity of c-Cbl is markedly increased in 
negatively correlation of obesity and associated lipid accumulation in muscle and whole-body 
insulin sensitivity. However, Cbl-b was decreased significantly in skeletal muscle of HFat-
fed mice. Taken together, these results indicate that the total c-Cbl activity is specifically 
increased in skeletal muscle but not in liver or fat during HFat-induced obesity, while Cbl-b 
was suppressed. 
Global c-Cbl KO HFat-fed mice showed a significant increase in the activity of different 
enzymes involved in muscle mitochondria FAO including CS, cytochrome c oxidase, and 
βHAD. These mice also exhibited an increase in glucose uptake, insulin action, and the 
protein level of acetyl-CoA carboxylase phosphorylation (pACC) in the skeletal muscle of 
obese mice (Molero, Waring, et al., 2006). Our finding of increased protein levels and 
activity of c-Cbl in skeletal muscle of HFat-fed mice suggests that skeletal muscle may be 
responsible for the enhanced energy consumption found in c-Cbl KO mice. However, these 
functions cannot determine whether this is due to a direct action of c-Cbl in skeletal muscle 
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that affects the whole body, or on the other hand, whether skeletal muscle metabolism may be 
influenced by the actions of c-Cbl in other tissues. It is of interest to note that the increases of 
mitochondrial markers for energy expenditure in skeletal muscle in the present study were 
much more moderate compared with HFat-fed c-Cbl KO mice (Molero, Waring, et al., 2006). 
One possibility might be that the compensatory increases in mitochondrial oxidative capacity 
and oxidation activity are still blunted in the present study because of the increased overall 
activity of c-Cbl. This possibility would be investigated in cultured muscle cells (Chapter 4) 
by molecular manipulation of c-Cbl. 
Apart from the mitochondrial associated energy metabolism, obesity is associated with a 
reduction in muscle formation in humans (Watts, McAinch, Dixon, O'Brien, & 
CameronǦSmith, 2013), muscle cells (Akhmedov & Berdeaux, 2013), and animals (D'Souza 
et al., 2015) as reviewed in (Section 1.2.4). The mRNA level for the key transcription factor 
myogenin regulating myogenesis was downregulated in the skeletal muscle of HFat-fed mice. 
This indicates that it is important to examine whether or not altering c-Cbl may affect 
myogenesis, which was subsequently addressed in Chapter 5. 
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Chapter 4: Effects of Cbl in Muscle Cell Energy Metabolism
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4.1 Introduction 
As reviewed in Chapter 1 (Section 1.5.3), previous studies from Molero et al. showed that 
mice lacking c-Cbl exhibit enhanced energy expenditure (Molero et al., 2004; Molero, 
Turner, et al., 2006). c-Cbl global KO mice were protected against HFat-induced obesity by 
increasing whole-body energy expenditure (Molero, Waring, et al., 2006). These studies 
indicate that c-Cbl may be an inhibitor of whole-body energy expenditure but did not 
determine whether this is due to a direct action of c-Cbl in skeletal muscle or other tissues.  
The findings from Chapter 3 revealed that in wild-type mice, c-Cbl is increased specifically 
in skeletal muscle by HFat feeding, which also induces obesity and insulin resistance, 
suggesting that skeletal muscle is a major site for the regulatory role of c-Cbl in whole-body 
energy expenditure as shown in the studies in c-Cbl KO mice (Molero, Waring, et al., 2006). 
To follow up these findings, the aim of this chapter was to investigate the cellular mechanism 
underlying the role of c-Cbl in regulating energy metabolism in muscle cells. Understanding 
the c-Cbl associated cellular mechanism controlling energy expenditure may reveal novel 
drug targets for the treatment of obesity.  
As reviewed in Chapter 1, energy metabolism in muscle cells is largely dependent on 
mitochondria because mitochondria are the apparatus used to generate energy within cells. 
Different mechanisms of mitochondrial dysfunctions have been suggested as potential causes 
for the development of obesity and/or insulin resistance, including impairment in 
mitochondrial capacity, mitochondrial function, and mitochondrial dynamics. It has been 
shown that mitochondrial dysfunction can cause intramyocellular lipid accumulation due to 
decreases in the utilisation of fuels, particularly fatty acids (Befroy et al., 2007; Mogensen et 
al., 2007). Intramyocellular lipid accumulation is associated with insulin resistance in skeletal 
muscle. It has been reported that obesity is related to the diminished activity of mitochondrial 
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oxidative enzymes in skeletal muscle (Turner et al., 2009). Thus, it is important to investigate 
the role of c-Cbl in mitochondrial capacity, oxidative function, and dynamics in muscle cells 
to understand how c-Cbl may affect the energy expenditure of muscle cells by regulating 
mitochondrial metabolism.  
The hypothesis for the studies in this Chapter was that c-Cbl negatively regulates the energy 
expenditure of muscle cells by inhibiting the mitochondrial capacity or oxidative function.  
This hypothesis was tested by conducting a series of experiments in the cultured C2C12 cell, 
a well-established murine muscle cell line. The role of c-Cbl was investigated by examining 
the effects of c-Cbl KD on energy metabolism, mitochondrial function, mitochondrial 
capacity, and mitochondrial dynamics, as well as the differentiation of C2C12. As a recent 
study reports that obesity may be related to the impairment in muscle differentiation 
(reviewed in Chapter 1, Section 1.2.4), the studies also compared the effects of c-Cbl KD 
between undifferentiated C2C12 (myoblasts) and differentiated C2C12 (myotubes). 
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4.2 Materials and methods 
4.2.1 Cell culture 
As described in Section 2.3.1, the C2C12 murine cell line was cultured in growth medium 
(GM) αMEM supplemented with 10% heat-inactivated FBS and 1% PSG, (all from 
Invitrogen, Australia) and maintained in a humidified incubator (95% air, 5% CO2) at 37°C. 
The C2C12 were seeded and allowed to reach full confluence. Cells were monitored and 
photographed using the Nikon TS100F inverted microscope and camera (Nikon Instruments 
Inc., USA). 
 
 
Figure  4-1 Experimental design of the c-Cbl study. 
C2C12 were seeded in the night before transfection. On the day, muscle cells were 
transfected with control or c-Cbl targeted shRNAs in Day0, when cells reach 70%‒80% 
confluency. After two days (Day2) of transfection, myoblasts were lysed for further 
metabolic assessment. Myotubes were grown in differentiation medium (DM) and were lysed 
5 days (Day5) post-transfection for further metabolic assessment. 
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4.2.2 Cell transfection 
As described in Section 2.3.4, at 70%‒80% cells confluency, c-Cbl specific and negative 
control short hairpin RNAs (shRNAs) plasmids (Invitrogen, Australia) were transfected with 
Lipofectamine™ 2000 (Invitrogen, #11668-019) following manufacturer protocols in Day0 
(Figure 4-1).  
4.2.3 Myoblasts differentiation 
To induce myoblasts differentiation, at Day2, the GM in myoblasts was changed to 
differentiation medium (DM); α MEM supplemented with 2% heat-inactivated FBS and 1% 
PSG for at least 4 days, as illustrated in Figure 4-1, to assess the metabolic function of 
myotubes. 
4.2.4 Western blotting 
As described in Section2.4, cells were washed with ice-cold PBS and homogenized in ice-
cold lysis HES-buffer supplemented with protease and phosphatase inhibitors. Protein levels 
in the homogenate were measured using the BCA protocol. Equal amounts of proteins 
(20‒40μg) were loaded and resolved on SDS-PAGE. Levels of protein were determined by 
the immunoblotting method using specific antibodies as described in Table 2-6. 
4.2.5 Real-time polymerase chain reaction (PCR) 
Total RNA was extracted from the cells using TRIzol® reagent as described in Section 2.8, 
according to the manufacturing protocol. Real-time PCR was carried out using SYBR Green 
PCR Master Mix method for murine PGC1α, FOXO1, and UCP3 (Genework, Australia). The 
expression of each gene was analysed in triplicate and normalised against the expression of 
housekeeping gene 18S using 2 delta CT methods. The primer sequences were described 
previously in Table2-7.  
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4.2.6 Measuring metabolic properties (XFe 24 Analyser) 
As described in Section 2.7, the XFe24 analyser measures physiological changes in cellular 
energy and metabolic pathways. It measures the shift between aerobic respiration through the 
oxygen consumption rate (OCR) and glycolysis through extracellular acidification rate 
(ECAR). OCR and ECAR were determined in myoblasts and myotubes. C2C12 myoblasts 
were seeded into an XFe24 cell culture plate in GM; however depending on the experiment, 
the medium may be replaced with DM to promote myotube formation. On the day of the 
experiment, cell medium is removed and replaced with assay (XF base) medium 
supplemented with glucose, sodium pyruvate and glutamine (pH 7.4) for 1 hour in a non-CO2 
incubator at 37 ºC to allow the medium temperature and pH to reach equilibrium. The 
cartridge sensors were calibrated and hydrated by an XFe24 analyser using XF calibrant as 
described by the manufacturer. The XFe24 analyser measured OCR and ECAR 
simultaneously for baseline and after the addition of Oligomycin (H+-ATPase inhibitor), 
FCCP (H+gradient uncoupler), Antimycin A (complex III inhibitor), and Rotenone (complex 
I inhibitor) (all from Sigma-Aldrich, Australia).  
4.3 Statistical analyses 
Statistical analyses were performed as described previously in Section 2.9. 
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4.4 Results 
4.4.1 Mitochondrial respiration in myoblasts and myotubes 
The seeding density and injection compound concentrations were first optimized. OCR and 
ECAR were analysed using a 2 mixes followed by 3 measurements cycle. Basal OCR 
increased in a proportionate manner to the increasing cell number from 5000, 10,000, 25,000, 
and 50,000. These cells were stimulated with different FCCP concentrations (0.3 μM‒ 0.6 
μM), (0.5 μM ‒ 1.0 μM), and (0.75 μM ‒ 1.5 μM). After the addition of 1.0 μM Oligomycin, 
FCCP showed the higher peak point at 0.5 μM – 1.0 μM on OCR, and the level of FCCP 
began to exhibit much lower respiration at 25,000 cells (Figure 4-2, A, C). For both basal and 
FCCP stimulated ECAR, 5000 and 10,000 cells did not increase (Figure 4-2, B, C). Further, 
basal OCR and ECAR values for different cell numbers were plotted to show the differences 
in the metabolic profile. Thus, the optimal seeding density is around 25,000 cells/well with 
0.5 μM–1.0 μM FCCP concentrations. A seeding density of 30,000 C2C12 cells and a 1.0 
μM FCCP concentration were chosen for further experiments. 
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Figure  4-2 Optimisation of C2C12 cell numbers and energy substrate concentrations. 
OCR (A) and ECAR (B) were measured on different muscle cell numbers. 5000, 10,000, 
25,000, and 50,000 cells/well were seeded and incubated for 24 hours under basal respiration 
followed by the addition of Oligomycin (1 μM), FCCP(0.3‒0.6 μM, 0.5‒1 μM, 0.75‒1 μM), 
Rotenone (1 μM), and Antimycin A (AA, 1 μM). (C) Relationship is shown between OCR 
and ECAR relative to cell numbers and FCCP concentrations. (Oligo: Oligomycin, FCCP: 
B  
C 
A  
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Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone, AA: Antimycin A, Rot: 
Rotenone). 
 
Experiments were performed in C2C12 mouse myoblasts and differentiated myotubes over 7 
days to examine cell morphology (Figure 4-3). To assess the development of oxidative 
respiration in C2C12, the cellular bioenergetics function was measured in proliferating 
C2C12 myoblasts and differentiated myotubes using the XF24 analyser (Seahorse, 
Biosciences). OCR was measured in proliferated myoblasts and differentiated myotubes in 
response to different substrates. The basal respiratory rate was higher in myotubes when 
compared to myoblasts (p<0.01). FCCP-induced maximal respiration was 1.3 times higher in 
myotubes than in myoblasts (p<0.01). ATP production, which is stimulated with the 
Oligomycin inhibitor, was increased in myotubes compared to myoblasts. Additionally, the 
ATP inhibition stimulated by Antimycin A and Rotenone was increased in myotubes (Figure 
4-4, A). ECAR displayed the cellular maximum glycolytic capacity. The basal glycolysis 
(ECAR) level was reduced significantly in myotubes compared with myoblasts (p<0.01, 
Figure 4-4, B). The total cell numbers in myotubes were significantly higher compared to 
myoblasts (p<0.01, Figure 4-4, C). 
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Figure  4-4 Comparison of mitochondrial respiration and glycolysis between myoblasts 
and myotubes. 
The OCR in basal; Oligomycin inhibitors, which induced ATP production; FCCP- induced 
maximal respiration; and Antimycin A (AA), and Rotenone (Rot) inhibitors that inhibit ATP 
(A) and basal ECAR in myoblasts and myotubes (B) were normalised to the total cell 
numbers (C). Data showed the means ± SE from 4 independent experiments per cell type. 
(Oligo: Oligomycin, FCCP: Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone, 
AA: Antimycin A, Rot: Rotenone) (**p<0.01). 
 
 
 
 
B C 
A 
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4.4.2 c-Cbl knockdown with shRNA in C2C12 muscle cells 
To investigate whether the absence of c-Cbl may impact mitochondrial function in 
proliferated myoblasts and differentiated myotubes, the respiratory profile of myoblasts and 
myotubes in c-Cbl KD was determined. Confluent muscle cells were transfected with 
negative control or c-Cbl targeting shRNAs. The expression of c-Cbl KD was assessed by 
Western blotting and normalised against αTubulin as βActin was changed during 
differentiation (myotubes) (Figure 4-5). c-Cbl expression was successfully reduced in 
myoblasts by about 80% compared to the control (p<0.01) using shRNA technology. This 
reduction of c-Cbl was maintained to myotubes by about 85% (Figure 4-6, A). This method 
was used for all the following experiments in this thesis. Experiments with less than 65% of 
c-Cbl KD expression in myoblasts were excluded. As it has been observed, many designed 
shRNAs are functional with a KD efficiency of more than 75 % (He et al., 2015).  
Furthermore, we investigated whether Cbl-b, another member of the Cbl family, was affected 
by knocking down c-Cbl. The results showed that c-Cbl KD had no effect on Cbl-b 
expression, regardless of myoblasts or myotubes (Figure 4-6, B). 
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Figure  4-5 Effect of c-Cbl knockdown on housekeeping proteins. 
C2C12 cells were transfected with c-Cbl (c-Cbl KD) or control (Cont.) plasmid using 
shRNA. βActin was changed during differentiation (A) compared to αTubulin (B). The data 
were immunoblotted from 6 independent experiments for βActin and αTubulin and were 
expressed as means ± SE (**p<0.01). 
βActin 
αTubulin 
Cont.   c-Cbl KD   Cont.   c-Cbl KD 
 Myoblasts    Myotubes 
A 
B 
Myoblasts Myotubes 
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Figure  4-6 Efficiency of knocking down c-Cbl by shRNA. 
c-Cbl was knocked down using shRNA against c-Cbl or control (Cont.) plasmid in C2C12. 
After 2 days of knocking down c-Cbl, myoblasts were lysed for SDS-PAGE followed by 
immunoblotting with a specific antibody for c-Cbl and Cbl-b. After 5 days of knocking down 
c-Cbl, myotubes were lysed. The data were expressed from 10 independent experiments 
(**p<0.01). 
A 
C 
c-Cbl 
αTubulin 
 Myoblasts    Myotubes 
Cont.c-Cbl KD   Cont.    c-Cbl KD 
Cbl-b 
αTubulin 
 Myoblasts   Myotubes 
Cont.    c-Cbl KD     Cont.       c-Cbl KD 
Myoblasts Myotubes 
B 
D 
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4.4.3 Effect of c-Cbl knockdown on mitochondrial respiration 
Following c-Cbl KD, basal respiration revealed small but significantly decreased in c-Cbl KD 
myoblasts compared with the control. The addition of FCCP mitochondrial uncoupler 
suppressed OCR in c-Cbl KD myoblasts by about twofold compared to control. The addition 
of Oligomycin and Antimycin A with Rotenone suppressed OCR, but not significantly in c-
Cbl KD myoblasts (Figure 4-7, A, C). In addition, c-Cbl KD decreased glycolysis in 
myoblasts (Figure 4-7, E). In contrast, c-Cbl KD increased basal and maximal respiration in 
myotubes (Figure 4-7, B, D). OCR and ECAR were normalised to total cell numbers. It is not 
surprising that cell numbers were higher in myotubes than myoblasts, and c-Cbl KD does not 
have an impact on cell numbers in both stages (Figure 4-7, G, H). These results in myotubes, 
which represents mature muscle tissue, are consistent with the higher mitochondrial 
respiratory rate in skeletal muscle of mice harboring c-Cbl loss of function (Molero et al., 
2004). 
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Figure  4-7 Effects of c-Cbl knockdown on OCR and ECAR profiles in C2C12 cells. 
OCR was measured using an XFe analyser in control and c-Cbl knockdown (KD) in 
myoblasts (A, C). OCR was measured in c-Cbl KD myotubes (B, D). The effect of c-Cbl KD 
in ECAR was measured in myoblasts (E) and myotubes (F). OCR and ECAR were 
normalised to total cell numbers (G, H). The data were presented as a means ± SE from 4 
independent experiments per cell type. (Oligo: Oligomycin, FCCP: Carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone, AA: Antimycin A, Rot: Rotenone) (*p<0.05, 
**p<0.01). 
 
4.4.4 Effect of c-Cbl knockdown on mitochondrial capacity 
To gain insight into the effect of c-Cbl on mitochondrial function during proliferation 
(myoblasts) and differentiation (myotubes), mitochondrial oxidative capacity (OXPHOS 
markers) was measured. Mitochondrial complex protein expression levels were enhanced, but 
not significantly, in c-Cbl KD myoblasts and myotubes (Figure 4-8). ATP synthase (complex 
V) increased significantly in c-Cbl KD by around twofold in myoblasts and 50% in 
myotubes. c-Cbl KD myoblasts displayed a significant increase in the expression levels of 
complex II. 
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Figure  4-8 Effect of c-Cbl knockdown on mitochondrial protein levels in myoblasts and 
myotubes. 
Protein levels of mitochondrial complex in c-Cbl KD in myoblasts (A) and myotubes (B). 
The data were presented the mitochondrial complexes on myotubes compared to myoblasts. 
The data were expressed as arbitrary units from 3 independent experiments per cell type 
(*p<0.05, **p<0.01). 
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4.4.5 Effect of c-Cbl knockdown on the AMPK signaling pathway 
As reviewed in Section 1.2.3.3, AMPK is the energy sensor and a key regulator of cell energy 
metabolism. The phosphorylation of AMPK at tyrosine (Thr172) in α-subunit is the most 
potent activator of its activity (D Grahame Hardie, 2007). Therefore, we analysed the effects 
of c-Cbl KD on the AMPK pathway by measuring the phosphorylation of AMPK at Thr172 
and the phosphorylation level of its substrate ACC at Ser79 in myoblasts and myotubes. c-
Cbl KD decreased the activation (phosphorylation) of AMPK (pAMPK, Figure 4-9, A) and 
the activation of ACC (pACC, Figure 4-9, C) in myoblasts. However, c-Cbl KD in myotubes 
significantly increased the phosphorylation of AMPK (by twofold, B), and ACC-Ser79 
phosphorylation (twofold, D). The total amounts of AMPK (Figure 4-9, E, F) and ACC 
subunits (Figure 4-9, G, H) were not changed during both c-Cbl KD myoblasts and 
myotubes.  
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Figure  4-9 Effect of c-Cbl knockdown on AMPK signaling pathway in myoblasts and 
myotubes. 
Following c-Cbl KD, the phosphorylation of AMPK was measured in myoblasts (A) and 
myotubes (B). The activation of ACC was measured in c-Cbl KD myoblasts (C) and ACC 
(D). The total amount of AMPK and ACC were measured and normalised against α Tubulin 
in myoblasts (C, D, respectively) and myotubes (G, H, respectively). The data was expressed 
as the means ±SE from 3‒4 independent experiments per cell type, (*p<0.05,**p<0.01). 
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4.4.6 Effect of c-Cbl knockdown on mitochondria biogenesis 
AMPK acts as a key regulator for mitochondrial biogenesis by enhancing cellular levels of 
NAD+ to activate SIRT1 activity. This leads to deacetylation and activation of PGC1α (B. B. 
Zhang et al., 2009). PGC1α is a master regulator for mitochondrial biogenesis and respiration 
in skeletal muscle. It has been shown that skeletal muscle, which is going through 
mitochondrial biogenesis, exhibited an increase in the expression of an outer membrane 
import receptor (TOM20) and other import machinery components (Takahashi et al., 1998). 
The cytosolic domain of TOM20 binds preproteins and initiates import receptors into mitochondria. 
These preproteins are directed to TOM20 through a heat shock protein 70 (HSP70) (Grey et al., 
2000). It is known that PGC1α interacts with different transcription factors, including 
forkhead box protein O (FOXO) 1 (C. Kang & Ji, 2013). In addition, it has been shown that 
PGC1α regulates uncoupling protein 3 (UCP3) in C2C12 (St-Pierre et al., 2003). 
Therefore, we measured the protein level of SIRT1, FOXO1, TOM20, HSP70, and the 
mRNA transcript levels of PGC1α and UCP3. 
As illustrated in Figure 4-10, mitochondrial biogenesis in c-Cbl KD was decreased on SIRT1, 
PGC1α, FOXO1, TOM20, and HSP70 in myoblasts (Figure 4-10, A, C, E, G, I, respectively). 
In contrast to the results of c-Cbl found in myoblasts, c-Cbl KD was highly increased on 
SIRT1, PGC1α by about threefold, FOXO1, and TOM20 in c-Cbl KD myotubes (p<0.01, 
Figure 4-10, B, D, F, H). However, the protein expression of HSP70 was found to be reduced 
by c-Cbl KD in myotubes (Figure 4-10, J, p<0.01). PGC1α activates the UCP3 mRNA 
expression in c-Cbl KD myotubes (Figure 4-10, L), while there is no effect in c-Cbl KD 
myoblasts. As it has been reported, the mRNA level of UCP3 was not changed in myoblasts 
(Boss et al., 1998). 
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Figure  4-10 Effect of c-Cbl knockdown on mitochondrial biogenesis in myoblasts and 
myotubes. 
Western blot analysis was performed, and the expression level of SIRT1, TOM20, and 
HSP70 antibodies were normalised against loading control αTubulin in myoblasts (A, G, I) 
and myotubes (B, H, J). Levels of mRNA transcripts of PGC1α, FOXO1, and UCP3 in 
myoblasts (C, E, K), respectively, and in myotubes (D, F, L), respectively, were determined 
by comparative qRT-PCR and normalised against loading control, 18S. The data showed the 
means ± SE from 3‒4 independent experiments (*p<0.05,**p<0.01). 
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4.4.7 Effect of c-Cbl knockdown on mitochondrial fission 
Mitochondria are highly dynamic organelles and continuously undergo fission, fusion and 
degradation processes. Each of these dynamic processes is critical for maintaining a healthy 
population of mitochondria, which control mitochondrial energy production and cell viability 
(Roy, Reddy, Iijima, & Sesaki, 2015). As reviewed previously in Section 1.2.3.5.1, 
mitochondrial fission or division is mediated by DRP1 and Fis1. Phosphorylation is the most 
wellǦstudied mechanism, with known sites for phosphorylation of DRP1 being at serine 
residues 616, which promote translocation of DRP1 into the mitochondria. 
Dephosphorylation at serine residues 637 has been shown to promote translocation of the 
cytosolic DRP1 to mitochondria and fission events (Cereghetti et al., 2008).  
The total capacity of DRP1 was reduced in c-Cbl KD in myoblasts (Figure 4-11, E). 
However, Fis1, another marker of mitochondrial fission, was activated (Figure 4-11, G) while 
the phosphorylation of DRP1 at serine residues 616 and 637 (Figure 4-11, A, C, respectively) 
were not affected by c-Cbl ablation in myoblasts. 
The phosphorylation of DRP1 at serine 637 in Cbl KD myotubes was decreased (Figure 4-11, 
D), and the total level of DRP1 was reduced in c-Cbl KD myotubes (Figure 4-11, F). 
However, the phosphorylation of DRP1 at serine 616 and Fis1 were not affected by knocking 
down c-Cbl in myotubes (Figure 4-11, B, H). 
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Figure  4-11 Effect of c-Cbl knockdown on mitochondrial fission proteins in myoblasts 
and myotubes. 
Changes in the protein levels of DRP1 at serine 616 (A), DRP1 at serine 637 (C), total level 
of DRP1 (E), and Fis1 (G) in c-Cbl KD myoblasts. Protein levels of DRP1 at serine 616 (B), 
DRP1 at serine 637 (D), DRP1 (F), and Fis1 (H) in c-Cbl KD myotubes. The semi-
quantification of Western blots data are shown as means ± SE from 3‒5 independent 
experiments (*p<0.05, **p<0.01). 
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4.4.8 Effect of c-Cbl knockdown on mitochondrial fusion protein content 
One of the other dynamic processes is mitochondrial fusion, which is required for the 
distribution of mitochondrial proteins, DNA, and lipids. Mitochondrial fusion is a process 
that involves integration of the outer and inner mitochondrial membrane and matrix content. 
The key regulators of these processes are the GTPase dynamic-related proteins, including 
MFN1 and MFN2 (Palmer, Osellame, Stojanovski, & Ryan, 2011). It has been shown that 
mitochondrial fusions are associated with mitochondrial metabolism (Bach et al., 2003). 
Mitochondrial fusions through MFN1 and MFN2 were inhibited in c-Cbl KD myoblasts 
(Figure 4-12, A, C, respectively). However, MFN1 was increased while MFN2 was 
decreased in c-Cbl KD myotubes (Figure 4-12, B, D, respectively).  
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Figure  4-12 Effect of c-Cbl knockdown on mitochondrial fusion proteins in myoblasts 
and myotubes. 
Changes in the protein levels of mitofusin 1 (MFN1, A) and mitofusin 2 (MFN2, C) in 
myoblasts and MFN1 (B) and MFN2 (D) in myotubes. Semi-quantification of Western blots 
from 3-4 independent experiments showed the means ± SE (**p<0.01vs. Control). 
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4.4.9 Effect of c-Cbl knockdown on mitophagy proteins 
Autophagy is a self-renewal process that is important for energy metabolism. Autophagy 
removes misfolded proteins and damaged organelles, including mitochondria and 
endoplasmic reticulum. It has been reported that enhanced autophagy can promote survival in 
response to stress by recycling macromolecules to maintain energy levels and removing 
damaged mitochondria (Y. Lee, Lee, & Gustafsson, 2012). 
Parkin is an E3 ubiquitin ligase, which is located at the outer mitochondrial membrane for 
ubiquitination to promote the uptake of mitochondria by autophagosomes. LC3A/B appears 
in Western blots as a double band; the top band represents the inactive cytosolic, and the 
bottom band represents the active lipid. LC3A/B interacts with the adaptor molecules on the 
mitochondria to promote their selective uptake and degradation. 
Parkin was found to be significantly higher in c-Cbl KD myotubes (Figure 4-13, B), while it 
was not changed in c-Cbl KD myoblasts (Figure 4-13, A). LC3 A/B was decreased in 
myoblasts (Figure 4-13, C) and enhanced in c-Cbl KD myotubes (Figure 4-13, D). 
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Figure  4-13 Effect of c-Cbl knockdown on mitophagy proteins in myoblasts and 
myotubes. 
These graphs represent mitophagy markers, Parkin (A, B) and LCII/I (C, D) in myoblasts and 
myotubes, respectively. The data from 3‒4 independent experiments are expressed as the 
means ± SE (**p<0.01vs. Control). 
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4.5 Discussion 
This chapter focused on the mechanism of c-Cbl on the energy expenditure of muscle cells 
with the focus on mitochondrial function. Loss of skeletal muscle mass or function may cause 
obesity (Kalyani, Corriere, & Ferrucci, 2014). It has been shown that c-Cbl deficient mice 
increased energy expenditure in skeletal muscle (Molero et al., 2004). The finding in Chapter 
3 indicates that c-Cbl was increased in skeletal muscle during HFat-induced obesity, 
suggesting that c-Cbl may suppress the ability of muscle to increase its energy expenditure. 
Thus, we hypothesised that c-Cbl may play an important role in muscle energy metabolism 
through the regulation of mitochondrial function, mitochondrial capacity, mitochondrial 
biogenesis, and mitochondrial dynamics. To better understand the role of c-Cbl functions at 
the molecular and cellular levels, in this chapter, c-Cbl was knocked down in muscle cells to 
examine the effect of c-Cbl on mitochondrial function, mitochondrial content, mitochondrial 
biogenesis, and degradation. 
Muscle cells (myotubes/myofibres) are developed from myoblasts. Muscle myotubes are 
frequently accompanied by a dramatic increase in the levels of mitochondrial function and 
mitochondrial content (Remels et al., 2010). It has been reported that myotubes are a highly 
metabolic cell type that relies on oxidative respiration, while myoblasts rely on glycolysis for 
their metabolic demands (Sin et al., 2015; Wagatsuma & Sakuma, 2013). To meet the high 
energetic demands, myotubes have large numbers of mitochondria arrayed in complex 
networks (Wagatsuma & Sakuma, 2013). Consistent with that, we found that the basal and 
the maximal respiration rate were 1.3times higher in myotubes when compared to myoblasts, 
suggesting that myoblasts were relying on glycolysis for ATP production rather than 
oxidative respiration.   
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4.5.1 Role of c-Cbl in mitochondrial energetic of muscle cells at proliferating stage 
Because c-Cbl and Cbl-b share a similar structure (Keane, Rivero-Lezcano, Mitchell, 
Robbins, & Lipkowitz, 1995; C. B. Thien & Langdon, 2005), they may play functionally 
redundant roles as a metabolic regulator. However, we found in Chapter 3 that Cbl-b showed 
different expression levels compared to c-Cbl in skeletal muscle from obese mice. We further 
determined whether Cbl-b was altered in c-Cbl KD myoblasts or not. The results showed that 
the KD of c-Cbl does not have an impact on Cbl-b. Thus, we rule out the possibility that Cbl-
b may influence the energy metabolism in c-Cbl KD muscle cells. 
c-Cbl KD myoblasts exhibited a significant decrease in basal and uncoupled oxygen 
consumption, and basal ECAR were decreased in c-Cbl KD myoblasts. However, the content 
of respiratory chain complex protein expression levels along with ATP synthase showed a 
significant increase in both subunits CII and CV. Complex II (respiratory complex II, 
succinate dehydrogenase), is the only enzyme that linked the respiratory chain to the Krebs 
cycle. Complex II oxidises succinate to fumarate as a part of the Krebs cycle. These results 
suggest that c-Cbl may promote energy production at the myoblast stage. 
It has been shown that mitochondria in muscle from c-Cbl KO mice were hyperatrophic 
(Molero et al., 2004). However, it was not clear whether the increase in mitochondria size 
reflects the direct changes of mitochondrial biogenesis, mitochondrial fusion, or both in 
muscle. In terms of mitochondrial biogenesis, AMPK has been suggested to play an 
important role in its regulation. AMPK is the energy sensor that maintains cellular energy 
homeostasis and its downstream target ACC, which was phosphorylated and decreased in c-
Cbl KD myoblasts. These results were consistent with mitochondrial oxygen respiration 
resulting from c-Cbl KD myoblasts. Because AMPK controls the expression of genes 
involved in energy metabolism in skeletal muscle, AMPK acts in coordination with another 
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metabolic sensor, the NAD+-dependent type III deacetylase SIRT1. AMPK enhances SIRT1 
activity by increasing cellular NAD+ levels, resulting in the deacetylation and modulation of 
the activity of downstream SIRT1 targets that include PGC1α and FOXO1. PGC1α levels are 
associated with skeletal muscle oxidative capacity, suggesting that it plays a major role in 
mitochondrial capacity (Garnier et al., 2003). SIRT1 and PGC1α were less significant in c-
Cbl KD myoblasts. Mitochondrial biogenesis is accompanied with increased outer membrane 
import protein through TOM20. Certain preproteins are directed to TOM20 via an HSP70-
preprotein complex in a process that does not require ATP (Mihara & Omura, 1996). c-Cbl 
KD in myoblasts was significantly decreased in both TOM20 and HSP70. 
Apart from mitochondrial biogenesis, mitochondrial content is influenced by degradation, 
and mitophagy is one mechanism for mitochondrial degradation. Our result showed that LC3 
II/I was decreased in c-Cbl KD myoblasts, which suggest that c-Cbl might be involved in 
mitochondrial degradation. These findings suggest that c-Cbl is important for mitochondrial 
biogenesis in myoblasts. 
To maintain a metabolically healthy environment, removal of damaged mitochondria through 
mitophagy requires cells to change fission and fusion pathway (Westermann, 2010). c-Cbl 
KD in myoblasts increased fission and decreased fusion pathways to maintain healthy 
mitochondrial function. These findings in myoblasts suggested that c-Cbl KD may rely on 
different tissues for their energy. Therefore, further studies are needed to examine the effects 
of c-Cbl in adipose tissue.  
4.5.2 Role of c-Cbl in mitochondrial energetic in mature muscle cells 
Muscle myogenesis is usually accompanied with mitochondrial bioenergetics because the 
expression levels of OCR and OXPHOS complexes are enhanced during C2C12 myogenesis 
(Remels et al., 2010). Myotubes are the mature form of muscle cells. The c-Cbl KD in 
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myotubes showed greater mitochondrial respiration and upregulation of a key protein marker 
for oxidative phosphorylation capacity, including complex I, III and UCP3. This suggests that 
c-Cbl is a suppressor of mitochondrial OXPHOS, and enhanced mitochondrial respiration by 
c-Cbl KD is due to increased mitochondrial capacity. These results in myotubes were 
consistent with the higher respiratory rate and enhanced metabolic function exhibited in c-Cbl 
KO mice (Molero et al., 2004). Also, these results provide evidence that c-Cbl has direct 
action in the muscle, independent of its action in other tissues. 
To explore a possible mechanism for the increased mitochondrial capacity in myotubes, we 
examined a variety of parameters known to be involved in mitochondrial biogenesis, 
mitochondrial dynamic, and degradation. Given the critical role of AMPK in regulating 
mitochondrial biogenesis, it is not surprising that AMPK and ACC were enhanced in c-Cbl 
KD myotubes. These results were consistent with the greater AMPK and ACC in skeletal 
muscle of c-Cbl KO mice and mutant c-Cbl mice (Molero et al., 2004; Molero, Turner, et al., 
2006). AMPK enhanced SIRT1 activity resulting in the deacetylation and modulation of the 
activity of FOXO1 and PGC1α in c-Cbl KD myotubes. These results suggest that c-Cbl KD 
may promotes energy expenditure in muscle cells through SIRT1 without the involvement of 
AMPK activation. However, further studies are required to investigate the mechanism by 
which c-Cbl affects AMPK activity. 
The muscle mitochondrial network undergoes a process related to fusion, fission, and 
mitophagy, which are coordinated to influence mitochondrial function. Fusion and  
mitophagy were upregulated and fission was downregulated in c-Cbl KD myotubes. This is 
suggested by an increase in MFN1, parkin, and LC3I/II, and a decrease in DRP1 activation at 
Ser 637. These findings indicated that mitochondrial quality in mature muscle cells was not 
affected when c-Cbl was knocked down. 
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In summary, these results demonstrated that the c-Cbl KD increased energy expenditure in 
muscle cells is likely attributed to an increased mitochondrial function and oxidative 
capacity. Moreover, the increased mitochondrial function and oxidative capacity also appears 
to be linked to AMPK mediated mitochondrial biogenesis. Our data suggest that c-Cbl may 
also influence mitochondrial functions by regulating their fission, fusion, and degradation 
process. However, the precise role of c-Cbl in mitochondrial dynamics is currently not clear. 
We propose that c-Cbl may play an important role in the regulation of the energy metabolism 
in muscle cells. However, the role of c-Cbl on muscle development as suggested by the 
changes in myoblasts and myotubes cannot be clearly defined from the obtained data in 
muscle energy metabolism. 
 
 
 
147 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: Roles of c-Cbl in Myogenesis and Lipid 
Accumulation 
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5.1 Introduction 
Mature skeletal muscle contains multinucleated cells called myotubes that are formed from 
the fusion of myoblasts. The process of forming myotubes from myoblasts (muscle 
progenitor cells) is called myogenesis. Skeletal muscle formation is a multistep process that 
requires proliferation of myoblasts, myotubes formation by the fusion of myoblasts, and 
expression of different transcription factors, including myocyte enhancer factor (MEF), 
MyoD, MHC, and myogenin. While MEF and MyoD regulate the myogenic lineage of 
myoblasts, MHC and myogenin drive the fusion of myoblasts into myotubes (E. J. Lee et al., 
2014; Mohun, 1992; Olson et al., 1991). As reviewed in Chapter 1 (Section 1.2.4), an 
increase in fat mass has been found to be associated with muscle dystrophy (Merlini, 
Vagheggini, & Cocchi, 2014). Skeletal muscle is an important contributor to whole-body 
energy expenditure at rest, and it could be argued that a change in muscle mass can influence 
the body energy balance (Frontera & Ochala, 2015). It has been reported that changes in 
mitochondrial activity affect the capacity of myoblasts to differentiate to myotubes and the 
expression of myogenin (Dyck, Heigenhauser, & Bruce, 2006). Consistent with this report, 
the results in Chapter 3 suggest that the myogenic differentiation in HFat-induced obesity in 
mice may be impaired along with the alteration in c-Cbl. However, the role of c-Cbl in 
myogenesis has not been studied. 
It has been reported that global c-Cbl KO in mice or c-Cbl depletion in adipocytes is not 
associated with impaired insulin action (Mitra et al., 2004; Molero et al., 2004). Surprisingly, 
these positive regulatory roles of c-Cbl in insulin action appear contrary to the negative 
regulatory role of c-Cbl in intracellular signal transduction initiated by RTK. As reviewed in 
Chapter 1 (Section 1.5.3), c-Cbl was initially identified as an E3 ubiquitin ligase and acts as a 
negative regulator of different receptor protein tyrosine kinase signalling pathways by 
targeting receptors for degradation and as an adaptor protein in tyrosine phosphorylation-
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dependent signaling (Fu, Hsu, Tang, & Shih, 2003; C. B. Thien, Walker, & Langdon, 2001). 
However, the role of c-Cbl KD in muscle cells is not clear. 
Therefore the aim of this Chapter was to investigate the mechanism of c-Cbl in myogenesis 
and lipid accumulation in muscle cells. We hypothsised that c-Cbl KD may enhance the 
formation of muscle by influencing the differentiation process of muscle cells and reduce 
lipid accumulation. This hypothesis was tested in muscle cells with the molecular 
manipulation of c-Cbl expression using the same approaches as described in Chapter 4 to 
examine the effects of c-Cbl KD on the key regulators of skeletal myogenesis. 
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5.2 Materials and methods 
5.2.1 Cell culture 
As described in Chapter 4, the C2C12 cell line was cultured in GM and maintained in a 
humidified incubator (95% air, 5% CO2) at 37 °C. C2C12 cells were seeded and allowed to 
reach full confluence (Figure 5-1). Muscle cells were monitored and photographed using the 
Nikon TS100F inverted microscope and camera (Nikon Instruments Inc., USA). 
5.2.2 c-Cbl knockdown or overexpression 
As described in Chapter 4, briefly, after cells reached 70% to 80% confluency with GM, 
C2C12 cells were transfected with c-Cbl and negative control shRNA plasmids or with c-Cbl 
overexpression (Qigen, Australia) in serum-free medium (Opti-MEM). Both shRNAs were 
transfected with Lipofectamine™ 2000 following manufacturer protocols (Invitrogen, 
#11668-019).  
5.2.3 Myoblasts differentiation 
As described in Chapter 4, to induce myoblasts differentiation, post-transfected cells were 
incubated with DM (α MEM containing 2% FBS) for 3 to 4 days (Figure 5-1). 
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Figure  5-1 Experimental design for the c-Cbl study during myogenesis. 
C2C12 were seeded in GM. Muscle cells were transfected with control or c-Cbl cloned in a 
pBluescript vector for ablation or cloned in pSRαNeo vector for overexpression in Day0, 
when cells reach 70%‒80% confluency. After two days (Day2) of transfection, the medium 
was changed to DM for 3 days (Day5). Myotubes were lysed at Day5 for further metabolic 
assessment. 
 
5.2.4 AMPK treatments 
To inhibit or activate AMPK, myotubes were incubated in the presence or absence of the 
AMPK antagonist, Compound C (20 μM, Sigma-Aldrich, #P5499), or the AMPK activator, 
AICAR (2 mM, TRC, #A611700) for 30 minutes in DM. 
5.2.5 Fatty acids preparation 
To induce insulin resistance, palmitic acid (Sigma-Aldrich, #P0500) was dissolved in ethanol 
absolute (EMPARTA). Palmitate solution was diluted with 2% BSA fatty acid free 
(BovoStar, #BSAS0.1) and filtered with a 0.33 mm filter. Transfected myotubes at Day5 
were incubated with palmitic acid for 16 hours at 37 ºC. For protein phosphorylation study, 
100 nM insulin (Actrapid®,  novo nordisk) was added for 15 minutes to the myotubes before 
cell lysates were harvested to measure insulin resistance expression. 
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5.2.6 Cell viability 
The effect of c-Cbl on cell proliferation was measured in myotubes using CellTiter 96® 
AQueous One Solution Cell Proliferation Assay (MTS, Promega, #G3580). MTS is a 
colorimetric method for determining the number of viable cells. The absorbance of 
dissolved formazan was measured at 490 nm in a CLARIOstar reader (BMG LABTECH). 
Briefly, after differentiation, cells were incubated with vehicle or palmitate treatment for 16 
hours; 20 μl of 5 mg/ml MTS was added to each well under the dark. The cells were 
incubated for 1 to 4 hours at 37°C with different concentrations of palmitate treatment (0.1 
mM, 0.2 mM, 0.4 mM, and 0.6 mM). 
5.2.7 Triglyceride determination 
As described previously in Section 2.2.4, cell lysates and standard glycerol solutions were 
mixed with triglyceride reagent. The absorbance was measured and related to cell proteins. 
5.2.8 Western blotting 
As described previously in Section 2.4, cell lysates were subjected to SDS-PAGE and 
Western blot analysis. After electrophoresis, the protein was transferred to PVDF membranes 
and blocked. The membranes were exposed to different primary antibodies and then washed 
and incubated with a peroxidase secondary antibody (Chapter 2, Table 2-6). Levels of protein 
were visualised by a chemiluminescence HRP substrate with Western Lighting Ultra Solution 
(Perkin Elmer, #NEL113001EA) using ChemiDoc (Bio-Rad Laboratories Inc., USA) for 
capturing images. 
5.2.9 Immunofluorescence 
As described in Section 2.5, cells were seeded and fixed on a coverslip. Cells were then 
blocked with goat serum and incubated with the following primary antibody: anti-desmin 
(1:200 dilution). Desmin is a muscle-specific protein and an important class-III subunit of the 
 153 
 
intermediate filament in skeletal muscle (Paulin & Li, 2004). After being washed, cells were 
incubated with the appropriate secondary antibody conjugated with Alexa Fluor 488 (Cell 
Signaling, USA) and counterstained with DAPI to visualise nuclei using a Nikon 
fluorescence microscope. The fusion index was calculated as the percentage of the average 
number of nuclei per desmin-positive cells above the total number of nuclei. The average 
numbers of nuclei in desmin-positive cells were measured with at least 3 nuclei in myotubes 
(Park et al., 2016; Teng et al., 2015). 
5.2.10 Migration (wound healing) assay 
In this assay, cells were plated in GM at a density of 5000 cells per well. Post-transfected 
cells were scratched on a confluent monolayer with small tips to scratch the cells, as shown in 
Figure (5-2).  
 
Figure  5-2 Representative wound closure images. 
Images from a scratch assay experiment at different time points were monitored using 
ImageXpress Micro XLS High Content System. 
 
5.3 Statistical analyses 
Statistical analyses were performed as described previously in Section 2.9.  
0 hour                      2 hours                       4 hours                 6 hours                    8 hours 
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5.4 Results 
5.4.1 Effect of c-Cbl knockdown on cell proliferation and migration 
To determine the effects of c-Cbl on cell numbers, transfected cells with c-Cbl shRNA were 
monitored. There were no significant changes in cell numbers between c-Cbl KD and control 
cells over the time period indicated (Figure 5-3). 
 
 
 
 
 
 
 
 
 
 
Figure  5-3 Effect of c-Cbl knockdown on cell proliferation in C2C12. 
Muscle cells were transfected with c-Cbl (c-Cbl KD). The cell number was quantified after 
the addition of DAPI using the ImageXpress system, and the results were expressed as a 
percentage of the nuclei number. The data showed the means ± SE from 5 independent 
experiments. Statistical comparisons showed no difference. 
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Subsequently, we determined whether the c-Cbl KD would affect cell regeneration by 
subjecting C2C12 cells with transfected c-Cbl to a migration assay. There were no 
differences between c-Cbl KD and the control in the wound closure process (Figure 5-4).  
 
 
 
 
 
 
Figure  5-4 Effect of c-Cbl knockdown on cell migration in C2C12. 
Muscle cells were wounded with a p20 pipette tip after c-Cbl ablation. Cells were imaged 
every 2 hours using an ImageXpress system with a point visiting and live-cell apparatus. Cell 
migration was expressed as the percentage of cell coverage in the initial cell-free zone. 
Values were presented as means ± SE from 3 independent experiments. 
  
KDC
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5.4.2 Effect of c-Cbl knockdown on cell fusion in myogenesis 
Myoblasts and myotubes are different in their behavior, morphology, and expression of 
different markers. Myoblasts are bipolar, spindle-shaped cells that immediately differentiate 
into elongated multinucleated myotubes and do not respond to growth factors in the medium. 
Preliminary results suggested that c-Cbl KD myoblasts fused more readily and formed mature 
myotubes compared to control cells when serum in the cultured medium was reduced (Figure 
5-5). 
 
 
Figure  5-5 Effect of c-Cbl knockdown on myogenesis in C2C12. 
C2C12 cells were transfected with control or c-Cbl targeting shRNAs. Microscopic images 
were taken from the control and c-Cbl KD cells cultured in GM (myoblasts) and then 
replaced with DM in confluent myoblasts for 2 days (myotubes). 
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Further, we quantified the preliminary observation in myotubes by staining c-Cbl KD in 
myotubes with DAPI to observe the nuclei and with desmin to observe the muscle cells 
(Figure 5-6, A). The c-Cbl KD induced a significant increase (p<0.03) in the myotubes 
fusion index compared to control cells (Figure 5-6, B), suggesting that c-Cbl may be 
involved in myonuclear accretion to promote myotubes formation. 
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Figure  5-6 Effect of c-Cbl knockdown on cell fusion in muscle fiber formation. 
Myotubes were immunostained after 5 days of transfection. (A) Muscle cells were stained 
with Desmin and nuclei with DAPI. (B) Fusion index quantification came from 3 different 
experiments (*p<0.05). 
 
5.4.3 Effect of c-Cbl knockdown on myogenic markers 
To further understand the molecular mechanisms underlying the regulation of myogenic 
differentiation by c-Cbl KD, myogenesis markers of were measured in myotubes. In 
agreement with an increase on fiber formation in c-Cbl KD, c-Cbl KD myotubes exhibited 
about twofold higher levels of myogenin, which is a key myogenic transcription factor 
(Figure 5-7, A) known to play a role in myogenic differentiation (Rochard et al., 2000). 
However, there are no changes in other myogenic proteins, including myocyte-enhancing 
factor 2 D (MEF2D), MHC, or MyoD (Figure 5-7, B, C, D). It is unlikely that this effect was 
due to the changes in chromatin remodeling as we observed no difference in the level of 
histone deacetylase 2 (HDAC2) (Figure 5-8). 
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Figure  5-7 Effect of c-Cbl knockdown on myogenic markers in myotubes. 
Expression levels of myogenin (A), MEF2D (B), MHC (C), or MyoD (D) were measured in 
C2C12 myotubes after knocking down c-Cbl (c-Cbl KD). The data showed the means ±SE 
from 3‒4 independent experiments (**p<0.01). 
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Figure  5-8 Effect of c-Cbl knockdown on chromatin remodeling in myotubes. 
Cells were transfected with control or c-Cbl targeting shRNAs (c-Cbl KD). Expression of 
HDAC2 was measured in myotubes. The data were obtained from 3 independent experiments 
and were represented as means ± SE.  
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5.4.4 Effect of c-Cbl overexpression on AMPK and myogenin 
As reviewed in Section 1.2.3, AMPK is the master regulator of whole-body energy 
expenditure, acts as a key regulator for mitochondrial biogenesis, is an important mediator of 
directional mitochondrial movement, and induced myotube formation in skeletal muscle. 
Thus, we further investigated whether the overexpression of c-Cbl would attenuate AMPK 
activation. 
c-Cbl was overexpressed by around 24% in myoblasts (Figure 5-9, A), and this reduction was 
maintained by around 35% in myotubes (Figure 5-9, B) to measure AMPK activation and 
myogenin protein expressions. Similar to what we observed in c-Cbl KD myoblasts, AMPK 
activation was reduced in c-Cbl overexpression myoblasts (Figure 5-9, C). We further found 
that c-Cbl overexpression significantly decreased AMPK activation in myotubes (Figure 5-9, 
D). Thus, the overexpression of c-Cbl ameliorates the function of AMPK in muscle cells 
(myotubes). To investigate the role of c-Cbl in the regulation of myogenesis, as we 
determined from the results previously (Section 5.4.4), we found that c-Cbl KD upregulates 
myogenin protein expressions in myotubes. Thus, the level of myogenin was determined in c-
Cbl overexpression, which may restrain it. The results showed that overexpression of c-Cbl 
attenuates myogenin levels in myotubes, although we could not detect any bands in 
myoblasts (Figure 5-9, E). Therefore, c-Cbl could be the molecular target for myogenesis. 
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Figure  5-9 Effect of c-Cbl overexpression on AMPK and myogenin. 
Cells were transfected with c-Cbl overexpression (c-Cbl OE) or negative control (WT) 
plasmids. After 2 days of transfection, myoblasts were lysed to measure the expression of c-
Cbl (A) and the activation of AMPK (C). Myotubes were lyzed after 5 days of transfection to 
measure the expression of c-Cbl (B), AMPK (D), and myogenin (E). Protein levels were 
determined by Western blotting with α Tubulin used as the loading control. The data showed 
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means ± SE, and the cell lysates were from 3‒4 independent experiments (*p<0.05, 
**p<0.01). 
 
5.4.5 Role of AMPK in c-Cbl mediated myogenesis 
In order to determine whether AMPK activation mediates the enhanced myogenesis observed 
in c-Cbl KD myotubes, the myotubes were incubated in the presence or absence of 
Compound C (CC) or AICAR in DM. AMPK activity was successfully reduced by CC 
(p<0.01) and enhanced by AICAR (p<0.01) as shown by Western blotting of ACC 
phosphorylation in control myotubes. The expression of ACC phosphorylation did not change 
upon AMPK inhibition or activation in c-Cbl KD cells (Figure 5-10, A).  
In the absence of the AMPK inhibitor, spontaneous myotube fusion occurred at greater speed 
in c-Cbl KD myotubes. AMPK inhibition with CC and activation with AICAR does not have 
an impact on myogenesis (Figure 5-10, B). However, we found that CC blocked myogenesis 
in myotubes, while myotube differentiation was normal in c-Cbl KD cells, which is 
evidenced via a microscope. Myotube formation was enhanced with AICAR-treated cells in 
control and c-Cbl KD cells (Figure 5-10, C).  
These results suggest that AMPK activation could drive the myogenic phenotype 
characteristic of c-Cbl ablation and in turn may be activated as a consequence of increased 
energy expenditure. Further studies could explain the effect of c-Cbl KD with AMPK 
activation. 
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Figure  5-10 Effect of c-Cbl knockdown on AMPK activity and myogenesis. 
Myotubes were treated with AMPK inhibitor (CC) or AMPK activator (AICAR) after 
transfection with WT or c-Cbl targeting shRNAs. c-Cbl KD promotes myotube formation 
independent of AMPK inhibition and activation. The levels of ACC (A) and myogenin 
(Myog, B) proteins were determined after the treatments. (C) Representative images of the 
control and c-Cbl KD cells are shown with CC and AICAR (*p<0.05, **p<0.01). 
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5.4.6 Role of c-Cbl knockdown on lipid accumulation 
5.4.6.1 Effect of palmitate on cell viability in myotubes 
To test the effect of chronic palmitate (mimic fatty acids) on cell viability in myotubes, 
muscle cells were seeded on a 96-well plate and after differentiation, cells were incubated 
with vehicle or palmitate treatment. The results showed that 0.1 mM, 0.2 mM and 0.4 mM of 
palmitate did not significantly suppress the viability in myotubes, but the cells started to die 
with 0.6 mM palmitic acid (Figure 5-11). Based on our finding and the study report by M. 
Yang et al. (2013), 0.2 mM of palmitic acid was chosen for further experiments to test the 
effect of c-Cbl on cell viability; this concentration induces insulin resistance in C2C12 
myotubes. 
 
 
 
 
Figure  5-11 Influence of palmitate on cell viability in wild-type myotubes. 
Myotubes were treated with palmitate for 16 hours. (A) The effects of palmitate on cell 
viability of C2C12 myotubes were evaluated by an MTS assay. (B) Photographs were taken 
after the addition of palmitate with the concentrations indicated (**p<0.01 vs. Vehicle). 
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We next measured the cell viability inc-Cbl KD myotubes incubated with either vehicle or 
0.2 mM palmitate for 16 hours using the MTS assay. Myotubes were then stimulated with or 
without 100 nM insulin for 15 minutes in order to induce insulin resistance state. The results 
showed that knocking down c-Cbl did not change cell viability in both basal and palmitate-
treated cells (Figure 5-12, A). c-Cbl KD with insulin-stimulation proliferates more 
significantly with time compared to the control. However, c-Cbl KD cells treated with 
palmitate and stimulated with insulin did not change the cell viability compared to the WT 
cells treated with palmitate and stimulated with insulin (Figure 5-12, B). Thus, c-Cbl KD 
myotubes do not have an effect on cell viability. 
 
 
 
Figure  5-12 Influence of palmitate on cell viability in c-Cbl knockdown myotubes. 
Following transfection with either WT or c-Cbl KD plasmids, cells were treated with either 
vehicle or 0.2 mM palmitate (pal) for 16 hours. (A) Cell viability of WT and c-Cbl KD 
myotubes was evaluated by an  MTS assay. (B) Cell viability of WT and c-Cbl KD myotubes 
were stimulated with 100 nM insulin (ins) for 15 minutes. The data were presented as means 
± SE from 3 independent experiments (*p<0.05 vs. WT). 
A B 
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5.4.6.2 Effect of c-Cbl knockdown on palmitate-induced triglyceride accumulation in 
myotubes 
The content of triglycerides was measured to investigate whether c-Cbl KD may impact lipid 
accumulation in myotubes. Palmitate increased triglyceride content by more than sixfold. 
Interestingly, triglyceride content was markedly reduced in c-Cbl KD myotubes. However, in 
the absence of palmitate, c-Cbl KD did not show a significant effect on the basal level of 
triglyceride in myotubes (Figure 5-13). 
 
Figure  5-13 Effect of c-Cbl knockdown on lipid accumulation in myotubes. 
c-Cbl KD myotubes were treated with 0.2 mM palmitate for 16 hours. Triglyceride (TG) was 
measured with a lipoprotein lipase-based colorimetric assay. The results represent the mean 
±SE from 3 independent experiments (**p<0.01 vs. c-Cbl KD, ##p<0.01 vs. WT). 
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5.4.6.3 Effect of c-Cbl knockdown on palmitate induced suppression of myogenesis 
To assess whether c-Cbl may have a negative impact on myogenesis under an insulin 
resistant state induced by the exposure of myotubes to palmitic acid, c-Cbl KD markedly 
increased the protein levels of myogenin (~ threefold) in myotubes. Incubation with palmitate 
reduced myogenin levels by more than 50%. This reduction was largely prevented by c-Cbl 
KD (Figure 5-14, A). Similarly, c-Cbl KD also preserved the morphological appearance of 
the myotubes in the face of the palmitate challenge and attenuated the myotubes loss the 
palmitate caused (Figure 5-14, B). 
 
 
 
 
 
 
Figure  5-14 Effect of c-Cbl knockdown on palmitate-suppressed myogenesis. 
Following transfection with c-Cbl or control plasmid, myotubes were treated with 0.2 mM 
palmitate for 16 hours. (A) Representative blots and densitometry of myogenin in muscle 
cells. (B) Representative images (4X) of muscle cells treated with vehicle or palmitic acid. 
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5.5 Discussion 
Although the role of c-Cbl in the control of energy metabolism has been shown in c-Cbl KD 
muscle cells (Chapter 4), the mechanism by which c-Cbl controls muscle fiber formation is 
not yet known. In this chapter, we aimed to determine whether c-Cbl may play a role in 
myotube formation, which may provide an additional link of c-Cbl to energy metabolism. 
The differentiation of myoblasts to myotubes was stimulated in c-Cbl KD cells independent 
of cell proliferation and migration. The differentiations of myotubes were enhanced in c-Cbl 
KD, which was indicated by increases in the fusion index and the protein expression of 
myogenin. HDAC2 is an enzyme that regulates gene expression by altering chromatin 
structure. It has been shown that inhibition of HDAC in obese diabetic mice enhanced 
oxidative metabolism and promoted energy expenditure in skeletal muscle (Galmozzi et al., 
2013). Our findings do not support the changes in chromatin remodeling as there was no 
difference in the levels of HDAC2 in c-Cbl KD myotubes. 
To examine whether AMPK plays a role in c-Cbl mediated changes in myogenesis, we 
overexpressed c-Cbl to investigate the response of AMPK activity and myogenin expression 
in muscle cells. The results in myoblasts showed that c-Cbl overexpression has the same 
effect as c-Cbl KD on AMPK activation. However, overexpression of c-Cbl was observed to 
attenuate AMPK and myogenin levels in myotubes. This finding appears to suggest a link 
between AMPK activity and c-Cbl‒induced inhibition of myogenesis. We further 
investigated the role of AMPK in c-Cbl‒mediated changes in myogenesis in c-Cbl KD 
myotubes. The changes in ACC and myogenin expressions in c-Cbl KD myotubes were not 
affected by either the inhibition or stimulation of AMPK. These results suggest that c-Cbl 
promotes myogenesis in muscle cells independent of AMPK activation.  
It has been reported that c-Cbl KO mice have reduced adiposity accompanied with enhanced 
insulin sensitivity (Molero et al., 2004). In Chapter 3, we found that c-Cbl expression was 
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associated with deteriorated insulin sensitivity in skeletal muscle in HFat-fed mice. 
Therefore, we determined whether c-Cbl KD in muscle cells may offer protection against 
muscle insulin resistance induced by saturated fatty acids such as palmitate. We found that c-
Cbl KD in myotubes reduced lipid accumulation in response to palmitate exposure. The 
result, which was supported by decreased TG, suggests that a lack of c-Cbl in muscle cells 
may enhance insulin sensitivity. The increased triglyceride content in palmitate-treated cells 
may result from two possibilities: one is increased incorporation of palmitate into triglyceride 
and the other possibility is inhibited FA oxidation (Listenberger et al., 2003). However, 
further studies are needed to confirm this result. 
Changes in muscle mitochondrial size have been associated with changes in energy 
expenditure (Kelley et al., 2002). It has been reported that obesity has significant negative 
effects on muscle mass (Akhmedov & Berdeaux, 2013) which is in line with another report 
that palmitate has a negative effect on the myotube morphology (Bryner, Woodworth-Hobbs, 
Williamson, & Alway, 2012). We found that palmitate caused myotube loss, and this 
appearance was observed under the microscope and proven by decreasing myogenin 
expression, which is ameliorated by c-Cbl KD in myotubes. Indeed, c-Cbl KO mice showed 
an increase in the average size of mitochondria using electron microscopy (Molero et al., 
2004). Thus, future studies should examine the size of myotubes, including the length and 
diameter, as well as contractility to definitively ascertain the functional role of c-Cbl in this 
regard. 
In summary, the results of this chapter suggest that c-Cbl KD enhanced myogenesis without 
the involvement of AMPK activation. Given that fatty acid increases lipid accumulation and 
suppresses myogenesis, c-Cbl KD attenuates palmitate-induced triglyceride accumulation and 
myogenesis suppression in myotubes. 
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Chapter 6: General Discussion 
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The overall aim of this thesis was to investigate the role of c-Cbl in muscle energy 
metabolism in relation to obesity and insulin resistance. This chapter summarizes the key 
findings of the studies performed in this thesis and provides the overall conclusions from 
these findings. This chapter discusses the potential implications and limitations of the study 
and proposes further research based on the findings from this thesis. 
6.1 Major findings 
As described in Chapter 1, the epidemic of obesity has been increasing at an alarming rate 
worldwide. High energy intake (particularly in the form of fat) and low energy expenditure 
are major risk factors leading to obesity. Obesity is associated with impairment in skeletal 
muscle metabolism, including mitochondrial biogenesis, muscle cell formation, and insulin 
resistance. Proper muscle function is required for maintaining regular physical activity for 
losing weight, improving energy metabolism, and reducing the complications associated with 
obesity (Slentz, Houmard, & Kraus, 2009). 
Chapter 3 used an HFat diet model to examine the metabolic characteristics of mice fed an 
HFat diet on obesity and related metabolic diseases. Consistent with previous reports from 
our group and other groups (Cantley et al., 2013; Chan et al., 2015; Savage et al., 2006; J. M. 
Ye et al., 2011), a lard-based HFat diet (45% Kcal) induced obesity (indicated by increased 
body weight and epididymal fat mass), whole-body insulin resistance (indicated by the 
increased iAUC in GTT together with ITT) and lipid accumulation (indicated by increased 
TG levels in the liver and skeletal muscle). In addition, an HFat diet reduced RER, while VO2 
and physical activity in mice during day and night times were not changed. Consistent with 
previous reports from our group and other groups, a HFat diet in mice increased 
mitochondrial function in skeletal muscle (Hancock et al., 2008; Li et al., 2016; Turner et al., 
2007). The results in Chapter 3 showed that a HFat diet induced obesity and insulin resistance 
in mice. These findings suggested that HFat-induced obesity is a good model to determine the 
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effects of Cbl proteins in key peripheral insulin-resistant tissues, including liver, white 
adipose tissue, and skeletal muscle. 
In relation to obesity, the major investigation in Chapter 3 was to determine the effects of Cbl 
protein level on the liver, adipose tissue and skeletal muscle during the development of 
obesity. Interestingly, consistent with the finding in skeletal muscle of obese Zucker rats 
(Wadley et al., 2004), c-Cbl was higher in skeletal muscle during HFat feeding, but it does 
not have an effect on liver, and adipose tissue. These findings suggest a relationship between 
c-Cbl in skeletal muscle and obesity. In addition, these findings support our hypothesis that a 
HFat diet induces obesity and glucose intolerance, and it upregulates c-Cbl expression in 
insulin-resistant skeletal muscle. Chapter 3 also showed that HFat-induced obesity may be 
associated with a decrease in skeletal muscle formation. Therefore, subsequent studies were 
focused on c-Cbl in muscle cells. 
Chapter 4 used a murine C2C12 cell line as an in vitro model of skeletal muscle to investigate 
the effect of c-Cbl on energy metabolism by knocking down c-Cbl using shRNA technology. 
Myoblasts were differentiated to myotubes, as a model of muscle cells. We investigated the 
role of c-Cbl in proliferating (myoblasts) and differentiation (myotubes) stages. 
In line with different studies, we found that myotubes rely on oxidative metabolism rather 
than glycolysis for their energy demands, while myoblasts are highly glycolytic (Patková, 
Anděl, & Trnka, 2014; Remels et al., 2010). 
6.1.1 c-Cbl in myoblasts at the proliferating stage 
c-Cbl KD in myoblasts decreased oxidative metabolism with around 45% reduction. These 
findings suggest that myoblasts may depend on glycolysis for their energy demand, when c-
Cbl is KD. However, c-Cbl KD reduced glycolysis levels by around 35% in myoblasts. It has 
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been shown that changes in mitochondrial function affect mitochondrial oxidative capacity, 
mitochondrial biogenesis, and degradation. In terms of mitochondrial content, c-Cbl KD 
myoblasts increased mitochondrial content through electron transport chain capacity in 
succinate dehydrogenase (complex II) and ATP synthase (complex V). This result suggests 
that at the differentiation stage c-Cbl may be required for maintaining mitochondrial energy 
production.  
It has been shown that PGC1α is associated with mitochondrial biogenesis in muscle cells 
(Wu et al., 1999). However, the level of the PGC1α protein in c-Cbl KD myoblasts was 56% 
reduced. Indeed, the level of ACC, a rate-limiting enzyme for mitochondrial FFA oxidation 
and UCP3, a muscle mitochondrial uncoupling protein, was decreased in c-Cbl KD myoblasts 
compared with control. To explore the mechanism of decreased ACC phosphorylation in c-
Cbl KD myoblasts, we examined the expression and phosphorylation state of the upstream 
ACC regulator AMPK. AMPK is the master regulator of mitochondrial biogenesis in skeletal 
muscle. Consistent with a decrease in ACC phosphorylation, we observed a significant 
decrease of about 50% of AMPK phosphorylation in c-Cbl KD myoblasts. AMPK regulates 
mitochondrial biogenesis by activating SIRT1 activity. However, based on the protein 
expression, c-Cbl KD in myoblasts ameliorates SIRT1 activity. Indeed, PGC1α‒mediated 
mitochondrial biogenesis and respiration by regulating the activity of a large number of 
transcription factors in muscle, including FOXO1 (Fernandez-Marcos & Auwerx, 2011). 
Mitochondrial biogenesis increased the expression of the mitochondrial protein import 
machinery components; TOM20 (Grey et al., 2000) and HSP70 are involved in this process 
(Mihara & Omura, 1996). Therefore, we examined the role of c-Cbl in these mitochondrial 
biogenesis markers. The total expression levels of FOXO1, TOM20, and HSP70 were 
reduced as well in c-Cbl KD myoblasts. These findings suggest that c-Cbl may be required 
for mitochondrial biogenesis at the muscle proliferation stage. 
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Besides mitochondrial biogenesis, mitochondrial dynamics are important in maintaining the 
metabolic function of mitochondria (Bach et al., 2003). It has been reported that activation of 
mitochondrial fission/division was necessary to induce muscular atrophy (Romanello et al., 
2010). It is not surprising that c-Cbl KD in myoblasts suppressed total mitochondrial fission 
content which is indicated by DRP1, but its phosphorylations at serine residues 616 and 637 
were not changed. However, the Fis1 protein level was enhanced. The effect of c-Cbl KD in 
mitochondrial fusion is similar to the effect of c-Cbl KD in mitochondrial biogenesis in 
myoblasts by decreasing mitochondrial fusion. In addition, downregulation of c-Cbl resulted 
in reduced mitophagy in myoblasts. These results suggest that c-Cbl may play a role in 
maintaining a homeostasis of mitochondrial dynamics and degradation. 
6.1.2 c-Cbl in mature muscle cells 
In contrast to myoblasts, muscle differentiation is closely associated with increased 
mitochondrial function. Mitochondria generate most of the required energy for cellular 
function through oxidative metabolism. In line with the finding in c-Cbl KO mice (Molero et 
al., 2004), c-Cbl KD myotubes enhanced mitochondrial function by 15% and mitochondrial 
content through ATP synthase by around 50%, suggesting that c-Cbl may have an impact on 
mitochondrial function in skeletal muscle. However, glycolysis levels were not changed in c-
Cbl KD myotubes. This finding suggests that c-Cbl KD may shift its metabolic status from 
glycolysis toward oxidative metabolism in muscle cells. 
c-Cbl KD in myotubes enhanced AMPK and ACC. These results in myotubes are consistent 
with c-Cbl KO mice as reported by Molero et al. (2004). This suggests that c-Cbl could be 
the main regulator of whole-body energy expenditure in mature muscle cells. Activation of 
AMPK has been linked to an enhanced expression of factors favoring oxidative metabolism, 
including UCP3 (Hood et al., 2015). Because the AMPK pathway was enhanced in c-Cbl KD 
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myotubes, the total protein levels of UCP3 were increased. These results suggest that c-Cbl 
may be an important upstream regulator of AMPK activity in muscle and that this effect may 
be a major contributor to enhanced energy expenditure in these cells. 
c-Cbl KD in myotubes has a similar effect on the master regulator of mitochondrial 
biogenesis PGC1α. c-Cbl KD increased expression levels of mitochondrial biogenesis 
markers, FOXO1 and TOM20, and it decreased HSP70 levels.  
Taken together, these data indicate that c-Cbl KD plays a crucial role in energy expenditure 
by increasing mitochondrial biogenesis in myotubes and ameliorate that in myoblasts. Thus, 
the enhancement of mitochondrial biogenesis could be achieved not only by exercise but also 
by depleting c-Cbl function. 
Interestingly, c-Cbl KD inhibits mitochondrial fission activity through its total capacity in 
myotubes. Mitochondrial fusion was enhanced in c-Cbl KD by MFN1, while MFN2 was 
decreased. As reviewed in (Section 1.2.3.5), each mitofusin has different roles in the fusion 
complex; depletion of MFN1 induces small vesicular mitochondria broadly distributed in the 
cell, whereas depletion of MFN2 leads to formation of larger vesicular mitochondria 
concentrated around the nucleus (Hsiuchen Chen et al., 2003), suggesting that c-Cbl may lead 
to broadly distributed mitochondria in myotubes. c-Cbl KD resulted in increased mitophagy 
in myotubes, suggesting that c-Cbl may also regulate mitochondrial function by influencing 
mitochondrial degradation. 
Overall, in myoblasts, c-Cbl KD plays a role in inhibiting energy metabolism, suggesting that 
there is another mechanism these cells rely on for their energetic needs. In contrast to 
proliferating myoblasts, c-Cbl KD improves energy expenditure through mitochondrial 
function, mitochondrial capacity, and mitochondrial biogenesis in mature muscle cells.  
 178 
 
Chapter 5 demonstrated the effect of c-Cbl in myotube differentiation in C2C12. While c-Cbl 
KD enhanced energy metabolism in myotubes, there was no effect on cell numbers, which 
was indicated by cell proliferation and migration studies. c-Cbl KD stimulates differentiation 
in myotubes by enhancing myotube fusion rate, and increased myogenic marker, that is, 
myogenin‒the myogenic regulatory factor that regulates the differentiation of myoblasts into 
myotubes (Hasty et al., 1993; Nabeshima et al., 1993). These findings suggest that c-Cbl KD 
may promote myoblast differentiation and regeneration in muscle cells.  
In Chapter 5, c-Cbl was overexpressed to determine whether c-Cbl affects the AMPK and 
myogenin expressions. In contrast to c-Cbl KD, we found that AMPK activation and 
myogenin were declining on c-Cbl overexpression. To confirm that AMPK in c-Cbl KD 
myotubes mediated myogenesis, AMPK was manipulated by inhibiting or stimulating AMPK 
in c-Cbl KD myotubes. The result showed that myogenin in c-Cbl KD was not affected by 
the stimulation or inhibition of AMPK. In summary, these results indicate that AMPK 
activity does not promote myogenesis through a mechanism mediated by c-Cbl. 
Skeletal muscle is an important site of insulin resistance in obesity. Therefore, the effect of c-
Cbl on lipid accumulation was investigated in C2C12 myotubes. Interestingly, the first 
finding of this study was that c-Cbl KD in myotubes reduced lipid accumulation, which was 
indicated by decreased TG levels. Skeletal muscle wasting often occurs with insulin 
resistance (X. Wang, Hu, Hu, Du, & Mitch, 2006). It has been reported that palmitate had 
negative effects on myotube size and morphology (M. Yang et al., 2013). Consistent with the 
finding in Chapter 3, myogenin was impaired during an insulin resistance condition. Not 
surprisingly, c-Cbl augmented myogenesis in an insulin-resistant state through the myogenin. 
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6.2 Summary and conclusion 
These studies indicate that c-Cbl plays a key role in the regulation of muscle energy 
metabolism, which is required to maintain energy expenditure. The results from muscle cells 
suggest that enhanced energy expenditure found in c-Cbl KO mice is primarily driven from 
skeletal muscle. However, the exact mechanism and targets of c-Cbl in skeletal muscle by 
which c-Cbl regulates energy metabolism are still unknown due to the complexity of the c-
Cbl protein itself.  
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Figure  6-1 Illustration of the role of c-Cbl in relation to energy metabolism in muscle. 
9Findings supportive of the hypothesis. 
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6.3 Limitations and future directions 
6.3.1 Animal studies 
It has been reported that greater insulin sensitivity and lower adiposity exhibited by mice with 
loss of c-Cbl function could be due to enhancement of energy expenditure in skeletal muscle. 
However, it is still unknown whether these effects are primarily driven by a direct action of c-
Cbl in the skeletal muscle, or, alternatively, the muscle phenotype is an indirect consequence 
in response to circulating nutrients or factors released by other tissues. To address this, future 
studies could aim to determine whether lack of c-Cbl in skeletal muscle of mice fed a HFat 
diet is sufficient to affect whole-body energy homeostasis and reduce adiposity. In addition, 
future studies could test whether excessive c-Cbl functions in mice may lead to obesity. 
These could be achieved using the adeno-associated virus 6 (AAV6) containing the skeletal 
muscle specific creatine kinase promoter. The muscle-specific creatine kinase promoter will 
ensure the expression of the transgenes in skeletal muscle only and not result in transgene 
expression in heart nor in a systemic inflammatory response (Gregorevic et al., 2006; 
Gregorevic et al., 2004). 
In order to consolidate the relevant results from c-Cbl KO mice, cultured primary cells 
isolated from quadriceps of c-Cbl KO mice and their respective control littermates could be 
used to examine energy expenditure using an XFe24 analyser as described previously in 
(Section 2.7). In addition, further study could aim to determine the mitochondrial FAO rate 
by adding 0.2 mM palmitic acid in cultured primary cells from c-Cbl KO mice. The change in 
OCR between basal and substrate-induced will be indicative of the mitochondrial fatty acid 
rate. To exclude the OCR due to the oxidation of other cellular substrates, the CPT inhibitor 
Etomoxir could be used after the addition of palmitic acid. The effects of insulin action on 
glycogen synthesis could be further measured in primary cells isolated from c-Cbl KO mice. 
This could be achieved by incubating the cells with palmitic acid in order to induce an 
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insulin-resistant state. Although the bile acid (BA) Farnesoid X receptor (FXR) has recently 
emerged as an attractive target of obesity (De Magalhaes Filho, Downes, & Evans, 2017), 
future study could aim to determine the correlation between c-Cbl and FXR. 
6.3.2 Functional studies 
Due to the time constraints, these studies were able to focus on the major role of c-Cbl in 
relation to energy metabolism in muscle cells using a Western blot technique. Although this 
technique is widely used in the laboratory to study molecular biology, there is a need to 
determine the functional levels of c-Cbl because it is not fully understood. 
Despite our finding from myogenesis, future studies could aim to examine the effect of c-Cbl 
depletion in mature myotubes on energy expenditure. This can be achieved by transfecting 
the myotubes with either control or c-Cbl-specific shRNA using a conditional tetracycline-
dependent expression system. Under this system, shRNAs are only generated when 
tetracycline, or its more stable analogue doxycycline, is added to the culture medium. 
As there are more than 150 proteins interacting or being a target of the ubiquitin ligase 
activity of c-Cbl, future studies could use proteomics methodologies to identify the 
downstream targets of c-Cbl ubiquitin ligase activity. Future studies could aim to determine 
the glucose metabolism of c-Cbl in L6, as C2C12 does not contain GLUT4 to allow glucose 
uptake assay. Co-transfection of c-Cbl and myogenin in C2C12 myotubes is a good technique 
to determine whether myotube differentiation will be further enhanced or deteriorated. In 
addition, assessment of insulin sensitivity in c-Cbl KD C2C12 myotubes needs to be further 
investigated in future studies by measuring the protein expression of AKT and glycogen 
synthase kinase 3 (GS3Kβ). It is well known that potassium channel Kv1.3 regulates body 
weight, energy homeostasis and insulin resistance (Xu et al., 2003). The body weight gain 
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increased with the removal of this channel (Upadhyay et al., 2013). As c-Cbl KO decreased 
body weight, potassium channel Kv1.3 could be involved as a target. 
6.3.3 Clinical implications 
The findings from this thesis provide a scientific rationale for further investigation of the c-
Cbl role in muscle energy metabolism in relation to the development and control of obesity in 
humans. They also suggest that c-Cbl may be targeted for the development of innovative anti-
obesity and diabetes therapies.  
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